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The main objective of this study was to test the efficacy of synbiotic food combinations 
carrying probiotic and prebiotic dietary fibres (DF) components for mitigating colonic 
inflammation that is associated with gut health issues such as inflammatory bowel disease 
(IBD). Although the exact aetiology of IBD is yet to be elucidated, emerging evidence 
supports the involvement of a recurrent tripartite pathophysiological circuit encompassing 
dysregulated immune responses, altered epithelial integrity and microbial dysbiosis. 
Therefore, the potential of dietary interventions incorporating food combination synergism to 
mitigate the inflammatory circuit, and thereby resolve or prevent the severity of colonic 
inflammation, was investigated. Whole plant prebiotic sugar cane fibre (PSCF) and green 
banana resistant starch (GBRS) flour prebiotics were evaluated for their individual as well as 
synbiotic efficacy in combination with probiotic Bacillus coagulans MTCC 5856 spores (B. 
coagulans) for ameliorating chemically-induced acute colitis and spontaneous chronic colitis 
in mice models of IBD.  
 
The research initially determined the stability and the bioefficacy of B. coagulans 
spores in-vitro by evaluating their ability to survive simulated digestion, adhesion to human 
colonic epithelial cells and immunomodulatory capacity. The tolerance of the probiotic B. 
coagulans spores to simulated digestion was tested by exposure to simulated saliva, gastric 
and intestinal juices. There was a high survival rate of 92% to the simulated digestion process. 
There was also substantial adherence to human colonic cells HT-29 (86%) and LS174T 
(81%). Furthermore, the spores exerted marked immunomodulatory effects in HT-29 cells by 
suppressing IL-8 and increasing IL-10 secretion. The B. coagulans spores also induced a 
pronounced differential immunomodulatory efficacy in response to lipopolysaccharide-
induced inflammation under co-treatment (increased IL-10 and reduced IL-8) relative to post-
treatment (suppressed IL-8 with no IL-10 detection) in HT-29 cells. These observations 
support the application of B. coagulans spores prior to or during the onset of inflammation to 
maximise the probiotic benefits in treating inflammatory bowel conditions 
 
The prophylactic efficacy of dietary supplementation with B. coagulans spores and 
PSCF alone or as synbiotic combination was then evaluated for their ability to attenuate 
dextran-sulfate sodium (DSS)-induced acute colitis in C57BL/6J mice. The study also aimed 
to analyse the beneficial effects of pre-conditioning the gut with supplemented diets prior to 
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induction of chemical colitis in imparting protection and amelioration against DSS-induced 
acute colitis. The mice were fed a normal chow diet supplemented with either whole plant 
PSCF alone, B. coagulans or its synbiotic combination (PSCF-synbiotic). The mice in control 
group (DSS-control) received normal chow. After the first seven days of supplementation, 
acute colitis was induced with 2% DSS administered in drinking water for seven days with the 
continuation of the supplementations. The disease activity indices (DAI), macroscopic 
markers, histological colonic damage, expressions of tight junction (TJ) proteins, mucus 
staining were analysed. The profile of colonic and serum cytokines and other inflammatory 
mediators (colonic iNOS activity and serum C-reactive protein level) were determined. 
Additionally, the faecal metabolomic and short-chain fatty acids (SCFA) (caecal, mucosal-
associated and faecal samples) profiles were also measured. Synbiotic supplementation 
ameliorated DAI and histological score (72% reduction, 7.38, respectively), more effectively 
than either B. coagulans (47% reduction, 10.1) and PSCF (53% reduction, 13.0) alone relative 
to the DSS-control. PSCF-synbiotic supplementation also significantly (P < 0.0001) preserved 
the expression of TJ proteins and modulated the altered serum IL-1β (−40%), IL-10 (+26%), 
and C-Reactive protein (CRP) (−39%) levels compared to the unsupplemented DSS-control. 
DSS insult in control mice resulted in decreased expression of TJ proteins and altered immune 
responses. Moreover, B. coagulans spores alone induced extra butyrate production in the 
caecum (+81%), but only +17% in mucosal-associated samples and +44% in faeces relative to 
DSS-control group. In contrast, the synbiotic combination resulted in substantial increase in 
butyrate levels across the whole length of colon with +80% in caecum, +57% in mucosal-
associated sample and +54% in faeces.  
 
The ability of B. coagulans spores and GBRS alone and as synbiotic combination 
(GBRS-synbiotic) was then examined for prophylactic efficacy in influencing the onset and 
disease outcomes of DSS-induced acute colitis in C57BL/6J mice. This study employed the 
same design where, after the first seven days of supplementation, acute colitis was induced 
with 2% DSS administered in drinking water for seven days with the continuation of the 
supplementations. The GBRS-synbiotic supplementation alleviated the DAI and histological 
damage score (67% reduction, 8.8 respectively) more than B. coagulans (52% reduction, 10.8 
respectively) or GBRS (57% reduction, 13.6 respectively) alone. Compared to the DSS-
control, synbiotic supplementation significantly (P < 0.0001) maintained the expression of TJ 
proteins. Moreover, synbiotic effects accounted for approximately 40% suppression of IL-1E 
and 29% of the increase in serum IL-10 while also reducing CRP (37%) to that of the DSS-
control. Additionally, relative to that of DSS-control, GBRS-synbiotic supplementation also 
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significantly raised the SCFA profile especially faecal butyrate level (+66%) more extensively 
compared to B. coagulans supplementation alone (+46%). Both the studies demonstrated 
marked prophylactic efficacy of the synbiotic supplementations (PSCF-synbiotic and GBRS-
synbiotic) in ameliorating the acute colitis in mice.  
 
A further study employed a spontaneous colitic Winnie (Muc2 mutant) mice model of 
IBD to determine if the previous results were specific to the DSS model or more generally 
applicable. In the Winnie model the chronic colonic inflammation results from a primary 
intestinal epithelial defect conferred by a missense mutation in Muc2 mucin gene. Winnie 
mice were fed normal chow diet supplemented with either B. coagulans, PSCF or its 
synbiotic combination for 21 days. Prominent features of the spontaneous colitis in Winnie, 
such as severe clinical manifestations, colonic histological alterations, dysregulated immune 
responses, altered SCFA levels and microbial dysbiosis, were examined to determine the 
therapeutic effect of the supplementations in mitigating chronic inflammation. All three 
supplementations reduced diarrheic stools as well as prevented body weight loss. PSCF-
synbiotic supplementation significantly ameliorated histological score in both proximal (P = 
0.0443) and distal (P < 0.0001) colon sections more effectively than B. coagulans and PSCF 
alone. Moreover, PSCF-synbiotic supplementation substantially modulated the altered 
colonic and serum cytokine levels as well as lowered serum CRP level by 29% compared to 
the unsupplemented Winnie-control. While, PSCF favoured the abundance of the bacterial 
genus Akkermansia, PSCF-synbiotic was effective in restabilising the depleted levels of 
Prevotella in Winnie colitic mice. PSCF-synbiotic was also markedly effective in elevating 
and normalising the levels of short-chain fatty acids along the length of the colon compared 
to that in unsupplemented Winnie-control mice. 
 
The potentiated health outcome effects of the synbiotic combinations observed in these 
studies may be associated with a synergistic direct immune-regulating efficacy of the 
probiotic and prebiotic components. The synbiotic combinations may also exert their effects 
by improved ability to protect epithelial integrity, stimulation of probiotic spores by the 
respective prebiotic fibre and/or with stimulation of higher levels of fermentation of fibres 
releasing SCFAs that mediate the reduction in colonic inflammation. Thus, the synergism 
between the probiotic and prebiotic components used in these studies could be attributed to 
the observed augmented beneficial effects. The knowledge obtained from thesis not only 
warrants investigation of synbiotic supplementations as an adjuvant therapy in human IBD, 
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but the results could also be applied to design novel functional food products targeted at 
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Chapter 1 
Introduction 
                                           
1.1 Significance of the topic 
 
Food is  being increasingly appreciated as an important vehicle carrying health-
promoting bioactives to reduce the risk of diseases (1) and is no longer merely a source of 
essential nutrients to satisfy human hunger. The choice of healthy foods and improved eating 
practices can facilitate a paradigm shift from illness to wellness. With the gradual change in 
consumers' perspective on food there is a huge demand for foods possessing health benefits 
beyond basic nutrition. This trend directs research towards the development of functional 
foods carrying probiotic bacteria (PB) and prebiotic dietary fibres (DF) for optimal wellness 
(2, 3). Considering the preference for “convenience food” among consumers (4), the 
challenge however, is to deliver these functional food ingredients in convenient ready-to-eat 
formats whilst preserving their optimum bioactivity. Shelf stable food formats fortified with 
probiotic and prebiotic ingredients are also required for application in defence and space 
programs or similar where long shelf life at ambient is needed (5-7). Additionally, limited 
availability of fresh, nutrient-dense food during deployment and space voyages also creates 
challenges to gut health resilience. The occurrence of gastrointestinal disorders can be 
promoted due to weakened immunity resulting from the environmental stresses (7, 9, 10). 
Functional food formats that can withstand wide temperature ranges, have long shelf life and 
are light weight are considered ideal for inclusion in meal packages for troops (8). Hence, 
delivering effective doses of probiotic and prebiotic ingredients through suitable food 
matrices is needed. Careful selection of compatible bioactive ingredients and understanding 
the mechanisms of bioefficacy will facilitate the development and optimisation of these 
functional probiotic and prebiotic shelf-stable foods.  
 
This research aimed at developing symbiotic combinations of functional food 
ingredients to lead the development of shelf stable value-added functional foods with anti-
inflammatory potential. The study focussed on understanding the interactions and 
mechanisms of actions of synergistic synbiotic combinations of probiotic spores and whole-
plant prebiotic DF in influencing the gastrointestinal health using animal models. 
Furthermore, the shelf-stable nature of such synbiotic food formats would allow storage at 
extended periods without refrigeration, suitable for combat ration packs and spaceflight meal 
packs. Additionally, improvement in the nutritional and functional value of such shelf stable 
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foods by fortification with anti-inflammatory food ingredients are likely to impact the gut 
health of civilians through enhanced eating practices. 
 
1.1.1 Problem background and the purpose of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
Gastrointestinal health is a strong determinate of an individual’s overall wellbeing and 
studies have demonstrated the significance of diet in influencing gut health (9-11). Diet is also 
a major influence on the composition of gut microbiota (12-14). As the role of gut microbiota 
is being increasingly understood and highlighted in health and diseases (12, 13, 15, 16) tools 
to manipulate the gut microbial profile are being sought. This has opened new research 
avenues to modulate health using functional foods as a vehicle for carrying health-promoting 
bioactives to prevent the risk or treat diseases (17) including gastrointestinal pathologies. 
Chronic inflammation of the gut is a hallmark feature of lifestyle diseases including 
inflammatory bowel diseases (IBD), obesity and related comorbidities (18). Such 
inflammatory conditions encompass overlapping features including altered chronic 
inflammation, weakened barrier integrity and microbial disturbances (dysbiosis). This study 
aimed to demonstrate the anti-inflammatory potentials of functional food ingredients 
employing animal models of IBD as a prototype of gut inflammation.   
 
Inflammatory bowel diseases (IBD) are a group of chronic relapsing gastrointestinal 
tract (GIT) disorders including ulcerative colitis (UC) and Crohn’s disease (CD) that are 
characterized by inflammation of the GIT and imbalance or dysbiosis of the gut microbiota 
(19). The incidence of CD and UC is rising globally (9, 19). Despite current medical 
treatments that focus primarily on immunosuppression (20), overall 20% of patients with CD 
still require surgery and over 10% of UC patients still require colectomy (21). This highlights 
the urgent need for research into prevention and management of these complex pathologies to 
avoid debilitating complications and the need for substantial risk medical interventions. 
 
The adoption of “Westernised” diet low in fruits and vegetables has been blamed as a 
potential factor for the recent rise in IBD incidence (9, 22). Even though the aetiology of IBD 
still remains unclear, involvement of three distinct recurrent features have been clearly 
identified that includes, gut dysbiosis, dysregulated immune response and altered colonic 
epithelial integrity (19). Application of preventive or therapeutic approaches that target this 
recurrent inflammatory cycle are needed. Dietary interventions are increasingly perceived as 
both preventive and corrective strategies to break the inflammatory cycle owing to their 
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ability to interact with the immune system, and to influence the gut microbiota composition 
and associated bacterial metabolic pathways (11, 23-27). In this context, dietary components 
such as PB and prebiotic dietary fibre (DF) are thought to be useful leading to potential 
resolution or prevention of IBD. The potential of these bioactive ingredients in ameliorating 
inflammation in the gut may be associated with their abilities to modify gut microbiota 
composition and metabolites, regulate secretion of immunomodulatory molecules and 
strengthen the colonic epithelial integrity (19, 26, 28).  
 
Probiotics are defined as “live micro-organisms which, when, administered in adequate 
amounts, confer a health benefit on the host” (29). Therapeutic efficacy of PB in treatment of 
GIT conditions including diarrhoea, irritable bowel syndrome and IBD have been 
demonstrated (30). The benefits from probiotic therapy however, is largely governed by the 
species and the strains used (31). It is clear that not all probiotics are equally beneficial since 
each may have an individual mechanism of action and differences in host characteristics may 
determine which probiotic species and strains could be effective (32-35).  
 
Maintenance of viability and functionality of PB during the industrial processing and 
storage, in the food/pharmaceutical preparations and during gut transit is thought to be 
necessary (36, 37). However, certain strains of commonly applied probiotics such as 
Lactobacillus and Bifidobacterium are reported to be sensitive to gastric transit and do not 
survive during the shelf-life of the products (38-41). From this perspective, probiotic Bacillus 
species that form spores offer advantage over other conventionally used PB in terms of 
survival in harsh conditions during processing, storage and gastric transit (42-45). A number 
of reports have demonstrated the probiotic efficacy of Bacillus spores in exerting 
immunomodulation and pathogen exclusion attributes in animals and humans (46, 47). 
Moreover, certain probiotic Bacillus species have been confirmed to confer anti-diarrheal 
effect (48, 49). These characteristics warrant research on their potential application in IBD to 
mitigate clinical manifestations and inflammation and to understand their mechanisms of 
action.  
 
For probiotics to be beneficial and confer sustained positive effects, they need to be 
present from either continued ingestion or from having an effective prolonged residence time 
in the gut. Therefore, promoting the survival and activity of the ingested probiotics to ensure 
greater number reach the colon and/or enhance their residence time and activity in the colon is 
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a viable strategy (50). This can be facilitated by prebiotics, which when combined with 
probiotics, can form an advantageous combination known as synbiotics (24).  
 
Prebiotics typically refer to selectively fermented non-digestible food ingredient, fibre 
or substances that pass the small intestine undigested and specifically support the growth 
and/or activity of health-promoting bacteria that colonize the colon (24, 51). Prebiotic dietary 
fibres (DF) have shown particular promise in attenuating colonic inflammation in humans (11, 
23). While the underlying mechanisms of DF are thought to be multifactorial, major potential 
mechanistic contributors to its beneficial effects are the dilution of toxins via stool bulking 
and the production of metabolites through bacterial fermentation, particularly short chain fatty 
acids (SCFA) (23).  
 
The health efficacy of DF may vary by the type of DF. Most studies examining the 
efficacy of DF have focused on purified ingredients that represent limited complexity in 
contrast to those that naturally occur in fruits and vegetables (52). However, enough evidence 
exists, and is recently being more recognized, to indicate that the actual biochemical 
complexity of naturally occurring DF such that in fruits and vegetables, is an important 
attribute in governing the microbial complexity of GIT (52-54). This highlights the prudence 
of developing functional food applications where the prebiotic fibres are representative of 
those in whole plant vegetables and fruits, and thus retain fibre biochemical complexity.  
 
In addition to modulating the gut microbiota, the prebiotic ingredients improve the 
survival, activity and/or metabolism of the target PB in the colon by selectively stimulating its 
growth when applied as synbiotic (55). Synbiotics which are combinations of probiotic and 
prebiotic ingredients, in functional foods could potentially confer augmented prophylactic and 
therapeutic effects to the host owing to either complementary and/or synergistic outcomes. 
Such two-point approach could possibly be more successful in delivering the required health 
benefits by impeding more than one inflammatory circuit components of IBD. Moreover, 
prebiotics have been confirmed to improve product stability during storage by influencing the 
survival of PB in the product during the shelf life (56). Thus, functional synbiotic foods that 
encompasses the synergy between the probiotic and prebiotic ingredients will be pragmatic 
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1.1.2 Research value of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
This study has evaluated the efficacy of DF and probiotic combinations in ameliorating 
acute and chronic colitis in murine models of IBD. The study employed probiotic Bacillus 
coagulans MTCC 5856 (B. coagulans) spores and two different prebiotic dietary fibres: 
whole plant prebiotic sugar cane fibre (PSCF) and green banana resistant starch (GBRS) 
flour. In-vitro cell culture screening was initially used to assess probiotic potential of the B. 
coagulans spores through measuring survival during simulated digestion, attachment to 
human colonic epithelial cells and immunomodulatory capacity. An IBD model using 
chemically induced colitic mice treated with B. coagulans spores alone or as synergistic 
synbiotic combination with either PSCF or GBRS was then used to determine their beneficial 
protective effect in mitigating acute inflammation. A further IBD model using chronic colonic 
inflammation in spontaneous colitic mice was also used to evaluate synergistic synbiotic 
treatment containing B. coagulans and PSCF.   
 
The delineation of the mechanism of action of the synergy between the synbiotic 
components is important to allow development of effective synergistic shelf-stable functional 
food design. While the research in this study was targeted to functional food supplements it is 
recognised that the results could also be applied to design novel commercial fresh food  
synbiotic products targeted at improving human gut health and enhanced eating practices. 
However, the scope of the research was limited to shelf stable formulations. The wider 
functional ingredient options of other non-shelf stable probiotics and other more natural and 
less concentrated sources of prebiotics was excluded although they may allow other health 
benefits and delivery forms to be effective in promoting gastrointestinal health.  
 
1.2 Research Strategy 
 
This thesis aims to determine the efficacy of probiotic and prebiotic combination 
(synbiotic) for improving gut health. The rationale behind the choice of Bacillus coagulans 
spores as probiotic, whole plant prebiotic sugar cane fibre (PSCF) and green banana resistant 
starch (GBRS) flour as prebiotic related to the goal of developing shelf stable functional food 
supplements. The desire to study the efficacy of prebiotic and probiotic in synbiotic 
combination stemmed from the need to understand synergistic functioning of these bioactive 
components in order to efficiently achieve augmented beneficial health outcomes with 
condensed forms of shelf-stable functional foods. While, numerous studies have confirmed 
health benefits from the individual application of probiotics and prebiotics (57-61), only some 
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reports support the application of synbiotic combinations for achieving  added health benefits 
(26, 28, 55, 62). Additionally, studies delineating the mechanism of synergistic interaction 
and bioefficacy of probiotic and prebiotic components are scarce. Elucidation of the 
synergistic mechanism is vital to the understanding of the factors and attributes involved in 
achieving the augmented benefits and optimisation of the beneficial synergism. The 
information on the mechanisms of the synergy will then allow further development or 
enhancement of therapies or food products for targeted health benefits as well as possible 
applications into improved eating practices. However, a careful selection of the compatible 
probiotic and prebiotic components was required to achieve the potentiated synbiotic benefits. 
In addition, selection of biochemically complex DF and stable probiotic that survives the 
gastric transit, manufacturing and storage temperatures was deemed important to ensure 
effective dose reaches the colon. 
 
The outcome goal of this study was to develop food products that would be shelf stable 
without refrigeration and retain efficacy over a prolonged shelf life. To achieve this, the study 
explored the application of probiotic spores considering the benefits of spores for retaining 
viability and functionality of PB during the industrial processing, storage and shelf-life of the 
product. The ability of Bacillus species to form spores confers this higher resistance to 
technological stresses encountered during industrial production and storage processes as well 
as a greater protection against the hostile gastric and intestinal conditions (63-66). Bacillus 
coagulans also has known health-promoting, anti-diarrhoeal and safety attributes (48, 67-69). 
Additionally, for legislative compliance, the  Bacillus coagulans MTCC 5856 spores used in 
the study are GRAS (Generally Recognised as Safe) probiotics with  Food Standards 
Australia New Zealand (FSANZ) specifically permitting  B. coagulans for probiotic 
application in food (70). B. coagulans spores have also been determined to survive during 
processing and storage of functional foods (43) thus, supporting their incorporation into 
extensive and novel delivery formats that do not need refrigeration. Furthermore, B. 
coagulans can metabolise a variety of plant substrates to acidic fermentation products  (64, 
71) making them candidates for synbiotic gut health outcomes when paired with prebiotic DF.  
 
The prebiotic ingredients for the study were selected for having the biochemical 
complexity of fruit and vegetable cellular materials in order to reflect natural whole food 
products in contrast to fibre fractions of purified ingredients. PSCF and GBRS are each 
prepared using technologies that focus on minimal processing and preserving the nutritional 
components of the respective plant materials (72-74). Such fibres, in addition to retaining 
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micronutrients and polyphenols, also contain both soluble and insoluble fibre fractions that 
have rapid- and poor-fermentable properties at ratios that more closely represent natural 
whole plant foods. Whole plant PSCF has a high total DF content (87%) (Appendix I) 
resistant to digestion and had been determined to impart positive effects on human gut 
microbiota in in-vitro study (75). GBRS flour, produced from Lady Finger bananas (Appendix 
II), was also selected as a rich source of resistant starch easily fermentable as well as 
containing potential bioactives such as 5-hydroxytyptophan (5-HTP) (72). Resistant starch 
(RS) from green banana has been demonstrated to prevent intestinal inflammation (76) and 
modulate oxidative stress (77) in animal models of colitis and impart anti-diarrhoeal effects in 
children (78, 79). The study therefore used prebiotics with different fermentation properties in 
combination with a probiotic ingredient known to digest fibres in order to amplify potential 
beneficial effects owing to synergy (55).  
 
Although, clinical trials are an integral part of validating the interventions targeted at 
improving human health, they do not necessarily allow understanding of the mechanism of 
action or the optimisation of test ingredients to achieve maximum benefits. To uncover the 
mechanistic functioning of synbiotic efficacy, examining affects on colonic and systemic 
inflammatory parameters is needed. This requires the collection of samples including colonic 
tissues, mucosal contents and blood through invasive procedures not generally practical in 
human subjects due to ethical implications. Moreover, the optimisation of compatible 
ingredients and the dose response information can more easily and practically be achieved 
using validated in-vitro and in-vivo animal models. This study, therefore, opted to screen the 
effective probiotic and prebiotic ingredients for synergistic synbiotic combinations using in-
vitro and in-vivo mice models to better understand their mechanism of action and allow 
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1.3 Objectives of the Thesis 
The overall aim of this present study was to develop shelf stable functional foods for gut 
and immune health by understanding the mechanisms to promote efficacy of synbiotic 
combination carrying probiotic and prebiotic components in promoting gut health by 
mitigating gut inflammation  
 
The detailed objectives were: 
x To determine the stability and bioefficacy of probiotic Bacillus coagulans spores 
in-vitro 
 
x To evaluate the individual and combined prophylactic beneficial effects of probiotic 
(B. coagulans spores), prebiotic (PSCF and GBRS) and their respective synbiotic 
combinations (B. coagulans-PSCF and B. coagulans-GBRS) in alleviating 
development of chemically-induced acute colitis in mice model of IBD 
 
x To investigate the individual and combined therapeutic beneficial effects of 
probiotic B. coagulans spores, PSCF and their synbiotic combination in 
ameliorating chronic colitis in spontaneous colitic Winnie mice model of IBD. 
 
 
1.4 Thesis Overview 
 
Chapter 2 reviews the background literature associated with the known causes and 
treatments of IBD, and the efficacy of probiotic bacteria, prebiotics to attenuate inflammatory 
gastrointestinal conditions such as IBD. In addition, this Chapter also reviews the evidence for 
a two-point synbiotic approach to exert augmented beneficial effects to mitigate gut 
inflammation.  
 
Chapter 3 evaluates the in-vitro ability of B. coagulans spores to survive simulated 
digestion. The ability of B. coagulans spores to adhere to human colonic epithelial cell lines 
and their immunomodulatory capacity in-vitro is also examined. The chapter is published in 
Journal of Functional foods, 2019 (DOI 10.1016/j.jff.2018.10.031) with minor modifications.  
 
Chapter 4 determines the prophylactic efficacy of diet supplemented with synbiotic 
combination of B. coagulans spores and whole plant PSCF in attenuating DSS-induced acute 
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colitis in mice model of IBD. The individual beneficial effects of B coagulans and PSCF 
supplemented diets alone are also compared. The chapter is published in Nutrients, 2019 (DOI 
10.3390/nu11040818) with minor modifications. 
 
Chapter 5 contrasts the prophylactic efficacy of diet supplemented with either B. 
coagulans spores, GBRS flour or its synbiotic combination in ameliorating disease outcomes 
of DSS-induced acute colitis in mice in comparison to the that of more complex slowly 
digesting PSCF. 
 
Chapter 6 confirms the therapeutic efficacy of diet supplemented with synbiotic 
combination of B. coagulans spores and PSCF in mitigating chronic inflammation using the 
different spontaneous colitic Winnie mice model of IBD. The individual beneficial effects 
exerted by B. coagulans- and PSCF-supplemented diets are also examined and compared to 
that of synergistic synbiotic combination. 
 
Chapter 7 discusses the combined Thesis evidence of potential impacts of synbiotic 
supplementation in mitigating the inflammatory cycle in IBD owing to the synergism of 
probiotic and prebiotic components. The potential mechanistic functioning of synbiotic 
combinations in exerting augmented health outcomes are outlined and the potential for 
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Chapter 2 
Review of the literature 
 
2.1 Introduction 
The significant role of specific dietary components in influencing either gut homeostasis 
or its dysfunction has long been appreciated (80). While the mechanism of diet in impacting 
gut health is multifactorial, its ability to govern the enteric microbiota is considered a major 
attribute in influencing the health and disease (9, 10, 81). High intake of diet rich in refined 
carbohydrates, fats, processed foods and low intake of fruits and vegetables has been linked to 
increased risk of gut inflammatory conditions (9, 82). IBD is a group of chronic relapsing 
gastrointestinal disorders that are characterized by inflammation of the GIT (19). IBD is a 
global disease, with over 1 million patients in USA and 2.5 million in Europe (83). IBD has 
emerged as a medical condition of concern in newly industrialised countries in Asia, South 
America and Middle East and its occurrence is rising worldwide. Australia has one of the 
highest incidence rates with more than 85,000 IBD patients and by the year 2022 this figure is 
expected to surpass 100,000 (84, 85). These data highlight the urgent need for research into 
prevention of IBD and innovations in health-care systems to manage this complex and costly 
disease.  
 
This review encompasses the literature associated with pathophysiological features of 
IBD as well as applications of prebiotic DF, probiotic spores and synbiotic combinations in 
attenuating the gut inflammation by targeting of resolve the inflammatory features of IBD.  
Dietary components such as prebiotic DF and probiotics are important in the context of IBD 
due to their ability to modulate microbial composition and metabolites, regulate immune 
parameters and strengthen the colonic barrier integrity thus leading to reduced gut 
inflammation (19, 26, 28). The use of synbiotic formulations that capture the synergy of 
probiotic and prebiotic functioning is considered a pragmatic approach to resolving the gut 
inflammatory cycle (26, 28, 86). The IBD pathophysiological circuit features of altered barrier 
integrity, dysregulated immune response and gut dysbiosis are discussed in detail. The 
efficacies of prebiotic DF and probiotic spores in influencing the gut inflammation parameters 
in humans and animal studies are highlighted. The evidence for application of complex DF 
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supporting the application of synergistic synbiotic combinations as a two-point approach in 
mitigating the inflammatory cycle in IBD.  
 
2.2 Inflammatory bowel diseases (IBD) 
 
2.2.1 Major forms of IBD  
 
IBD is comprised of two major, partially overlapping but distinct, clinical entities: 
ulcerative colitis (UC) and Crohn’s disease (CD).  CD involves the entire GIT but UC is 
limited to the colon and rectum (19). Both diseases are characterised by a series of relapses 
and remissions. CD is a transmural, granulomatous condition that may involve any part of the 
GIT but there is a higher incidence in the ileum and the colon. In contrast, UC explicitly 
involves the colon of the intestine and manifests as superficial inflammation confined to the 
mucosal and submucosal layers of the intestinal wall (87). Unlike UC, CD is commonly 
associated with complications such as strictures, abscesses and fistulas. Microscopic features 
of UC include cryptitis and crypt abscesses while, that of CD include thickened submucosa, 
transmural inflammation, fissuring ulcerations and non-caseating granulomas (88). Both 
forms of IBD can begin relatively early in life and persist for long periods and also present as 
overlapping symptoms including rectal bleeding, abdominal pain, weight loss, diarrhoea and 
fatigue, leading to decreased quality of life (89). Additionally, both UC and CD are associated 
with an increased incidence of gastrointestinal cancer that has a high mortality rate (90).  
 
2.2.2 Aetiology and pathogenesis of IBD  
 
Although, the etiopathology of IBD remains largely unknown, emerging evidence 
supports the interrelated roles of genetic, environmental, microbial and immunological factors 
(88, 91). IBD is thought to result from an inappropriate and continuing inflammatory response 
to commensal microbes in a genetically susceptible host (88). Alterations in the intestinal 
epithelial and mucosal barrier are known to support bacterial translocation resulting in 
dysfunctional intestinal inflammatory cascade (92-94), leading to pathologic proliferation of 
inflammatory mediators. There is an increasing level of evidence highlighting the key role of 
intestinal microbiota in driving inflammatory response during disease development and 
progression (95-97). The microbial imbalance in the colon, also known as gut dysbiosis, is 
associated with dysregulated immune responses (98) that further disturbs the colonic health. 
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colonic mucosal barrier, dysregulated immune response and gut microbial dysbiosis as 
hallmarks of this complex pathology (19).   
 
2.2.3 Compromised colonic mucosal barrier function in IBD  
 
The colonic mucosal barrier is composed of inner and outer mucus layers impregnated 
with antimicrobial factors and underlying epithelial cells stitched together with connecting 
protein networks called tight junctions (TJs) (99). These cells establish a barrier that separate 
the microbiota, food and other luminal contents from the innate and adaptive immune system, 
while allowing nutrient absorption and waste secretion. In a healthy gut, the continuous 
mucus layer in the colon keeps the surface epithelium out of contact with luminal microbiota 
thus, there is relatively little interaction between them maintaining the immune tolerance to 
the luminal microbes (19, 100). In IBD, this mucosal barrier is disrupted, resulting in 
translocation of the intestinal microbiota and activation of immune system leading to 
aggravation of the disease (100). As with dysbiosis, it is debated whether alterations noted in 
barrier function are the result or the causes of the disease (19).  
 
The inner mucus layer shows increased permeability in IBD mediating interaction of the 
microbiota with otherwise inaccessible epithelial surfaces (101-103). The increased 
permeability in IBD could be attributed to several factors including altered composition of the 
mucus components secreted by goblet cells, reduced mucin (100), reduced glycosylation 
products (104), decreased trefoil factor (105) or decreased secretion of antimicrobial factors 
into the mucus by epithelial cells (Reg3J), Paneth cells (defensins) and plasma cells 
(Immunoglobulin (Ig) A) (106-108). In UC, but not CD, the mucus layers are thinner or 
absent and the goblet cells responsible for mucus production are depleted (103). Mice models 
of UC with mutation or deficiency in major protein Muc2 have been shown to develop 
spontaneous colitis (109, 110) thus, indicating an important role of mucus in maintaining the 
barrier integrity. Certain members of the IBD-associated microbiota are known to utilise 
mucus as energy source and tightly regulate its production. This suggests that alterations in 
the mucus may be as a result  of dysbiosis rather than a cause (111, 112).  
 
The increased paracellular permeability in IBD may also be a result of abnormalities 
in the tight junction proteins that connect the epithelial cells (113, 114). Both 
environmental factors (microbes, diet) and genetic factors can influence TJ integrity (115). 
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gain access to the immunologically active submucosa. Subsequently, the interaction of 
microbial components, including lipopolysaccharides, flagellin, pilli and lipoteichoic acid, 
with the immune system triggers the inflammatory immune response thus sustaining the 
disease condition (116, 117). 
 
2.2.4 Dysregulated immune responses in IBD  
 
The mucosal immune system orchestrates homeostasis by balancing the host response 
to pathogens while not responding to stimuli from commensal microbiota and dietary 
antigens (91). Commensal bacteria dwelling in the intestinal lumen contribute to immune 
tolerance. However, in IBD, their translocation to the lamina propria triggers a pro-
inflammatory response leading to perturbation of immune homeostasis. The disruption of 
barrier function also initiates innate immune responses to the invading bacteria by innate 
immune cells, including macrophages and dendritic cells (DCs). Additionally it alters 
lymphocyte function in both the LP and mesenteric lymph nodes (MLN), and the T cell 
population of the normal gut mucosa (19).  
 
Immune cells involved in the pathogenesis of IBD are the lymphocytes and antigen-
presenting cells (APCs), that interact through an array of cytokines. Under normal 
physiological states, inflammation is regulated by a delicate balance of T-helper (Th)-1, 
Th17, Th2, Th3, Th9, and regulatory-T (Treg) cells (118-120). Cytokines are essential 
mediators of the communication between activated immune cells and non-immune cells, 
including epithelial and mesenchymal cells (121). A prime mediator of the intestinal 
inflammation is tumour necrosis factor alpha (TNF-D) which is produced by macrophages 
and Th 17 cells. Increased TNF-D expression has been implicated in both UC and CD 
(122). Consequently, TNF-D elicits expressions of Interleukin (IL)-1E and IL-6, both of 
which are also increased in the serum of IBD patients (123, 124). Interferon gamma (IFN-
J) is another central mediator that is elevated in IBD and associated with the severity of the 
disease (118, 125). Another cytokine that is closely related to disease activity is pro-
inflammatory IL-8, which is found to be increased in IBD patients (126, 127). Although UC is 
often described as a Th2-mediated disease, CD is traditionally viewed as a Th1 condition. 
However, the classic paradigm has recently been changed, since cytokines can have diverse 
and opposing actions (128) and there are some distinct differences in the cytokine profile 
between UC and CD. For instance, IL-13 that affects the tight junctions and apoptosis is 
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helps maintain immune homeostasis. It has been shown to be affected in the inflamed mucosa 
and granulomas of CD patients (131). By inhibiting the release of pro-inflammatory cytokines 
and antigen presentation, IL-10 mediates attenuation of mucosal inflammation (132). 
Overexpression of IL-23 in the intestinal mucosa has been determined to inhibit IL-10 
production. This then weakens the defensive barrier by suppressing the production of IgA in 
the gut (133).  
 
Immune mediators, particularly cytokines, play a vital role in IBD, hence several 
current therapies are targeted towards immunosuppression and modulations of immunological 
pathways and responses (134). Current pharmacological treatments used in clinical practice, 
like thiopurines, anti-tumour necrosis factor (TNF) and corticosteroids are effective but, have 
limitations. The introduction of anti-TNF agents, like infliximab, into clinical UC and CD has 
been for both for the induction of remission and as maintenance therapy. This has markedly 
improved the clinical outcomes of IBD patients (135). However, these drugs are expensive 
and associated with unpredictable side-effects including infusion reactions, infections and 
lymphoma. Furthermore, nonresponse or loss of response to anti-TNF commonly occurs in 
CD patients, suggesting limited efficacy of the drug treatment approach (136). Research for 
new oral and parenteral substances regulating the alternative immune pathways like the IL-
12/23 axis, IL-6, Janus Kinase inhibition and tumour growth factor (TGF)-E pathway has 
intensified (134). The inhibition of adhesion and migration of leukocytes into the inflamed 
intestinal mucosa has also received much attention. However, IBD is a very heterogenous 
condition, where patients have varied genetic and environmental backgrounds, and can 
display a wide variety of clinical phenotypes. In addition, unpredictable responses to different 
immune therapies makes it difficult for clinicians to choose the appropriate drug according to 
risk factors and clinical course (134). Moreover, cytokines have prominent and complex roles 
in IBD pathogenesis and the cytokine-based therapies therefore, must have higher specificity 
and reduced toxicity. Furthermore, the limited efficacy of the current immune-therapies in 
clinical practice (20) highlights the need for the developing therapies that target modulation of 
not, only immune responses, but subsequently mediate regulation of the epithelial barrier 
integrity and microbial dysbiosis, that play equal roles in the IBD pathogenesis. While, the 
immune system is therefore known to play a crucial role in the IBD pathogenesis, emerging 
evidence suggests a key role of invading gut microbiota in potentiating the pro-
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2.2.5 Microbial dysbiosis in IBD  
 
Healthy gut microbiota plays a key role in metabolism of food and drugs, development 
GIT epithelium, development of and modulation of immune system and protection from 
infections (139). The microbial profile of the GIT is shaped by both genetic and 
environmental factors (140). Compared to that of healthy individuals, microbiota in IBD 
patients have been consistently shown to present as altered in the microbial composition, as 
well as being reduced in overall biodiversity. This is often referred to as dysbiosis (141-145). 
Though the key role of dysbiotic microbiota in the pathogenesis of IBD has long been 
perceived, the extent to which the microbial alterations are a cause or an effect of 
inflammation remains a debate (137).  
 
In IBD, both expansion of potential pathogens and global changes in composition 
(increased or decreased abundance of indicator species) have been reported. For instance, one 
of the most consistent findings is a reduction in the commensal spore-forming and butyrate-
producing Clostridium clusters IV and XIVa of the Firmicutes phylum (142, 143, 146). Also, 
the abundance of Faecalibacterium prausnitzi, also belonging to the Firmicutes phylum, is 
often reduced in the stools of CD patients (142, 147-149). However studies focused on 
mucosal biopsies have also contradicted this association (150, 151). The members of 
Ruminococcaceae of the Firmicutes phylum are also depleted in IBD, especially in ileal CD 
(143, 152). Other SCFA-producers including Odoribacter and Leuconostocaceae are reduced 
in UC, and Phascolarctobacterium and Roseburia are depleted in CD (152). Roseburia 
species belonging to the Firmicutes phylum are also well known butyrate producer candidates 
of the gut microbiota (153-155). The abundance of Roseburia is reduced in all IBD subgroups 
(152), and is connected to the family of Ruminococcaceae as it relies on its members to 
produce acetate, which it uses to produce butyrate (156). Reduction in butyrate producing 
bacteria is thus an important marker of dysbiotic pattern in IBD.  
 
Conversely, members of the Proteobacteria phylum, such as Enterobacteriaceae 
including Escherichia coli, are consistently elevated in IBD patients relative to healthy 
individuals (143, 157). Ileal CD patients were noted to host increased proportion of adherent-
invasive E.coli (158-160). In a study by Sasaki et al., E. coli isolated from UC subjects, unlike 
that from CD subjects, were comparatively less invasive (161). Invasive E. coli from UC and 
CD patients in their study, were shown to induce IL-8 and tumour necrosis factor (TNF)-α 
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complexes. These observations suggest a potential pathogenetic role of adherent-invasive E. 
coli in CD. It is interesting to note however, that E. coli Nissle strain is used as probiotic with 
affirmed immunomodulatory potential (162). Klebsiella oxytoca is commonly linked to 
antibiotic-associated colitis (163). Fusobacterium spp., that are adherent and invasive, have 
been noted in higher numbers in UC subjects compared with healthy individuals (164). The 
invasive potential of human F. nucleatum correlates positively with IBD status of the host, 
identifying it as a potent driver of IBD pathogenesis (165). Conclusively, higher abundance of 
specific members of Proteobacteria also serves as a signature of microbial dysbiosis in IBD.  
 
The evidence suggesting a role of Bacteroidetes in dysbiosis is conflicting, with some 
reporting their significant reduction in IBD (143, 166, 167) and during antibiotic associated 
diarrhoea and Clostridium difficle diseases (168, 169), while other studies report dominance 
of Bacteroidetes  spp. in IBD (102, 170, 171). The increased prevalence of Clostridium 
difficile is also reported in IBD (172, 173). Bacteroides spp. and Clostridium spp. are the key 
species for generation of SCFAs in the colon. They have been reported to be diminished in 
IBD subjects in comparison with healthy counterparts  (174, 175). The population of B. 
fragilis also has been reported to be diminished in IBD patients in comparison with healthy 
subjects (174). Capsular polysaccharide A from Bacteroides fragilis has been shown to 
stimulate colonic Treg cells, improving the production of anti-inflammatory cytokine IL-10 
and thus providing protection against experimental colitis in mice (176). Also, mucin-
degrading bacteria such as Ruminococcus gnavus and R. torques are increased 
disproportionately to total mucosa-associated bacteria in intestinal epithelium of both CD and 
UC (112). Certain bacterial species such as Akkermansia muciniphila and Enterohabdus 
mucosicola are also known to degrade mucus and can thrive on mucus layer (177). While, 
some studies reported decline of A. muciniphila (112, 178, 179) in IBD patients, others noted 
its increased abundance in rodent IBD models (180-182). However, A. muciniphila belonging 
to Verrucomicrobia phylum is abundantly present in healthy humans accounting for about 1-
4% of the bacterial population in the colon (183, 184) and known to be a modulator of gut 
homeostasis (185). The extracellular vesicles of A. muciniphila were shown to protect against 
DSS-induced colitis suggesting its anti-inflammatory potential (186). To reach clear 
consensus, more well-designed clinical studies are required to analyse the roles of specific 
bacteria in inflammation for which confounding observations were noted. 
 
Increased prevalence of sulphate-reducing bacteria (SRB) was also reported in IBD in 
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SFB metabolise sulphate into hydrogen sulphides, which are detrimental to colonocytes.  
Hydrogen sulphides also hinders butyrate utilisation, stimulate cell hyperproliferation, deter 
phagocytosis and induce bacterial inhibition (188). The hydrogen sulphide producer, 
Desulfovibrio spp. have been also related to IBD (189). SRB populations, or their metabolic 
activities, were significantly higher in studies comparing UC patients with those of healthy 
controls or with UC patients in remission (190-192) as well as in the DSS mice model of 
colitis (193).   
 
Inflammation by itself may be also a potent driver of the failure to resolve dysbiosis 
(194). Certain bacteria, including members of Enterobacteriaceae family are reported to 
better survive under the prevailing conditions in the inflamed gut, than the anaerobic 
commensals that dominate in healthy gut (195-198). Salmonella enterica serovar 
Typhimurium, for instance, has reduced susceptibility to host-derived antimicrobials and has 
developed the capacity to incorporate host compounds produced during inflammation for 
growth (199-201). Artis (202) postulated that elevation of potentially harmful microbial 
populations induces a pro-inflammatory cycle. According to this theory, opportunistic species, 
for instance adherent invasive E. coli, interact with the mucosal surface to weaken barrier 
integrity and trigger host immune responses against other commensals. This supports their 
own survival in the gut while lengthening dysbiosis. Inflammation-induced aberrancies of 
potentially anti-inflammatory species (such as SCFA producers) may aggravate the cycle of 
inflammation, concurrently favouring the growth of resistant pro-inflammatory species (203). 
No consistent differences between the probiotic genera Lactobacillus and Bifidobacterium 
have been identified (175, 204). Psychotropic bacteria including Yersinia spp. (205, 206) are 
associated with IBD, while role of Listeria spp. (207-210) in IBD is contradictory.  
 
There is therefore no clear consensus on general differences between the microbiota of 
CD and UC and whether these changes are primary or secondary events. Some studies report 
similarities in CD and UC (143, 211, 212), whereas other investigators show disease-specific 
changes (157, 161, 170, 213, 214).  Similarly, some researchers describe differences between 
the microbial population in active and in inactive IBD (157, 211, 215), whereas others see no 
difference between active and inactive IBD states (170). Studies in murine models of IBD 
suggest that bacterial composition changes with colonic inflammation and/or infection (196, 
216-218), thus implying that the inflamed mucosa and/or altered inflammatory environment 
selectively affects the growth and adherence of different bacterial species. The gut microbiota 
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bacterial communities in the colon of the mammals. Rodent models have been instrumental in 
demonstrating the interaction of the intestinal microflora and the mucosal immune system 
(216). In spite of this care should be taken in translating the results from murine to human 
diseases (219). Changes in the composition of the gut microbiota can lead to alterations in the 
metabolites (220, 221) and have been implicated to have role in IBD pathogenesis as shown in 
mice models of IBD (217, 222, 223).  
 
2.2.6 Altered metabolomic profile in IBD  
  
Compositional and functional alterations in the colonic microbiome are likely to have 
significant impact on the pathogenesis of IBD (137, 146). Metabolomic studies have helped to 
establish the correlation between microbial composition and specific metabolic pathways 
thus, leading to assessment of a specific molecule products on IBD pathogenesis (137). 
Morgan and co-workers, compared the gut microbiota of healthy individuals and IBD patients 
and reported that 12% of metabolic pathways were significantly different, compared with only 
2% of genus-level alterations (152). Particularly, decreased carbohydrate metabolism and 
amino acid biosynthesis in favour of nutrient transport and uptake was identified. Moreover, 
increase in virulence and secretion pathways, as well as higher expression of genes related to 
oxidative stress, were noted. In another study, relative abundance of bile salt hydrolase 
showed substantial reduction particularly among Firmicutes from patients with CD (224). The 
levels of secondary bile acids were found to be reduced in IBD patients, particularly during 
flares of the condition, supporting the previous finding (225). In this context, bile acid 
signalling has been shown to be protective in DSS and 2,4,6-trinitrobenzenesulfonic acid 
models of colitis by inhibiting pro-inflammatory cytokine production (226). These findings 
emulate the microbial responses to the inflammatory intestinal milieu of IBD and indicate that 
the functional and compositional differences are extremely informative when studying 
dysbiosis (137).  
 
The depletion of certain bacteria and loss of their protective functions are also known to 
negatively affect the SCFA production. Many of the protective functions of the bacteria are 
associated with their ability to ferment dietary fibres to generate SCFA (227). The major 
SCFA in the gut are acetate, propionate and butyrate, which account for more than 95% of all 
the SCFA content (228). While, acetate and propionate are found in both small and large 
intestines, butyrate is found mainly in the colon and caecum (229). Their concentrations in the 
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of energy for the colonocytes (231) and regulate T cell homeostasis (232). Decreased 
abundance of members of Bacteroides and Clostridium groups IV and XIVa (143), that 
preferentially produce butyrate and other SCFA, could explain the observed SCFA reduction 
in faecal extracts of IBD patients  (146, 221). SCFA produced by these members of Clostridia 
spp. have been shown to elevate  Treg cell function in the intestinal mucosa via activation of 
G-protein-coupled receptors (GPRs) (232). This process enhances the restoration of immune 
tolerance and decreases inflammation in mouse model of colitis (232, 233). Reduction in the 
abundance of F. prausnitzi, that are also major butyrate producers, is linked with high risk of 
postoperative recurrence of ileal CD and its administration has been demonstrated to reduce 
inflammation in 2,4,6-trinitrobenze sulfonic acid (TNBS)-colitic mice (147).  
 
Beneficial effects of SCFA in IBD patients have been reported (234-237). SCFA 
mixture (sodium acetate, sodium propionate and sodium butyrate) enemas as an adjuvant 
therapy have been shown to enhance the efficacy of classic IBD treatments such as 5-
aminosalicylic acid and corticosteroid therapy (238). Butyrate, acetate and propionate, by 
binding to specific GPRs (GPR41, GPR43, GPR109A), have been examined to benefit 
epithelial integrity and modulate immune response (227, 239-241). Collectively, SCFA have 
profound effects on the regulation of gut immunity and the pathogenesis of IBD.  
 
Compositional and functional alterations of the enteric microbiome induce metabolic 
changes that can add to the toxicity of gut inflammation in IBD. Of note, fibre-rich diets are 
known to elevate SCFA production and have received much attention owing to their 
beneficial effects in reducing gut inflammation  (23, 59, 77, 239). Moreover, manipulating the 
dysbiotic microbiota to reduce the abnormal abundance of pathogenic species and enhancing 
the activity of the beneficial species has tremendous potential for therapeutic benefit (145). 
Furthermore, therapies that function by targeting the overall inflammatory circuit seem more 
pragmatic over therapies that are based solely on either immunosuppression or by influencing 
microbiome function. In this context dietary ingredients, such as prebiotic DF and probiotics, 
that function by influencing the gut microbiota composition and associated metabolic 
functions as well as regulating the immune system and barrier integrity, are thought to be 







    20 
2.3 Dietary interventions in IBD 
 
Despite the pharmaceutical approaches to disease control having improved in recent 
years, the limited efficacy and side-effects of the current immune-therapies in clinical practice 
(20) has highlighted the need for more research and development of alternative, safe and 
effective  treatments. The current IBD paradigm focusses on three main areas: the microbiota 
and metabolites, the mucosal barrier and the immune system (19). Research findings have 
shown the impact of dietary components such as prebiotic DF and probiotic on all  three 
components the IBD paradigm (23, 25, 26). Prebiotic DF and probiotic are developing as 
preventive and corrective treatment therapies for IBD (242) by aiming to reduce gut 
inflammation and thus consequently helping to prevent relapse.   
 
2.3.1 Prebiotic Dietary fibre approach in attenuating IBD 
 
2.3.1.1 Implications of low-fibre diet in IBD 
 
Besides the role of genetic predisposition in the development of IBD (88), diet is a 
major factor affecting the enteric microbiota. Numerous studies have considered the role of 
specific dietary components in the development of IBD and the in the course of the disease (9, 
23). The trend towards “Westernised-diet”, characterised by high dietary intake of refined 
carbohydrates, animal proteins, ultra-processed foods and low intake of fruits and vegetables 
rich in DF, has been linked with increased risk of both CD and UC  (82). A systematic review 
of literature by Hou et al. (9) concluded that a high intake of total fats, polyunsaturated fatty 
acids, omega-6 fatty acids and meat were consistently associated with increased risk of 
developing UC and CD. High vegetable intake was also consistently linked with reduced risk 
of UC, whereas fibre and fruit intake were consistently associated with decreased risk of CD.  
 
DF is a vital component of diet in the context of IBD. A protective effect of a high-fibre 
diet on the intestinal disorders was pointed out by a study that observed a low incidence of 
colon cancer and other non-infectious intestinal diseases among the populations of African 
countries, whose diet was typically rich in DF (80). Another study investigating and 
comparing the human gut microbiota from children, characterised by a modern western diet in 
European children and a rural high-fibre diet in African children, revealed distinctly increased 
microbial diversity in African communities with high abundance of bacteria of genus 
Prevotella capable of metabolising DF, and low abundance of certain pathogens and high 
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this dietary switch on the gut microbiota of children (81). Their findings clearly illustrated 
that the gradual increase of animal proteins (meat and dairy products), saturated fats, and 
processed and refined foods to the rural vegetarian diet of urban African children markedly 
altered their microbial profiles and gut functioning with, concomitant reduction in microbial 
population able to ferment DF and a sharp rise in other bacterial groups with capacity to 
metabolise animal proteins, animal fats and sugars. The authors concluded that dietary habit 
modifications, in the course of urbanisation, play a role in shaping the gut microbiota, and that 
prior fibre-degrading bacteria are at risk of being eliminated by the advent of westernised 
lifestyle. However, it is commonly observed that IBD patients are permanently on low fibre 
diets, regardless of disease activity (243, 244). Continuation of a regular diet is recommended 
during mildly to moderately active disease states, both in UC and CD patients by the 
European Crohn’s and Colitis Organisation. The fibre-restricted diet should always be used on 
a temporary basis and is indicated in few cases including, acute relapse (with diarrhoea and 
cramping), intestinal stenosis, and small intestinal bacterial overgrowth and some post-surgery 
instances (23, 245). Slow and gradual reintroduction of high-fibre foods is recommended 
during the periods of no symptoms and no or mild disease activity (23, 246).  
 
2.3.1.2 Prebiotic dietary fibre – a definition 
 
The majority of DF originates from plant cell walls (PCW) that are key in maintaining 
plant structure and function. Chemically DF is mostly comprised of carbohydrate polymers 
that resist digestion in the mammalian small intestine but undergo fermentation by bacteria in 
the colon (52). According to the American Association of Cereal Chemists (AACC) (247), DF 
is “the edible parts of the plants or analogous carbohydrates that are resistant to digestion and 
absorption in the human small intestine, with complete or partial fermentation in the large 
intestine”. Based on this AACC report of 2001, DF promote beneficial physiological effects 
including laxation, and/or blood cholesterol attenuation, and/or blood glucose attenuation. In 
compliance with this definition DF includes non-starch polysaccharides (NSP) and resistant 
oligosaccharides (e.g. cellulose, hemicellulose, pectin), analogous carbohydrates (e.g. resistant 
potato dextrins), lignin, and substances associated with NSP and lignin complex in plants (e.g. 
waxes, cutin) (247). CODEX Alimentarius commission in 2009 denoted DF as carbohydrate 
polymers with ten or more monomeric units, which are neither digested nor absorbed in 
human small intestine and belong to the following categories: edible carbohydrate polymers 
naturally occurring in the food consumed; carbohydrate polymers, which have been obtained 
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have physiological benefit to health; or isolated or synthetic fibres that have been shown to 
have physiological benefit to health (248).  
 
Some dietary fibres, such as inulin-type fructans and galacto-oligosaccharides, are also 
categorised as prebiotics. Prebiotics were defined by Gibson et al. as “non-digestible food 
ingredients that beneficially affect the host by selectively stimulating the growth and/or 
activity of one or limited number of bacteria in the colon and thus improve host health” (24). 
The selection criteria for a compound to be recognised as prebiotic include: “(i) resistant to 
gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption, (ii) 
fermentation by intestinal microbiota, and (iii) selective stimulation of the growth and/or 
activity of intestinal bacteria associated with health and wellbeing” (249). In 2015, Bindels et 
al. (51) proposed that an updated definition highlighting the influence on overall microbial 
diversity as the key factor rather than targeting specific species and defined prebiotic as “a 
non-digestible compound that, through its metabolization by microorganism in the gut, 
modulates the composition and/ activity of the gut microbiota, thus conferring a beneficial 
physiological effect on the host”. This definition emphasised the physiological effects of 
metabolites that result from fermentation, especially SCFA’s. However, it limited prebiotics 
to interactions with gut microbiota (with microbial fermentation as the key to the prebiotic 
concept) and excluded extraintestinal sites such as vagina and skin (250). Although fructo-
oligosaccharides, galacto-oligosaccharides and lactulose fulfil all the prebiotic definition 
requirements, several other dietary carbohydrates, as well as polyphenols and polyunsaturated 
fatty acids converted to respective conjugated fatty acids, are also potential prebiotic 
candidates assuming convincing weight of evidence in the target host (249, 250). 
 
2.3.1.3 Types of dietary fibre 
 
From the physiological point of view, the two main types of DF are water soluble (e.g. 
fructans, pectin, E-glucan) and water insoluble (e.g. cellulose, some hemicelluloses, lignin) 
DF. Despite the fact that the solubility is not always associated with a particular physiological 
effect, as pointed out by the experts of the Food and Agriculture Organisation of the United 
Nation/World Health Organisation (FAO/WHO) in 1998 (251), this division is still used and 
current (23). DF can be then divided into fractions that are rapidly fermented (e.g. 
oligosaccharides), slowly fermented (e.g. gums) and those that are hardly fermented (e.g. 
wheat bran). Soluble DF is a type of fibre that dissolves in water and includes pectins, 
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gel depending on its chemical structure and molecular weight. Soluble DF tends to slow the 
colonic transit time and nutrient release as well as inhibit the action of D-amylase (52, 252). 
This in turn, can lead to a reduced glycaemic response, thus regulating blood glucose (253, 
254). The degree to which PCW polysaccharides can be fermented varies considerably, with 
lignin that is considered insoluble, being very resistant to fermentation, and pectin, which is 
highly soluble, usually being fermented completely.  
 
Generally soluble fibres are assumed to be fermented more rapidly than insoluble fibres 
in the colon (255-257) although this perception is changing (258, 259). The most active sites 
are the caecum and proximal colon where most carbohydrates disappear (256). The types of 
DF that reach the colon, however, have significant implications for the site of its degradation. 
The mean transit time of the caecum is only 1-3 hours and the main NSP degraded at this site 
are soluble fractions (e.g. pectin, E-glucan, soluble arabinoxylans etc) (260). 
Depolymerisation of soluble fractions, as well as swelling and high water binding capacity, 
are some of the factors that encourage easier microbial colonisation and degradation of these 
substrates (261, 262).  
 
Insoluble fibres pose a significant challenge to gut microbiota owing to its reduced 
surface area and the hydrogen-bonding networks that hold the carbohydrate chains together 
(263). Insoluble fibre fractions may also be extensively degraded during the passage of the 
colon. For instance, a linear xylan present in the aleurone cells of rye was shown to be slowly, 
but completely fermented. In contrast, cellulose, arabinoxylans and xylans, when present in 
lignified tissues, are more resistant to degradation in the colon (260). Common insoluble DF 
include cellulose and lignin. Williams et al. (52), noted, that there is no standardised method 
for separating soluble and insoluble fibres and conditions used may differ in term of 
temperature, solvents and fibre to solvent ration. All of these govern the partition of fibre 
materials into soluble and insoluble fractions, hence, so the categorisation has substantial 
limitations.  
 
Non-fermentable water-insoluble fibres increase the volume of the stool, and by 
mechanical stimulation/irritation of the gut mucosa also reduce faecal transit time (23). 
Fermentable insoluble fractions, such as some forms of resistant starch (RS), undergo partial 
fermentation by the gut microbiota. RS is the sum of starch and starch degradation products 
that are not digested and absorbed in the small intestine and reach unaltered into the colon 
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insoluble fibre and some of the benefits of water-soluble fibre. SCFA’s produced via bacterial 
fermentation are frequently cited as the important contributor to the beneficial effects of DF 
(265).  
 
Moreover, certain polyphenols present in fruits and vegetables, ingested as a part of the 
diet, have been shown to impart anti-oxidant and anti-inflammatory effects and hence, are of 
considerable interest for prevention and treatment of colitis (52, 266). A number of dietary 
polyphenols, including those from berries, green tea and curcumin, have been extensively 
tested and shown to alleviate chemically-induced colitis in rodent models in a dose-dependent 
manner (266). Moreover polyphenols, upon reaching colon, are known to interact with gut 
microbiota thus, influencing the gut microbial diversity (267, 268).  
 
2.3.1.4 Efficacy of dietary fibre in resolving gut 
inflammation in IBD 
 
While the underlying protective mechanisms of DF are likely to be multifactorial, the 
production of SCFA via bacterial fermentation is frequently cited as a major contributor to the 
beneficial effects of DF (23). Of the SCFAs produced, butyrate is the one that serves as major 
source of energy for colonocytes, mediating improvement of villi growth and crypt 
development. It also contributes to mucin production, improvement of intestinal barrier via 
tight junctions and stimulates production of Treg cells and anti-inflammatory cytokines (232, 
269, 270). Butyrate has also been shown to stimulate peroxisome proliferator-activated 
receptor (PAPRJ) (271). PAPRJ antagonises several pro-inflammatory pathways such as 
STAT, AP-1 and NF-NB thus, its activation mediates anti-inflammatory mechanism 
involved in the prevention of inflammatory and immune-mediated diseases (272).  
 
In addition to providing energy to intestinal epithelial cells, and regulating mucosal and 
systemic immune responses (265, 270), the production of SCFA’s lowers the luminal pH that 
helps in influencing the composition of gut microflora by curtailing potentially pathogenic 
disease-causing bacteria ( e.g. Bacteroides and C. difficile) and stimulating growth of 
protective phenotypes (e.g. Firmicutes, Bifidobacteria and Lactobacillus) (270, 273, 274). 
Some beneficial bacteria like Bifidobacterium infantis have certain enzymes that hydrolyse 
saccharides, resulting in their own proliferation (275). Other microorganisms can support the 
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releases free fructose during oligofructose degradation that supports the proliferation of other 
organisms that are incapable of fermenting oligofructose themselves (276). Other mechanisms 
for DF in influencing health include dilution of toxins via stool bulking, improvement of the 
colonic barrier function, modulation of microbiota and regulation of mucosal and systemic 
immune response (23, 277). Moreover, DF’s are also known to exert anti-adhesive effects by 
inhibiting colonisation of pathogens to gut epithelium. Inulin has been shown to inhibit the in-
vitro intestinal colonisation of C. difficile (278), an organism implicated in IBD that can cause 
nosocomial diarrhoea, colitis and even death particularly after antibiotic treatment (279). 
Thus, DF may influence the immune system and gut microbiota directly or indirectly via 
bacterial fermentation.  
 
Evidence from rodent experimental models of IBD have suggested significant ability of 
DF to alleviate colitis. A number of experimental colitis studies (Table 2.1) have reported that 
prebiotic DF consumption is associated with reduction in the severity of inflammation, 
stimulation of immune responses and modulation of gut microbiota composition. Some 
studies advocate the application of combination of DF to exert supplementary effects owing to 
possible multiple mechanisms of action. Kleessen et al. (280) compared the dietary 
supplementation of inulin, fructo-oligosaccharide (FOS) or the combination of both prebiotics 
in gnotobiotic rats colonised with human enteric bacteria. FOS was found to effectively 
stimulate Bifidobacterium and Lactobacillus growth while inulin significantly increased 
luminal butyrate concentration. The mix of fructans stimulated the levels of Lactobacilli spp. 
and Clostridium coccoides-Eubacterium rectale cluster. The results correlate with that of 
other studies which reported complementary benefits in reducing inflammation when 
prebiotic combinations were used (274, 281). Prebiotic DF therapies aimed at modifying gut 
environment should be given early in the course of disease as evidenced from pre-treatment in 
DSS-induced colitis mice models  (239, 282). Kiwifruit is a rich source of plant secondary 
metabolites such as ursolic acid, carotenoids, and a range of polyphenols (283). Kiwifruit 
extracts have been demonstrated to inhibit cytokine production by LPS-stimulated 
macrophages and epithelial cells isolated from IL-10 gene deficient colitic mice (284), and by 
influencing immune signalling pathways and metabolic processes within the colonic tissue 
thus decreasing disease activity (285).  
 
A germinated barley foodstuff (GBF) prepared from brewer’s spent grain by physical 
isolation (milling and sieving) has been demonstrated to attenuate mucosal damage in DSS-
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was comprised of glutamine-rich protein and the hemicellulose-rich fibre. GBF was reported  
to support maintenance of epithelial cell populations, facilitate epithelial repair, suppress pro-
inflammatory NF-NB-DNA binding activity with increased SCFA production supporting the 
Bifidobacterium population, thereby preventing experimental colonic injury (287). The 
authors also reported that the low-lignified hemicellulose fibre fraction also modulated stool 
water content by its large water-holding capacity.  
 
 


















FOS –  





x Reduced chronic intestinal inflammation 
x Increased numbers of Bacteroides and 
Prevotella, decreased Clostridium 
cluster XI 
 
x Reduction in colitis 
x Increased Bifidobacterium spp. 
decreased Enterobacteriaceae and 






(Synergy1) (1:1) – 






x Reduced colitis severity 
x Decreased in IL-1β and increased TGF-
β concentrations 
x Increased Lactobacillus and 
Bifidobacterium 
x counts  
(281) 
 
Inulin – 1 % in 
drinking water, or  




x Reduced colitis severity 
x Increased Lactobacilli counts 
(293) 
FOS – 1 g/day TNBS-
induced rats  
x Reduction of inflammation 
x Reduced MPO activity and caecal pH 
x Increased lactate and butyrate 
concentrations 
x Increased LAB counts  
(294) 





x Reduced severity of colitis  
x Reduced damage to distal colon  
x Increased crypt depth and area 
(295) 
 







x Amelioration of colitis 
x Reduced MPO and alkaline phosphatase 
activity, lowered proinflammatory 
cytokine (IFN-γ, IL-17, and TNF-α) 
x Increased colonic Occludin expression 
(296) 









x No reduction in severity of colitis  
x Higher amounts of butyrate in distal 
colon 
 
x Reduction in severity of colitis 
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Lactulose – 0.06 % 





x Stimulated growth of Lactobacillus spp. 
x Reduced levels of adherent and 
translocated aerobic bacteria 
(298) 
Lactulose –  




x Ameliorated DSS-induced colitis in dose 
dependent manner 
(299) 
GOS – 4 g/kg diet TNBS-
induced 
colitis rats 
x No reduction in severity of 
inflammation 
x Increased total bacteria and 
bifidobacteria in faeces 
(300) 








cancer in rats  
x Increased parabacteroides, Barnesiella, 
Ruminococcus, marvynbryantia and 
Bifidobacterium 
x Increased SCFAs and reduced colitis 
severity 
x Reduced pro-inflammatory cytokines 
(COX-2, NF-kB, TNF-α and IL-1β) 
(301) 
 




x Reduction of severity of colitis 
x Declined levels of Clostridium 
coccoides, Enterococcus spp. and E. coli 
(302) 
 




x 20-day pre-treatment attenuated  
clinical & inflammatory parameters 
x Improved anxiety-like behaviour 
(282) 




x Increased Ig A and decreased IgE levels 
in MLN and faeces 
(303) 




x Attenuated clinical signs 
x Reduced serum  D-1 acid glycoprotein 
x Increased caecal butyrate 




GBF – 100 g/kg 
diet        
DSS-induced 
mice 
x Reduced disease activity and prevented 
body weight loss 
x Reduced serum IL-6 level and 
histological damage to mucosa 
x Suppressed mucosal STAT3 expression 
and NFNB activity 
x Elevated caecal butyrate and lowered bile 
acid 
(288) 
GBF – 100 g/Kg 
diet        
DSS-induced 
rats 
x Prevented bloody diarrhoea and mucosal 
damage 
x Elevated faecal acetate and butyrate 
levels 




There are only a few studies investigating the DF intervention in IBD patients (Table 
2.2) and these have generally presented conflicting results. Lindsay et al. (305) reported 
excellent efficacy of supplementation of FOS as a 15g dose for 3 weeks in reducing disease 
activity index (DAI) in moderately active CD patients. In a separate work, supplementation of 
15 g of FOS for 4 weeks by Benjamin et al. (306) however, did not prove clinically beneficial 
in improving CD based on DAI. Moreover, the microbiome of treated subjects showed no 
differences in the faecal numbers of Bifidobacterium or F. prausnitzii from baseline. It is 
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with documented diagnosis of CD for at least 3 months while, the earlier study that showed 
improvement with prebiotics (305) was in recruited patients with moderately active CD. This 
implies the importance of application of prebiotic during the onset of disease to harness 
maximum benefit. Oat bran, which is a rich source of β-glucans, has also been shown to 
benefit patients with inactive UC (307). This 12-week pilot randomised control trial showed a 
36% increase in the faecal butyrate level at 4 weeks and improvements in abdominal pain or 
gastroesophageal reflux after oat bran intervention. In humans, combinations of DF have also 
proved successful in modulating gut microbiota and improving disease symptoms in IBD 
patients (308, 309). Another randomised crossover trial with UC patients compared the effects 
of three 7-day supplement periods of fructans (oligofructose as Raftilose P95®, RS and 
digestible carbohydrate intake) with a glucose placebo (310). In all these patients, fructans 
supplementation had a fermentation ability of 83% and was associated with an elevation in 
faecal butyrate excretion relative to RS supplementation which had a 46% fermentation 
ability and resulted in elevated faecal isobutyrate and isovalerate excretion. This suggested 
that different DF’s vary in their fermentation ability and different SCFA can be produced 
depending on the type of DF. Similarly, wheat bran intake in inactive UC children was more 
effective in reducing bile acid concentration than a psyllium supplement (311). The reduction 
in specific bile acids in this study was beneficial in patients as these are reported to induce a 
proliferative response in the gastric mucosa of rats. Bile acids may also increase mucosal cell 
proliferation in other parts of GIT (311). Hemicellulose-rich GBF feeding to UC patients was 
shown to increase stool butyrate concentrations and luminal Bifidobacterium and 
Eubacterium levels (292) leading to disease improvement with clinical and endoscopic scores 
as markers (289, 292, 312). GBF supplementation, along with standard drug therapy in mild 
to active UC patients, has been confirmed to reduce serum levels of TNF-D, IL-6 IL-8 (290) 
and C-reactive protein (CRP) (291).  
 
Owing to the conflicting outcomes of the human studies, a single generalisation cannot 
be made as to the benefits or otherwise of the currently applied prebiotic DF’s. However, 
given the complex nature of DF and varying biochemical structures of different plant 
materials, different studies comparing different fibres could significantly influence the 
varying outcomes in each study. Furthermore, results are likely to be affected by the dosage 
and length of time of DF intake as well as the disease type (UC or CD) and disease state 
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and to modulate gut microbiota, which may be associated with health benefits in patients with 
IBD, supports their application in resolving gut inflammation.  
 
 




















FOS –  
15 g/day 
n= 10 adults 
(10/0);  
3 weeks 
x Increased faecal 
Bifidobacterium counts 
x Improved disease activity  






n= 103 adults 
(54/49); 
4weeks 
x No significant clinical benefits 
x No differences in faecal 
numbers of Bifidobacterium or 
F. prausnitzii  
x Increased IL-10 dendric cell 
staining and reduced IL-6 










IN) –  
10 g 
twice/day 
n= 45 adults  
(25/20); 
4 weeks 
x Improvement in disease activity 
in active CD patients 
x Reduced faecal Ruminococcus 
gnavus and increased B. longum 
counts 











n= 7 adults  
(4/3);  
2 weeks 
x Diet consumption was feasible  
x No adverse effects 
x Improved quality of life and 
gastrointestinal functions 
x No significant differences 





OF-IN –  
4g thrice daily 
with standard 
drug therapy 
n= 19 adults 
(10/9);  
2 weeks 
x Reduced calprotectin at day 7 
x Reduced dyspeptic symptoms 








OF-IN –  
10 g 
twice/day 
n= 56 adults  
(231/25); 
4 weeks 
x Increased relative faecal 






FOS and RS 
– 14.3 g/day 








x 83% fermentability recorded for 
FOS and 46% for RS 
x RS increased faecal excretion of 
butyrate 
x FOS reduced excretion of 











UC: n= 14 
adults (7/7);  
4 months 
 
CD: n= 17 
adults (8/9);  
4 months 
x No clinical benefits observed in 
terms of clinical activity, 







Oat bran –  
60 g/day 
n= 19 adults 
(19/0);  
3 months 
x Increased faecal butyrate 
x Reduced signs of colitic relapse 






GBF –  
30 g/day 
thrice daily 
n= 10 adults 
(10/0);  
4 weeks  





GBF –  
20-30 g/day 
n= 18 adults 
(11/7);  
4 weeks 
x Decreased clinical activity 
index scores 
x increased faecal counts of 
Bifidobacterium and 













x Decreased clinical activity with 
reduced visible blood in stools 




GBF –  
30 g/day 
thrice daily 
n= 10 adults;  
4 weeks 
x Clinical and endoscopic 
improvements 





Husk –  
3.52 g/day 
n= 29 adults 
(16/13);  
4 months 
x Reduced gastrointestinal 
symptoms: of abdominal pain, 
diarrhoea, loose stools, urgency, 
bloating, incomplete 















alone and 10 
g sachets of 
Psyllium 
twice/day 
n= 102 adults 
(30/37/35); 
12 months 
x Both failure and continued 
remission of similar 
approximation 














n= 41 adults 
(20/21);  
2 months 
x Reduced serum levels of TNF-D, 











n= 41 adults 
(20/21);  
2 months 
x Reduced abdominal pain and 
cramping 
x Reduced serum CRP 
(291) 
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2.3.1.5 Purified versus whole-plant complex dietary fibres 
 
Whole plant sources including fruits, vegetables, and grains are natural sources of DF. 
However fibre supplements that are composed of isolated or extracted fibres (using chemical, 
enzymatic or aqueous processes) from natural sources are also widely available and are 
considered as a subgroup of functional fibres (23). The most common sources of fibre in 
available supplements are natural, including psyllium, glucomannan, inulin, wheat dextrin, or 
flax, and synthetic, such as methylcellulose and calcium polycarbophil. With the increased 
consumer perception of beneficial effects of DF, much research has focussed on the testing of 
single purified sources of DF’s. these are usually extracted from plants, sometimes by the use 
of harsh chemical procedures (52). A number of studies have been performed to examine the 
effect of various purified DF including polydextrose and soluble maize fibre (318), maize, 
dextrin, pullulan, RS (257), aloe vera gel extract and powder, Larch extract, Undaria 
pinnatifida fucoidans, Tragacanth gum, ghatti gum (319), amylose, amylopectin, dextran, 
xylan, polygalacturonate, pectin (320), apple pectin (321) and high amylase maize starch 
(322)  on human gut microbiota. However, when, determining the specific effects of purified 
fibres on health, particularly on the microbiota, the limited biochemical complexity of the 
purified ingredients, in contrast to that of naturally occurring in fruits and vegetables, cannot 
be overlooked. The actual biochemical complexity of naturally occurring DF such that in 
fruits and vegetables is being recently recognised and appreciated as a vital attribute in 
influencing the gut microbial complexity (52-54).  
 
The most natural form of DF consumed is as PCW’s from cereals, fruits, vegetables and 
other-plant based foods.  In this material  soluble polysaccharides are typically present 
alongside insoluble cellulose in an hydrated but insoluble form (52). Purified fibre ingredients 
do not accurately duplicate the soluble to insoluble fibre ratios of natural plant sources. This 
differences can affect the fermentation time and rates in the colon. For instance, in an in-vitro 
study, which compared more complex arabinoxylan with purified arabinoxylan, showed that 
purified form had a much faster rate of gas production, and was fermented to a greater extent 
(323). Separate work comparing fermentation of inulin with arabinoxylan oligosaccharides 
noted that inulin rapidly fermented and led to microbiota changes in proximal colon, whereas 
arabinoxylan oligosaccharides were fermented in the distal colon of the in-vitro model (324). 
Moreover, isolated DF fractions tend to ferment much faster than when consumed as complex 
structures from whole plant foods (325) and thus ultimately differently affect specific areas of 
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accessibility thus modulating microbial activity. These findings indicated more slowly 
fermentable substrates will be more likely to ferment for a longer trajectory within the colon, 
compared with more rapidly fermented substrates (326). DF that can ferment more slowly, 
and for a longer trajectory within the colon, is likely to be more beneficial in IBD by 
providing a trophic effect of the fermentation products (SCFAs) to the entire length of the 
colon while suppressing rapid gas production that can lead to abdominal cramps.  
 
Despite the appreciation of biochemical complexity of DF to influence colon health, 
only a few studies (76, 77) have investigated the effects of DF functional products that closely 
resemble whole-plant sources, prepared with minimal processing to retain fibre complexity 
and other bioactive compounds, on outcomes of disease in IBD. This emphasises the need for 
efforts to develop functional DF supplements based on natural foods which have the carrying 
plant cell wall complexity of the intrinsic DF and other bioactive compounds. In this context, 
green banana flour, which is a rich source of RS, has been shown to have potential in 
ameliorating experimental TNBS-colitis in mice (76, 77). The benefits of green banana flour, 
owing to RS content, was associated with increased SCFA levels, increased mucin production 
and reduced oxidative stress in the colon. The green banana based-diet has been demonstrated 
to impart anti-diarrhoeal effects in humans (78, 79). The anti-diarrhoeal action is postulated to 
be mediated by its high content of amylose-RS, that elicits SCFA production in colon, thus, 
stimulating colonic salt and water absorption (327, 328). RS-rich flour, produced from green 
lady finger bananas, been reported to retain a high content of RS as well as vitamins and 
minerals (72). Moreover, this particular GB flour is reported to contain 5-hydroxytryptophan 
(5-HTP), a serotonin precursor, which in a separate work, has been shown to alleviate mood 
disturbances in DSS and TNBS mouse models of colitis (329).  
 
Sugar cane fibre has also been reported to preserve the cell wall components and retain 
other intrinsic nutritional bioactive components (73, 74). It can be prepared by wet diffusion 
of the stem to remove most of the sucrose from the cut cane, which is then dried and ground 
to a flour. Such fibre, in addition to retaining other micronutrients and polyphenols, also 
contains both soluble and insoluble benefits as well as rapid- and slow-fermentable fibres and 
at ratios that more accurately represent those present in other natural whole plant foods (330). 
In a recent in-vitro study (75), this sugar cane fibre product has been shown to impart positive 
effects on human gut microbiota, and be effective in maintaining the microbial diversity 
compared with other fibres tested. The sugar cane fibre in this study was also reported to 
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to other commercial fibre products tested (i.e. Benefiber–wheat dextrin and Macro Organic 
Psyllium husk). Previous studies have reported sugarcane to be rich in cellulose, 
hemicellulose (331, 332), contain a range of β-1, 4, and α-1, 4 linkages between glucose, 
xyloglucans, xylans, glucomannan, arabinoxylan, glucuronoxylan and D-galacturonic acid 
(333, 334). Thus, fibre supplement from sugar cane stems has a complex biochemical fibre 
network similar to that of other whole plant foods. It could be used as a potential DF to impart 
prebiotic effects in gut inflammatory conditions but more studies on complex DF 
supplements, with biochemical fibre complexity similar to that in fruits and vegetables, is 
required to appreciate their benefits in IBD. Dysbiotic microbiota metabolise DF differently to 
the microbiome of healthy subjects and can consequently affect the levels and types of 
metabolites produced (335). Since, gut microbial dysbiosis is a hallmark of IBD, application 
of probiotic microorganisms to repopulate the gut with beneficial microbial phenotype, seems 
to be a pragmatic approach to enable maximum DF benefits to be attained.  
 
2.3.2 Probiotic approach to ameliorating IBD  
 
The mounting evidence that has drawn correlations between certain intestinal bacterial 
flora types and IBD pathogenesis, has resulted in many attempts to modify gut microflora by 
administering probiotics (242, 336, 337). The first ever study that administered probiotic to 
inactive UC patients was in 1917. It showed promising results in maintaining remission by 
application of E. coli Nissile (338). Probiotics subsequently been mentioned by many 
reviewers as a promising therapy for IBD (339-343). Multiple mechanisms have been 
suggested to explain the protective effects of probiotic against intestinal inflammation. 
Probiotics have the potential to directly or indirectly resolve the tripartite pathophysiological 
circuit in IBD. Mechanisms of probiotic benefits may include manipulation of intestinal 
microbiota, pathogen suppression and/or exclusion, immunomodulation, induction of 
epithelial cell proliferation and strengthening the intestinal barrier (344). The success of 
probiotics however, is largely dependent on the species and strains used (31). It is evident that 
not all probiotics are equally beneficial as each may have an individual mechanism of action 
and the host characteristics may determine which probiotic species and strains could be 
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2.3.2.1 Current probiotic delivery foods and associated 
challenges 
 
There is a growing demand for probiotics among consumers based on their perceived 
health benefits.  In the food sector, incorporating probiotics into variety of food matrices to 
provide added health benefits beyond their basic nutrition is a global trend (336). 
Lactobacillus and Bifidobacterium species are well established, globally accepted and the 
most consumed probiotic species for their potential health benefits (345). Other preferred 
probiotics include strains of Streptococcus, Enterococcus, Saccharomyces and Bacillus 
species  (43). However, certain strains of commonly applied PB belonging to Lactobacillus 
and Bifidobacterium species, are reported to be sensitive to gastric transit (38). Despite their 
ability to confer health benefits, not all of these microorganisms can be successfully 
administered as probiotics through pharmaceutical supplements or functional foods owing to 
their inability to resist hostile conditions during gastric transit or withstand harsh 
manufacturing and storage conditions (346).  
 
In addition to their therapeutic application as pharmaceutical supplements, probiotics 
are being incorporated into a variety of food products. Probiotic preparations must meet strict 
criteria related to quality, safety and functionality (347). A key quality criterion is that they 
contain accurately defined numbers of viable cells as expressed on the product label. Some 
investigators reported significantly lower levels of bacterial numbers than stated (348-352), as 
well as inconsistency in their probiotic properties when applied in some commercial food and 
pharmaceutical products. This included reduced ability to survive simulated digestion and 
decreased adherence to human intestinal epithelial cells (349, 352). Currently, refrigerated 
dairy products that carry conventional PB’s such as Lactobacillus and Bifidobacterium 
strains, are the major delivery forms for probiotic food. The colder storage temperatures and 
rich growth media assist retention of viability for these conventionally used probiotic strains 
(353). Some Lactobacillus strains are known to lose their viability by the end of the shelf life 
in cold storage even in dairy products (348, 351) thus, limiting their full probiotic potential. 
Lactose intolerance, high fat and cholesterol, milk allergies and also the growing trend 
towards vegetarianism have led to the demand of non-dairy probiotic foods (354). Moreover, 
probiotic-supplemented foods that have an extended shelf life without refrigeration are more 
convenient. Efforts are therefore being made to improve viability of PB during manufacture 
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than in a dairy food base. In this context, Bacillus species, due to their ability to form spores, 
offer potential advantage over other conventionally used PB in terms of their application in 
probiotic supplements and functional foods (64, 355).  
 
Spore based probiotics, being inherently heat-stable, makes them an excellent choice as 
a functional ingredient to be incorporated into food that requires heat application during 
manufacture. The spores can maintain viability and thus efficacy after incorporation into food 
products during manufacture. The spore supplemented food products can be stored at room 
temperature without any deleterious effect on the viability. Moreover, spores have the 
capacity to tolerate the low gastric pH (356) unlike, in some Lactobacillus and 
Bifidobacterium strains (357, 358), thus ensuring delivery to the colon intact of the entire 
effective dose of ingested bacteria. These attributes not only offer an opportunity to carry 
probiotics through acidic foods such as yoghurt or fruit juices, but also opens avenues for 
incorporating probiotic spores into shelf-stable food systems such as snack bars, baked goods, 
breakfast cereals and chocolates without affecting cell viability during non-refrigerated 
storage. This is not possible with conventional PB’s. Also, with increased demand for dairy-
free milk products, Bacillus spores can also be applied to develop probiotic non-dairy drinks. 
Thus, the robustness of spores, when coupled with health-promoting attributes, makes them 
an attractive functional ingredient in food for improved gut health in humans.   
 
2.3.2.2 Bacillus as probiotic  
 
Bacillus species are spore-forming, Gram-positive aerobic bacteria common in soil, 
water, dust and air. These microorganisms enter the gut by association with food (359). 
Bacillus species have the capacity to form spores when growth conditions are unfavourable 
and can exist in the dormant stage for many years. However, favourable conditions, such as 
specific nutrients, pH, temperature and moisture, can trigger germination of spores into 
vegetative cells (360, 361). Bacillus species have been used as probiotics for at least 50 years 
with the Italian product known as Enterogermina® registered 1958 in Italy as medicinal 
supplement (355). Bacillus, as a source of probiotics, has sparked scientific interest only in 
the last 15 years with just a few principal reviews in the area (355, 359, 362, 363). 
 
Bacillus spores are regularly consumed by humans unintentionally through fermented 
foods. Natto is a Japanese food made by fermentation of cooked soybeans with B. subtilis var. 
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has been associated with stimulation of the immune system (364). Nattokinase produced at 
higher levels by B. subtilis var. natto has been shown to induce immune stimulation and 
produce vitamin K2 which can exert anti-cancer properties (365-367). Co-culturing B. subtilis 
natto with Lactobacillus in vitro has been shown to improve the viability of Lactobacillus 
through production of catalase and subtilisin (364). This synergism could be useful in 
designing functional foods carrying both Bacillus and Lactobacillus probiotics cells to 
influence the viability of Lactobacillus, in addition to conferring their collective beneficial 
effects.  
 
Fermented soybean foods based on Bacillus spp. have a long history and are consumed 
in Korea, Japan, China, Southeast Asia and some African countries (355, 368-370). Certain 
Bacillus strains have been credited to improve biological function and the textural and sensory 
attributes of fermented food products when used as starter culture (371-373). The 
antimicrobial substances produced by Bacillus species inhibit food pathogens (369, 373, 374) 
and could therefore potentially play a vital role as protective starter cultures against 
pathogenic microorganisms contaminating foods. This function has been previously 
designated for bacteriocin producing LAB (375). In addition, Bacillus species isolated from 
various traditional food products have been shown to have probiotic efficacy that presents the 
means to develop functional foods with health benefits. A fermented soymilk, employing B. 
subtilis as the starter culture and purple sweet potato extract as a fermentable substrate, 
exhibited high antioxidant activity in-vitro (376). Also, cheonggukjang, a Korean soybean 
paste produced with the co-inoculation of B. subtilis W42 and B. amyloliquefaciens MJ1-4, 
exhibited high antioxidant, anti-fungal and fibrinolytic activity (377). Cheonggukjang 
fermented with B. licheniformis-67 suppressed obesity related parameters in high fat diet 
induced obese mice (378). Surfactin produced by B. subtilis CSY191 during fermentation of 
doenjang (a Korean fermented soybean paste) was shown to inhibit the growth of human 
breast cancer cells in-vitro (379). More in-depth studies exploring the probiotic potential of 
Bacillus-based foods will facilitate the awareness of spore-based probiotics among 
consumers. 
 
2.3.2.3 Potential probiotic mechanisms of Bacillus in IBD 
 
In contrast to that of conventional lactic acid bacteria (LAB), the mechanisms 
potentially responsible for the beneficial attributes of Bacillus species remained relatively 
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probiotics are now known to also mediate benefits to the host via immunomodulation and 
pathogen exclusion (via antimicrobial production and competition for receptors and nutrients). 
Oral administration of Bacillus spores has also proved effective in modulating immune 
response and balancing gut microflora in animal and human studies (Table 2.3 and 2.4).   
 
 





Immune response Reference 
B. subtilis A102 
 





x Increased macrophage and 
NK cell activities via 
induction of interferons in 
mice 
(380) 
B. subtilis PY79 
 
 







x Increased systemic spore 
coat-specific IgG levels  
(381) 
B. subtilis PY79 
 
 









C57BL/6 mice  
 
x Increased anti-spore specific 
IgG titres, 
x Increased anti-spore faecal 
sIgA   
x Increased production of 
IFN-J & TNF-D in GALT 












1 × 109 





x Stimulated cell proliferation 
in germinal centres of 
Peyer’s patches 
x Increased stimulation of 
antigen-presenting cells and 
T lymphocytes 
(383) 
B. subtilis PB6  1.5 × 107  






rats   
x Reduced plasma pro-
inflammatory cytokine 
levels (TNF-D, IL-1E, IL-6, 
IFN-γ) 
x Increased plasma anti-
inflammatory cytokine 
levels (IL-10 and TGF-E) 
 
(384) 
B. subtilis natto 
 
1 × 1010 





x Increased serum IgG and 













x Suppressed activation of 
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B. subtilis PB6 
(Anaban) 












x Increased IL-10 secretion  
      and decreased TNF-D, IFN-
γ  








 B. subtilis 
PY79 
 (heat-killed) as 
adjuvant 








x Increased levels of both 
systemic IgG and mucosal 













x Increased concentrations of 
TNF-D, IFN- γ, IL-1E, IL-6, 
IL-10 and MIP-2 
(389) 








contains 5 × 
107 B. 
subtilis CFU 









Dawley rats  
 
x Reduced percentages of Th1 
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Balb/c mice  
x B. subtilis alone and B. 
subtilis + 5ASA both:  
x Improved disease activity 
score and prevented 
histological damage  
x Increased expression of TJ 
proteins (claudin-1, 
occludin, JAM-A and ZO-1) 
x Reduced expressions of IL-
6, IL-17, IL-23, and TNF-α) 
x More significant 
improvement in all above 
parameters with B. subtilis + 
5ASA relative to B. subtilis 
alone 
(392) 
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x Under pre-treatment 
conditions, B. coagulans 
compared to B. subtilis 
reduced mRNA expression 
and secretion of IL-8 
x Under post-treatment 
condition only B. subtilis 
suppressed IL-8 secretion 
but could not sustain 
inhibition beyond 3 hours 
(394) 
 = NK- Natural killer, GALT- gut-associated lymphoid tissue, MIP- macrophage inflammatory protein  
 
Immune modulation is one of the vital probiotic attributes that reflects its probiotic 
effectiveness. There are efforts by some researchers to delineate whether the intact spores can 
elicit immune response or if their germination into vegetative cells (VCs) is necessary for the 
probiotic effect.  The metabolically inactive nature of spore raises scepticism on their capacity 
to induce immune response. Bacillus spores however may  elicit better immune response in 
GIT compared to their VCs  (382). Multiple studies have ascertained the ability of ingested 
spores to germinate in the murine GIT (382, 395, 396). Nonetheless, the immune response 
that followed was not confirmed to be triggered solely by the germinated VCs and was partly 
hypothesized to be mediated by the ability of intact spores being able to trigger immune 
response by themselves (395). Anti-spore specific serum IgG and faecal secretory IgA titres 
showed significant immune response following immunization of mice with B. subtilis PY79 
spores but not with VCs dosing, compared to a naive control group (382). The research 
supported the conjecture that Bacillus spores are immunogenic and can generate specific local 
and systemic immune responses and hence cannot be considered simply as nutrient food. 
Ciprandi et al. (397) however, had previously reported the inability of Bacillus subtilis spores 
to influence the immune response, while its vegetative forms enhanced mitogenic-induced T 
cell proliferation in their study. Different doses and/or strains of B. subtilis used in different 
studies could have contributed to such discrepancies.  
 
Spinosa et al. (398) concluded that the claimed probiotic effect should be attributed to 
spores or alternatively, to vegetative growth outside the intestine. No detectable levels of VCs 
of B. subtilis in intestinal samples of mice were found while, both VCs and spores were 
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cell proliferation in germinal centres of Peyer’s patches (PP) following oral administration of 
Bacillus spores. Stimulation of antigen presenting cells and T lymphocytes was also reported 
to be markedly enhanced. In the same study, B. subtilis spores, as autoclaved and germination 
defective forms, failed to stimulate expression of Toll-like receptor (TLR) genes for TLR2 
and TLR4 compared to VCs and intact spores. Hence, they, concluded that spores must 
interact with another TLR, and by this mechanism help activate innate immunity. Leser et al. 
(399) concluded that a substantial level of growing VCs in GIT is not a pre-requisite for mode 
of action of Bacillus probiotics. In their experiment 70-90% of the dietary-supplemented 
Bacillus spores germinated in the proximal part of pig GIT, but only limited outgrowth of the 
VC population was noted. To get a clear understanding of this issue, stringent investigation is 
needed that compares the immune efficacy between heat-killed spores, intact spores and the 
vegetative forms for a specific Bacillus species/strains.  
 
Nevertheless, substantial numbers of animal studies have demonstrated the ability of 
orally administered spores to stimulate immune system and exert beneficial effects. Some of 
the important studies affirming the immunomodulatory efficacy of oral administration of 
spores have been highlighted in Table 2.3. Following oral inoculation, a small proportion of 
B. subtilis spores have been shown to penetrate Peyer’s patches and interact with gut-
associated lymphoid tissue (GALT), and to accumulate and germinate in macrophages (381, 
382, 395). The small size of spores probably mediates their uptake by M-cells that are 
localized in the mucosal epithelium of the intestine, and are then further disseminated to the 
Peyer’s patches where they interact with dendritic cells (DCs), macrophages or B cells before 
their transportation to efferent lymph nodes (381). In another study (384), oral administration 
of B. subtilis PB6 to TNBS-induced colitic rats successfully lowered the plasma pro-
inflammatory cytokines (TNF-D, IL-1E, Il-6 and IFN-J), while, increasing anti-inflammatory 
cytokines (IL-10 and TGF-E). Similar excellent immunomodulatory and anti-inflammatory 
effects were confirmed for B. subtilis R179 strain in DSS-induced colitic mice while, also 
reducing mucosal colonic damage and inducing microbial modulations (393).  
 
Spores can therefore directly interact with the immune system to prevent activation of 
inflammatory mediators (384, 387, 392). A recent in-vitro study by Azimirad et al. (394), 
indicated that the time of spore probiotic treatment could substantially influence its 
immunomodulatory capacity. In their study, differential immune regulating effects on 
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induced HT-29 cells were confirmed. B. coagulans spores, compared with B. subtilis spores 
under pre-treatment conditions in LPS-induced HT-29 cells, significantly reduced the 
secretion and mRNA expression of pro-inflammatory IL-8. While, under post treatment 
conditions, only B. subtilis, but not B. coagulans, spores suppressed IL-8 secretion although 
they could not sustain IL-8 inhibition beyond 3 hours. The observations of this study 
suggested that the immunomodulatory effect may be species/strain specific and time of 
probiotic treatment to achieve the intended benefits by managing inflammation is a vital 
factor. It can thus be concluded that application of B. coagulans spores before or during the 
onset of inflammation, will be pragmatic in mitigating an altered immune response in IBD to 
achieve optimum benefits.  
 
Apart from immunomodulatory capacity, the ability of PB to modulate dysbiosis is an 
essential attribute for its application in IBD. The antimicrobials produced by probiotics are 
one of the prime mechanisms that function by inhibiting pathogens in the GIT to create a 
healthy microbial balance. In this context, Bacillus species produce a large number of 
antimicrobials, including bacteriocins and bacteriocins-like inhibitory substances (e.g. 
Subtilin and Coagulin) as well as antibiotics (e.g. Surfactin, Iturins A, C. D. E, and Bacilysin) 
(359, 400). B. clausii strains in Enterogermina® have been demonstrated to produce 
antimicrobials with activity against Gram-positive bacteria (401). B. coagulans produces 
coagulin, a heat-stable, protease-sensitive bacteriocins-like substance with activity against 
Gram-positive bacteria (402). Lactosporin is an antimicrobial produced by B. coagulans 
ATCC 7050 that has been demonstrated as effective and safe with potential application for the 
control of bacterial vaginosis (403).  Furthermore, B. coagulans is capable and industrially 
used as an efficient producer of lactic acid (404) that is known to inhibit pathogenic growth. 
The anti-cancer property of surfactin from Bacillus species have been affirmed to kill human 
breast cancer MCF-7 cells through induction of apoptosis (379, 405). While, secretion of 
these anti-microbial compounds would require the Bacillus to be in their vegetative state, the 
spore administration has also been reported to be able to induce microbial changes in the gut.  
 
A single oral inoculum of 1×109  Bacillus subtilis spores, given 24 h prior to chickens 
being challenged with  Salmonella enterica Serotype  Enteritidis and Clostridium perfringens, 
was reported to be sufficient to suppress colonisation and persistence of both pathogens (406). 
Another study demonstrated the efficacy of oral administration of B. subtilis var. natto spores 
in influencing faecal microflora (especially Bacteroides and Lactobacillus species) in mice 
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were fed with an egg white diet but, stabilized when diet was supplemented with B. subtilis 
var. natto spores. However, in the case of a casein diet supplemented with spores, the 
numbers of Lactobacillus spp. remained unchanged, while, the numbers of Bacteroidaceae 
increased. Administration of intact spores of B. subtilis natto in mice in their study was found 
to increase faecal Bacteroidaceae and Lactobacillus counts unlike autoclaved spores. B. 
Subtilis spores have been successfully demonstrated to suppress enteropathogenic infection of 
Citrobacter rodentium in a mouse model of traveller’s diarrhoea (407).  Consumption of B. 
coagulans and subsequent use of prebiotics was  demonstrated in vitro by Nyangale et al. 
(408) in elevating populations of beneficial genres of bacteria (Faecalibacterium prausnitzii, 
Clostridium lituseburense) as well as SCFA production in faecal microbiota of elderly 
volunteers. In a following placebo-controlled study by the same group of workers, 
consumption of B. coagulans spores (GBI-30, 6086) increased numbers of beneficial F. 
prausnitzii, in humans (409). Oral administration of skim milk supplemented with B. 
coagulans B37 and B. pumilus B9 spores in rats decreased faecal coliform counts with 
concurrent increase in Lactobacillus count in treatment group (410). Feeding of B. coagulans 
lilac-01, along with soya pulp, to cholic acid fed rats, suppressed the production of secondary 
bile acid, improved gut permeability and lowered the bactericidal effect of bile acid which in 
turn supported the growth of beneficial intestinal microbiota (411). In a recent study, B. 
subtilis administration in mice ameliorated dextran sulphate sodium (DSS)-induced dysbiosis 
and gut inflammation by balancing beneficial and harmful bacteria (393). B. subtilis-treated 
colitis mice group showed specific reduction of Acinetobacter spp., Ruminococcus spp., 
Clostridium spp. and Veillonella spp. with increase in members of Bifidobacterium spp. 
Lactobacillus spp. and Butyricicoccus spp. In addition to a beneficial effect on the gut 
microbiota and an immune-regulating effect in DSS-induced mice, significant ability of these 
spores in increasing total SCFA levels and preventing the damage to intestinal barrier function 
was also recorded. Increased expression of mucin, recovery of intestinal permeability and 
increased expression of TJ proteins were shown to contribute to the recovery of DSS-induced 
injury by the administration of B. subtilis spores (393). The application of B. clausii spores in 
the treatment and prevention of gut barrier impairment has also been largely supported in the 
last years (412).    
 
The excellent ability of Bacillus spores to induce immunomodulation, coupled with its 
efficacy to balance gut flora and restore gut barrier, has heralded its application as probiotic in 
human application in managing GIT inflammatory conditions. Some of the prominent clinical 
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gastrointestinal conditions are listed in Table 2.4. Oral administration of Bacillus spores has 
been affirmed to reduce abdominal pain and bloating in patients with irritable bowel 
syndrome (IBS) and improve the quality of life (48, 413, 414). Bacillus spores, as an adjuvant 
with antibiotics, has proved effective in reducing the incidence of antibiotic-associated 
diarrhoea and adverse effects related to antibiotics (415, 416). Apart from showing benefits in 
gut-related conditions, Bacillus spores have been determined to be effective in alleviating 
other inflammatory conditions in clinical studies of rheumatoid arthritis (417), respiratory 
infections (46) and generalized gingivitis (418). In a recent diet-controlled study, B. 
coagulans in combination with casein protein significantly enhanced post-exercise recovery 
while decreasing muscle soreness in recreationally trained males (419). In addition to 
conferring direct benefits over host health, natural food products involving Bacillus strains are 
now being explored in the management of systemic clinical syndromes including metabolic 
disorders (378, 420, 421). Therefore, the excellent ability of Bacillus spores to modulate gut 
health makes it an attractive choice as functional probiotic ingredient in pharmaceuticals and 
foods targeted for improved gut health and resolving gut inflammation in IBD.  
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B. coagulans  
GBI-30, 6086 –  





n= 39 elderly, 28 
days crossover 
with 21 days 
washout period 
x Increased 




x Peripheral blood 
mononuclear cells 
(PBMCs) showed 
increase in IL-10 
after stimulation with 
LPS 
(409) 
B. coagulans  
GBI-30, 6086 –  





n= 44 adults 
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x Reduced abdominal 
pain and bloating 
significantly 
(414) 
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flatulence) 
B. coagulans  







n= 28 adults, 
10 days 
x Decreased mean 
values for duration of 
diarrhoea 
x Reduced frequency 
of defecation 
x Lowered abdominal 
pain 
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n= 141 children 
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intensity 
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n= 244 babies 
aged <36 weeks 
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x No significant 
difference in the 
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onset sepsis (LOS)  
x Full feeds achieved 
significantly faster in 
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2.3.2.4 Bacillus coagulans spores as potential probiotic 
ingredient in IBD 
 
Many Bacillus species have been examined for their probiotic efficacy including 
Bacillus subtilis, Bacillus coagulans, Bacillus clausii, Bacillus cereus, and Bacillus 
licheniformis (359). Bacillus probiotics are commercially available for use in humans as 
dietary supplements, in animals as growth promoters and in aquaculture for promoting growth 
and disease-resistance (355). So far commercial products of Bacillus composing functional 
foods are not popular in the nutraceutical market because the debate over probiotic versus 
pathogen tag of Bacillus species is still persisting. Hence, it is important to accurately 
examine the phenotypic and genotypic characteristics of selective Bacillus species and their 
substantiation with those having generally regarded as safe (GRAS) status, to reach a 
consensus over the same (425). Nevertheless, apart from the application of probiotic Bacillus 
spores in dietary supplements, they are also being incorporated and explored into variety of 
food matrices to provide added health benefits beyond basic nutrition (43, 377, 378, 426).  
 
Bacillus coagulans (earlier known as Lactobacillus sporogenes) spores are one of the 
most promising spore probiotic candidates and now being incorporated as probiotics 
ingredient owing to the excellent stability during processing and storage of the products and 
gastric transit (47, 64). The exceptional stability of B. coagulans spores at manufacturing and 
storage temperatures as well as its ability to survive the gastric acidity validates the 
incorporation of Bacillus spores as probiotic ingredient in foods and pharmaceuticals (43, 44). 
In addition to their distinguished stability, ease of incorporation in to food as well as approved 
GRAS status of certain B. coagulans spores has encouraged its utilization in the number of 
commercial food products (64). Moreover, germination of these spores does not occur in 
many foods and hence the product quality is not affected because of their inactive metabolism 
(427). The capacity of B. coagulans to withstand high temperature processes, and maintain 
viability and stability relative to commonly applied probiotic strains, is being explored to 
formulate functional foods that require baking and boiling.  
 
Some commercial probiotic formulations containing B. coagulans spores are currently 
available as ingredients including B. coagulans MTCC 5856 (marketed as LactoSpore®) and 
B. coagulans GBI-30, 6086 (marketed as GanedenBC30) and are characterized by the ability 
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retaining its probiotic properties (43, 426). Fares et al. (426) formulated pasta incorporating B. 
coagulans GBI-30 spores utilising wheat flour rich in polyphenols. The probiotic strain in 
their study, maintained viability during the pasta-making and cooking processes (~ 9.0 Log 
CFU/ 100g). In another study (43), B. coagulans MTCC 5856 spores were found to be stable 
in variety of food products during processing and storage with different nutritional profiles. 
The PB was showcased to be stable during baking and storage at frozen conditions of banana 
muffins (92% viability) and waffles (86% viability) for up to 12 months. Moreover, over 95% 
spore viability was recorded in chocolate fudge frosting, hot fudge toppings, peanut butter, 
strawberry preserve and vegetable oil at room temperature up to 12 months. An 87% viability 
was exhibited by B. coagulans spores after brewing with coffee at 90 °C for 2 minutes and 
retained 66% viability even after maintaining temperature at 77 °C for 4.0 h (43). 
Furthermore, probiotic spores were found to be stable in apple juice up to 6 months at 
refrigerated condition and concentrated glucose syrup at 4±3 and 25 ± 2 °C for up to 24 
months. The stability of B. coagulans spores, in range of food products with different 
nutritional profiles and variation in the proximate parameters such as protein, fat, 
carbohydrate and moisture, validate its suitability to be incorporated as stable probiotic in 
variety of functional food matrices. Moreover, its stability in food during room temperature 
storage can be employed to incorporate these probiotic agents in novel foods that are shelf-
stable without refrigeration, which is unlikely to be achieved in the case of commonly applied 
LAB. In light of the above reports, it can be stated that B. coagulans spores are an excellent 
choice for stable application in functional foods as probiotic ingredients. 
 
Despite a number of drugs containing B. coagulans having entered the global 
pharmaceutical market, and already proven their clinical efficacy (428), the pharmacological 
effects and the underlying mechanisms of action of this spore probiotic still remains poorly 
understood. While, excellent immunomodulatory capacity of B. coagulans have been 
demonstrated in most studies (47, 386, 409, 429, 430), a few studies have also reported its 
antiviral activity (431, 432) and capacity to modulate gut microbiota (433). B. coagulans 
spores have been shown to be of benefit in number of GIT conditions including antibiotic-
associated diarrhoea (434, 435), IBS (48, 413, 414, 436) and flatulence (422) in humans. B. 
coagulans has been shown, not only to improve the indices (386), but also reduce the 
recurrence of C. difficile-induced colitis in mice (433). The study confirmed beneficial effects 
of B. coagulans spores in improving stool consistency and attenuating colonic histological 
and biochemical indices in mice. B. coagulans has also been shown to be effective in 
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mechanisms of functional efficacy are still not completely understood, and efforts are 
underway to evaluate their mechanistic action. Although B. coagulans have been shown to be 
effective in ameliorating experimental colitis in mice and reducing diarrhoea and related GIT 
conditions in humans, its efficacy in human IBD patients has not been explored. This may be 
due to lack of understanding of its mechanistic action. More in-depth in-vivo and in-vitro 
studies focussing on delineating the mechanistic functionality of B. coagulans spores are 
required to encourage increased therapeutic application in human IBD and in functional foods 
aimed at maintaining gut health.  
 
2.3.3 Synbiotics in IBD  
 
2.3.3.1 Synergistic and complementary synbiotics 
 
The combination of prebiotic and prebiotic is termed as synbiotic (24) and the 
encompassing synergy between the two components is thought to augment the beneficial 
effects on the host. The synbiotic concept was first introduced in 1995 and two types of 
synbiotic approaches exist (55):  
x Complementary synbiotic, whereby the probiotic is chosen based on the specific 
desired effects on the host, and the prebiotic is independently chosen to selectively 
increase the level of the beneficial microbiota. The prebiotic may promote the growth 
and activity of the probiotic, but only indirectly as a part of its target range. 
x Synergetic synbiotic, whereby the probiotic is chosen based on specific beneficial 
effects on the hosts, but the prebiotic is chosen to specifically stimulate the growth and 
activity of the selected probiotic. Here, the prebiotic is selected to have higher affinity 
for the probiotic and is chosen to improve its survival and growth in the host. It may 
also increase the level of beneficial host gastrointestinal microbiota, but the primary 
target is the ingested probiotic.  
 
Kolida and Gibson (55) explained that, in a complementary approach, each component 
is administered in a such a dose as to elicit a desirable effect via the vehicle of the 
administration which usually requires a relatively high prebiotic dose to mediate an effect on 
the gut microbiota. In contrast, with synergistic approach, synbiotic is perceived as a single 
product, whereby the primary role of the prebiotic is to enable the survival and activity of the 
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smaller dose of the probiotic is required (55). Moreover, while both approaches may directly 
or indirectly comply with the synbiotic definition, it is the synergistic approach that has most 
pragmatic implications on the host health. While, the current synergistic synbiotic approach 
limits the role of prebiotic in influencing the growth and activity of the probiotic, the direct 
prebiotic beneficial effects on the gut microbiota, as well as on the colonic barrier integrity 
and immune regulation, also need to be accounted for. In the synergistic approach, the 
potential to elicit the combined beneficial effects of probiotic or prebiotic owing to synergism 
is greater. This includes increased SCFA production and thus results in mediating potentiated 
gut health benefits to the host.  
 
2.3.3.2 Synergistic synbiotic – a two-point approach for 
resolving the inflammatory loop in IBD 
 
Synergistic synbiotic seems to be pragmatic two-point approach in mitigating 
inflammatory loop in IBD. Each bioactive component could function independently (e.g. 
direct immune-regulating effects, effects on colonic barrier integrity or influence on the gut 
microbiota profile) while also mediating the synergistic benefits by interaction of probiotic 
with prebiotic to stimulate increased SCFA production via fermentation thus, targeting the 
overall inflammatory circuit of IBD. For synbiotics, a small number of preliminary in vivo 
studies have been performed relative to that of probiotic and prebiotic and the focus has been 
almost exclusively on disease management. Experimental studies on DSS-induced colitis rat 
model testing the pre-treatment effect of administration of Bifidobacterium infantis DSM 
15158 or B. infantis DSM 15159, alone or in combination with Synergy1 (Oligofructose and 
inulin), observed marked attenuation in disease markers (i.e. bacterial translocation, SCFA, 
cytokine production, myeloperoxidase and malonaldehyde) (439). While, all treatments 
induced a significant improvement in the DAI, an additive effect was noted when Synergy1 
with B. infantis DSM 15159 was used. It was noted to mediate an increase in succinate 
production and subsequently suppress neutrophil infiltration. This was a well-defined study 
comparing the effect of each of the synbiotic constituents alone and in combination and 
investigating the effect of strain specifically against the disease. In another study, 
Lactobacillus paracasei, combined with FOS and arabinogalactan, also showed curative 
effects on DSS–mice model of colitis (440). L. plantarum 299 with oat fibre however had no 
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There are not many well-designed clinical studies investigating the effect of synbiotics 
for IBD. In a small randomised, placebo-controlled study (442) with 18 active UC patients, 
administration of synbiotic Synergy 1 (combination of B. longum and with OFI) twice daily 
for a month, produced statistically significant reduction in β-defensin, TNF-α and IL-1α, more 
epithelial regeneration of on mucosal biopsies, and a trend towards a reduction in  
endoscopically visualized levels of inflammation. The study also followed a rational 
procedure for probiotic selection that would complement the selected prebiotic as well as 
target the disease. A selection of 19 Bifidobacterium isolates were screened for their 
suitability as probiotic in terms of aerotolerance, acid tolerance, bile-salt tolerance, adhesion 
to epithelial cells and their ability to survive freeze drying and long-term storage. The ability 
to metabolise FOS as an energy source, as well as the ability of the strains to reduce 
production of pro-inflammatory cytokines in the HT-29 epithelial cells, was also determined. 
In another large open label study with 120 active UC patients (86), significant improvement in 
their health-related quality of life after receiving synbiotic combination after 4 weeks was 
reported, but a similar effect was not observed for patients receiving either probiotic B. 
longum or prebiotic psyllium. Moreover, only synbiotic patients were noted to have reduced 
CRP levels. In a separate study, administration of synbiotic combination of B. breve and GOS 
administration in 41 UC patients resulted in improvement in endoscopically defined levels of 
inflammation in the synbiotic group when examined after 1 year of follow-up. The synbiotics 
significantly reduced the faecal counts of Bacteroidaceae and faecal pH (443). A multicentre, 
randomized, placebo-controlled study (444) investigating the efficacy of synbiotic 2000 (1010 
CFU of each Pediacoccus pentoseceus, Leuconostoc mesenteroides, L. casei spp. paracasei 
F1977:1, Lactobacillus plantarum 2362, and 2.5 g each of β-glucans, resistant starch, inulin, 
and pectin; Medipharm) in 30 ileal resection CD patients over a period of 24 months failed to 
note an effect on remission or disease scores compared to placebo.  
 
Research in IBD using synbiotic treatments is therefore still in its infancy. It is 
evident, however, that when an informed selection of the probiotic and complementary 
prebiotic that can function synergistically is made, pilot studies have been successful. 
Although, the considerable efficacy of synbiotic therapy in imparting benefits is appreciated, 
the challenge however, is to determine the best combination of probiotic and prebiotic in 
order to achieve maximum benefits. Geier et al. proposed that the first attempt should be 
focussed on combining probiotics and prebiotics that have demonstrated individual benefits to 
determine if there are any synergistic effects, followed by a more structured approach that 
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probiotic and select the prebiotic accordingly (445). The selection of prebiotic and probiotic 
for an effective synbiotic should not only focus on the ability of prebiotic to support the 
growth and survival of probiotic, but also the ability of a probiotic to efficiently metabolise 
the selected prebiotic to generate increased SCFA that are known to be beneficial in resolving 




The current IBD paradigm focusses on the tripartite pathophysiological circuit that 
encompasses three distinct inflammatory features: the altered colonic epithelial integrity, 
dysregulated immune response and dysbiotic microbiota. The limited efficacy of current 
therapies focusing primarily on immunosuppression highlights the need for an alternative and 
relatively pragmatic approach that would target to resolve the overall inflammatory loop of 
IBD. With the considerable efficacy in targeting these distinct features of the IBD 
inflammatory circuit, prebiotic DF and probiotic are developing as preventive and corrective 
treatment therapies for IBD. Synbiotic, which is a two-point approach carrying probiotic and 
prebiotic components, seems to be a pragmatic approach owing to the potentiated synergetic 
benefits in mitigating inflammation IBD. To achieve augmented benefits from the synbiotic 
therapy, the best combination of probiotic and prebiotic is vital. Thus, there exists a 
possibility to develop synbiotic combinations of compatible probiotics and prebiotics with 
established health benefits and those that function synergistically to augment the synergistic 
health outcomes. A careful selection of DF with biochemical complexity and probiotic with 
marked stability and functionality to generate potent synbiotic preparation is a key to achieve 
its augmented benefits.  On this premise, synergistic combination of B. coagulans spore (with 
its marked immunomodulatory capacity coupled with its ability to metabolise wide variety of 
plant cell wall material), with prebiotic dietary fibre supplements such as whole-plant 
prebiotic sugar cane fibre and green banana flour with complex dietary fibre content and other 
intrinsic bioactive components could be explored to prevent or mitigate the onset of 
inflammatory circuit in IBD. The information could then be applied to develop novel 
functional shelf stable synbiotic food products targeted for preventing and treating gut 
inflammation in humans. Pre-clinical analyses using suitable in-vitro and in-vivo models to 
determine the efficacies of the synbiotic ingredients in improving the outcomes of the 
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Chapter 3 
Probiotic Bacillus coagulans MTCC 5856 
spores exhibit excellent in-vitro functional 
efficacy in simulated gastric survival, mucosal 
adhesion and immunomodulation 
 
3.1 Abstract  
 
Probiotic Bacillus coagulans MTCC 5856 spores were evaluated in-vitro for their 
ability to survive simulated digestion, adhesion to colonic cells and immunomodulatory 
properties. The spores showed significant survival (92 %) during simulated digestion and 
substantially adhered to the human colonic cells HT-29 (86%) and LS174T (81%) compared 
with the L. acidophilus control. They exerted marked immunomodulatory effects in HT-29 
cells, by reducing IL-8 and increasing IL-10 secretion. Moreover, they exhibited pronounced 
differential immunomodulatory efficacy in response to lipopolysaccharide-induced 
inflammation under co-treatment (increased IL-10 and reduced IL-8) relative to post-
treatment (reduced IL-8 with no IL-10 detection) in HT-29 cells. This observation supports 
the application of B. coagulans spores before or during the onset of inflammation to maximise 
the probiotic benefits in treating inflammatory bowel conditions. The results provide 
additional evidence of the probiotic properties of B. coagulans spores and support their 




Probiotics are “live microorganisms which, when administered in adequate amounts, 
confer various health benefits to the host” (29). Many studies have confirmed the therapeutic 
efficacy of probiotic bacteria when applied to the treatment of several gastrointestinal diseases 
including diarrhoea, IBD and irritable bowel syndrome (30). In addition to their therapeutic 
application as pharmaceuticals, probiotics are being incorporated into a variety of food 
products. Currently, refrigerated dairy products that carry probiotic bacteria such as 
Lactobacillus and Bifidobacterium strains are the major delivery forms for probiotic food. The 
colder storage temperatures and rich growth media assist retention of viability for these 
conventionally used probiotic strains (353). However, certain strains of Lactobacillus and 
Bifidobacterium are reported to be sensitive to gastric transit (38). Despite the commercial 
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due to lactose intolerance, cholesterol content and the trend towards vegetarianism. Therefore, 
alternative and convenient probiotic food formats that can be stored without refrigeration, 
such as breakfast cereals, pasta, cookies and snack bars are being explored (447).  
 
In this context, the ability of Bacillus species to form spores has been explored to 
develop shelf-stable food products. Spores confers higher resistance to technological stresses 
encountered during industrial production and storage processes and greater protection against 
hostile gastric and intestinal conditions (pH, bile and digestive enzyme) (63, 65, 66). These 
characteristics are not displayed by all species of Lactobacillus (448). They enable more 
sustained viability and thus support their incorporation into wider and novel delivery formats.  
 
B. coagulans is a spore-forming, Gram-positive, facultative anaerobic, L (+) lactic acid 
producing organism. Products supplemented with B. coagulans can be stored at room 
temperature without any deleterious effect on their viability (43). It is one of the most 
promising spore-forming probiotics, is currently available as a dietary supplement worldwide 
(449), and has been reported to support healthy digestive (48, 422) and immune functions 
(432, 450). However, the behaviour and mechanisms of immunomodulatory and anti-
inflammatory influence of B. coagulans within the gastrointestinal tract is unclear. The 
functional attributes that reflect probiotic efficacy include viability and persistence in the 
gastrointestinal tract, adhesion to intestinal cells, antagonism against bacterial infection, and 
immunomodulation. Few studies have been performed to affirm the immunomodulatory 
ability of probiotic bacteria belonging to Bacillus species, particularly in their spore form. 
Such information is necessary for appreciating the probiotic effect of B. coagulans spores for 
its application in human health. This study aimed to investigate the gastric stability, adhesion 
capacity, cytotoxic effect and immune modulatory attributes of B. coagulans spores in-vitro 
not previously explored.  
 
3.3 Materials and methods 
 
3.3.1 Bacterial strains and media 
 
LactoSpore® containing probiotic strain Bacillus coagulans MTCC 5856 (6 × 109 
spores/gm) was supplied by Sabinsa Corporation (Australia) and was produced by Sami Labs 
Limited (Bangalore, India). LactoSpore® is a commercial proprietary preparation of Sabinsa 
Corporation, USA which contains spores of B. coagulans MTCC 5856 (bearing internal 
reference number SBC37-01). Bacillus coagulans MTCC 5856 has generally regarded as safe 
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MTCC 5856 (B. coagulans) spores at a dose of 2 × 109 CFU/gm were tested in this study. 
Viable spore counts in the test sample were determined at the end of adhesion and gastric 
survival assays following the method of Majeed, et al. (43) with slight modification. Briefly, 
the test sample was incubated in a water bath for 30 min at 75 °C, followed by immediate 
cooling to below 45 °C. This suspension was further serially diluted in sterile saline and the 
viable count was enumerated by spread plating on glucose yeast extract agar (GYEA), 
following their incubation at 37 °C for 48 to 72 h. GYEA was prepared in-house following 
the recipe from USPC monograph (451).  Each analysis was performed in triplicate and the 
average mean of spore viable counts are expressed in Log CFU/mL. Lactobacillus 
acidophilus DDS-1 was obtained in freeze-dried, free-flowing lyophilized form from UAS 
labs, Madison, WI, USA. It was used as the control for in-vitro simulated digestion and 
adhesion assays against B. coagulans spores at a dose of 2 × 109 CFU/mL. Viable counts of L. 
acidophilus were determined by spread plating on De Man Rogosa (MRS) agar supplemented 
with 0.05% (w/v) L-cysteine following their incubation at 37 °C for 48 h. The overall 
experimental design of the in-vitro screening of B. coagulans spores is illustrated in Figure 
3.1.  
 
Figure 3.1. The in-vitro experimental design for probiotic screening of B. coagulans spores. The capacity of 
B. coagulans spores to survive the simulated digestion, adhere to human colonic HT-29 and LS174T cells and 
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3.3.2 Tolerance of B. coagulans spores to the in-vitro simulated 
digestion 
 
A static in-vitro digestion model was designed to assess the survivability of B. 
coagulans spores. The methods of Belguesmia et al. (452) and Chávarri et al. (453) were 
followed for the preparation of simulated saliva juice and simulated gastric and intestinal 
juices respectively (Figure 3.1). This model reproduced the temperature, pH, bile salts 
concentration and enzymes involved in the digestion processes, mimicking the physiological 
conditions in the gastrointestinal environment. L. acidophilus strain was used as control. 
Bacterial spores and L. acidophilus cells were exposed to the gastric stressors, as they would 
be encountered during gastric transit starting from the mouth, followed by stomach, and then 
the intestine. One mL of respective bacterial aliquots (at a concentration of 2 × 109 CFU/mL) 
were separately added to 9 mL of simulated salivary juice (SSJ) [KCL (0.894 g/L), NaH2PO4 
(0.887 g/L), Na2SO4 (0.568 g/L), NaHCO3 (1.680 g/L), CO (NH2)2 (0.198 g/L)] and adjusted 
to pH 6.8 ± 0.2. This was then incubated at 37 °C for 5 min to represent buccal conditions. 
Following the treatment, the B. coagulans spores and the L. acidophilus cells were pelleted by 
centrifugation at 3,000 rpm for 5 min to recover spores for the gastric step. After discarding 
the supernatant, the pellets (containing spores and cells) were resuspended in 9 mL of 
simulated gastric juice (SGJ), consisting of 9 g/L of sodium chloride containing 0.3% pepsin 
(Sigma-Aldrich) and adjusted to pH 3.0 ± 0.2. SGJ was then incubated at 37 °C for 2 h. At the 
end of the incubation step, the SGJ was then neutralised immediately by washing with 
phosphate buffered saline (PBS) at pH 7. This was then followed by centrifugation at 3,000 
rpm for 5 min to recover B. coagulans spores and the L. acidophilus for the subsequent 
intestinal step. The pellet was resuspended in 9 mL of simulated intestinal juice (SIJ) which 
was prepared by dissolving bile salts (0.3% w/v; Sigma-Aldrich) and pancreatin (0.1% w/v; 
Sigma-Aldrich) in sterile saline solution (0.5% w/v) and adjusting to pH 7.5. SIJ carrying 
spores/bacteria was then further incubated at 37 °C for 2 h. After each step of the simulated 
digestion process, samples were collected and evaluated for the spore and L. acidophilus cell 
survival according to the enumeration method described in Section 3.3.1 for the respective 
bacteria. The analysis was performed in triplicate for three independent experiments. Average 
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3.3.3 Cell lines and culture 
 
Human mucus secreting colonic adenocarcinoma cell lines, HT-29 (ATCC£ HTB-38¥) 
and LS174T (ATCC£ CL-188¥) cells were purchased from American Type Culture 
Collection (ATCC), Virginia, USA. HT-29 cells were cultured in McCoy’s 5a (Modified) 
Medium (Gibco, Life Technologies, Melbourne, Australia) while, LS174T were cultured in 
RPMI 1640 Medium (Gibco, Life Technologies) supplemented with 10% foetal bovine serum 
(Gibco, Life Technologies), L-glutamine (300 mg/L), and 100 U/mL each of penicillin and 
streptomycin.  Cells were cultured in 5% CO2 at 95% relative humidity and 37 °C. Media was 
replaced every 2-3 days. When cells reach 80% confluence, the spent medium was completely 
removed 24 h prior to each experiment and the cells were fed with fresh medium lacking 
antibiotics to avoid damage to bacterial cells. At confluence, the cells were detached from the 
flasks using trypsin-EDTA solution and reseeded at a density of approximately 5 × 104 
cells/mL in 24-well cell culture plates (Greiner CELLSTAR®, Sigma-Aldrich) for the 
adhesion, cytotoxicity and cytokine experiments.  
 
3.3.4 Adhesion capacity 
 
B. coagulans spores and L. acidophilus cells (control) were suspended in the respective 
cell culture media devoid of serum and antibiotics at a concentration of 2 × 109 CFU/mL in 24 
well plate. Respective bacterial suspensions (1 mL) were then applied separately on confluent 
monolayers of HT-29 and LS174T cell lines in 24-well plate following the method of 
Belguesmia et al. (452). After 4 h of incubation at 37 °C with 5% CO2, monolayers were 
washed three times with sterile Hank’s Balanced Salt Solution (HBSS) to remove non-
adherent bacteria. 1 mL saline was then added to each well, the cells were scraped, and the 
liquid aspirated into a pipette to loosen the cells from the plate surface. These suspensions 
containing adherent bacteria were then serially diluted and plated onto their respective agars 
to determine the viable count number as described previously in Section 3.3.1. The 
experiment was performed in triplicates for three independent experiments and results are 
expressed as percentage of adhesion.  
 
3.3.5 Cell viability and cytotoxicity assays 
 
The effect of B. coagulans spores on the cell viability after 8 hours of incubation was 
assessed using the level of Lactate Dehydrogenase (LDH) in culture supernatants and the 
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MTCC 5856 spores were suspended in respective cell culture media devoid of serum and 
antibiotics at a concentration of 2 × 109 CFU/mL. Spore suspensions (1 mL) were then 
applied to each well on confluent monolayers of HT-29 and LS174T cells in each in 24-well 
plate. The plates were then incubated for 8 h at 37 °C with 5% CO2. HT-29 and LS174T cells 
untreated with B. coagulans spores served as controls. The samples were then collected for 
two different assays as follows:  
 
LDH assay: At the end of incubation, culture supernatants from both HT-29 and 
LS174T cells were collected for testing LDH activity. Cytotoxicity of spore treatment was 
investigated using the LDH in-vitro toxicology assay kit (Sigma-Aldrich, NSW, Australia), 
according to the manufacturer’s instructions. Briefly, respective cell culture supernatants were 
centrifuged at 250 × g for 4 min. An aliquot containing 50 μL of cleared supernatant was 
mixed with 100 μL of a solution containing LDH assay substrate, LDH dye and LDH cofactor 
and incubated at room temperature for 20 min before the reaction was terminated by the 
addition of 15 μL of 1 N hydrochloric acid. Absorbance at 490 nm was measured 
spectrophotometrically using a plate reader (Spectra Max M2 microplate reader, Sunnyvale, 
CA). Each sample was measured in triplicate. 
 
Trypan blue dye exclusion test: At the end of incubation, the cells were scrapped and 
aspirated with a pipette to loosen the treated and untreated cells from the plate surface and the 
cell suspensions were collected. Cell viability was examined using Trypan blue (Sigma) 
exclusion stain with a Countess™ automated cell counter (Invitrogen™, Thermo Fisher 
Scientific). This analysis was performed in triplicate for three independent experiments. 
 
3.3.6 Cytokine analysis 
 
The efficacy of B. coagulans spores to exert immunomodulatory effects on two 
cytokines, pro-inflammatory IL-8 and anti-inflammatory IL-10 was determined on HT-29 
cells challenged by lipopolysaccharide (LPS) treatment following the previous method (455). 
HT-29 cells were selected for the cytokine assay as the enterocyte-like HT-29 cells represent 
a well characterised model to study the enterocyte immune response to bacterial infections 
(456, 457). B. coagulans spores (2 × 109 CFU/mL) were suspended in McCoy’s 5a medium 
devoid of serum and antibiotics. HT-29 confluent monolayers in 24 well plate were subjected 
to probiotic/LPS treatment under the following conditions: (a) Non-LPS-stimulated cells and 
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added to the wells with confluent HT-29 cell monolayers and incubated at 37 qC, 5 % CO2 for 
8 h. (b) Co-treatment with B. coagulans of LPS-stimulated cells: 1 mL (2 × 109 CFU/mL) of 
probiotic spore suspension and 100 ng/mL LPS (Lipopolysaccharides from Escherichia coli 
K-235; Sigma Aldrich) were simultaneously added to the cell monolayer and incubated at 37 
°C, 5% CO2 for 8 h,  (c) Post-treatment with B. coagulans of LPS-stimulated: cells were 
initially challenged with LPS and incubated for 4 h at 37°C, 5% CO2. Following this, 
probiotic spore suspension (2 × 109 CFU/mL) was then applied to the LPS-treated cells and 
incubated for additional 4 h 37 °C, 5% CO2. HT-29 cells without probiotic treatment or LPS 
served as a negative control, while LPS – HT-29 cells incubated with LPS for 8 h served as a 
positive control. All the supernatants were collected and centrifuged at 1,000 × g for 15 min at 
4 °C.  The supernatant was then collected and used for quantification of IL-8 and IL-10 
cytokines using a Bio-Plex Pro™ Human Cytokine Assay (Bio-Rad®, Australia). The 
cytokine results were read on a Bio-Plex® 200 Systems instrument. The experiments were 
performed in triplicate and the results are reported as mean ± standard errors.  
 
3.3.7 Statistical analysis 
 
GraphPad Prism software (Version 7.0) was used to carry out all the data analyses. 
Statistical differences between groups were measured using Two-way analysis of variance 
(ANOVA) and Tukey’s post-hoc procedure for simulated digestion while, for the 
immunomodulation assay One-way ANOVA was applied.  T-test was applied to the adhesion 
assay results to determine statistical differences between B. coagulans and the L. acidophilus 
control and to the cytotoxicity assay results to confirm statistical differences between the 
control cell lines and B. coagulans. Data are expressed as mean ± standard errors (SEM) 
calculated over three independent experiments performed in triplicate. The differences 
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3.4 Results 
 
3.4.1 Survival of B. coagulans spores following in-vitro simulated 
digestion  
 
Figure 3.2. Survival of B. coagulans spores in the three compartments of digestion simulated in-vitro: 
mouth, stomach and intestine. L. acidophilus served as a control. The samples were taken at each step and the 
viable number of CFU/mL was evaluated on respective agar medium. Values are means ± SEM of three replicate 
experiments. The values of groups designated with different letters are significantly different at 240 min. For 
overall survival of individual bacteria * P < 0.05 compared to 0 min (***P < 0.001, ****P < 0.0001). 
 
The survival curves of B. coagulans spores and of the L. acidophilus control during 
simulated digestion process are shown in Figure 3.2.  B. coagulans MTCC 5856 spores used 
in this study showed very high resistance to the conditions encountered during the simulated 
digestion process which was approximately five times greater compared with that of the L. 
acidophilus control. No significant decrease in B. coagulans spore count was detected after 
exposure to simulated mouth (SSJ) (P > 0.99) and gastric (SGJ) (P = 0.06) conditions 
compared with that of the initial inoculum. There was a significant decrease in L. acidophilus 
count at the end of gastric phase (P = 0.0003), with further significant drop (P < 0.0001) in 
the cell count of 1.03 Log CFU/mL at the end of intestinal phase. For B. coagulans spores, a 
drop of only 0.64 Log in viable spore count (P < 0.0001) was recorded at end in the simulated 
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L. acidophilus












































A.                                                                        B.                                                                        
compared with 87.6 % survival for L. acidophilus, following 240 min of simulated digestion 
demonstrates its substantial resistance to digestion. 
 
3.4.2 Adhesion capacity of B. coagulans spores 
 
 
Figure 3.3 Adhesion of B. coagulans to (A) HT-29 and (B) LS174T cells after 4 h. Percentage of adherent B. 
coagulans spores and L. acidophilus (control) to HT-29 and LS174T cells after contact with bacterial 
suspensions for 4 h and washing of the cell monolayer. Values are means ± SEM of three replicate experiments.  
 
 
The adhesion assay confirmed the ability of B. coagulans spores to adhere to both 
human colonic cells. Although, the L. acidophilus control showed significantly (P = 0.03) 
higher adhesion capacity to HT-29 cells (91.7 ±1.3%), B. coagulans spores also showed 
excellent adhesion at a rate of 85.8 ± 2.1 % (Figure 3.3A).  In LS174T cells (Figure 3.3B) 
however, both L. acidophilus and B. coagulans showed statistically equal adhesion capacity 
(P = 0.14) with adhesion rates of 85.07 ± 2.4 % and 80.6 ± 1.45% respectively. No significant 
difference (P = 0.08) was observed between the cells lines for their capacity to support 
adhesion of B. coagulans spores.  
 
3.4.3 Cytotoxicity analysis 
 
The cytotoxic effect of spores on the HT-29 and LS174T cells was investigated after 8 h 
treatment with B. coagulans spores (Figure 3.4). The results showed that B. coagulans MTCC 
5856 spores had no negative influence on viability of either of the colonic cell lines. An 
increase of extracellular LDH, which is indicative of cell membrane damage and cell death, 
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A.                                                                        B.                                                                        
C.                                                                        D. 
compared with their controls (p = 0.86, 0.67 respectively). Moreover, the treatment with 
spores was found not to result in any loss of viability in HT-29 cells (Figure 3.4C) or LS174T 
cells (Figure 3.4D) as confirmed by the Trypan blue exclusion test. These results show that B. 
coagulans MTCC 5856 spores do not exert cytotoxic effects on human colonic cell lines.  
 
 
Figure 3.4. Effect of B. coagulans spores on cell viability. Percentage LDH release in (A) HT29 cells and (B) 
LS174T cells. Viability of cells represented as mean % LDH release after 8h treatment with B. coagulans spores 
versus untreated control. Viability of (C) HT-29 and (D) LS174T cells as determined by Trypan blue exclusion 
test and is represented as % viable cells remaining after 8 h treatment with B. coagulans spores versus untreated 
control. Values are means ± SEM of three replicate experiments. 
 
 
3.4.4 Immunomodulatory effect of B. coagulans spores 
 
The cytokine assay showed that B. coagulans MTCC 5856 spores led to significant 
reduction in the release of the pro-inflammatory cytokine IL-8 under normal and LPS-
stimulated conditions (Figure 3.5A). HT-29 cells treated with B. coagulans MTCC 5856 
markedly reduced (P < 0.0001) the IL-8 levels (114.8 pg/mL) compared with that secreted by 
HT-29 (negative control) cells (584.73 pg/ml). LPS stimulation of HT-29 cells induced 












































































A. IL-8 B. IL-10 
comparison with the positive control of LPS-stimulated cells, IL-8 secretion was substantially 
reduced by the co-treatment (69.24 pg/mL), and the post-treatment (641.1 pg/mL) of HT-29 
cells with B. coagulans MTCC 5856 spores. A significant reduction (P= 0.0018) of IL-8 
secretion was noted under the co-treatment condition relative to the post-treatment condition. 
 
B. coagulans MTCC 5856 displayed significant ability to induce anti-inflammatory IL-
10 secretion by HT-29 cells in both inflamed and non-inflamed conditions (Figure 3.5B). In 
comparison with the control HT-29 cells (3.11 pg/mL), the IL-10 secretion was markedly 
elevated (P < 0.0001) in non-inflamed cells treated with B. coagulans MTCC 5856 spores 
(19.88 pg/mL). Co-treatment of LPS-stimulated cells with B. coagulans MTCC 5856 (23.90 
pg/mL) significantly (P < 0.0001) induced the secretion of higher concentrations of IL-10 
compared to that secreted by non-treated LPS-inflamed cells (3.23 pg/mL). No IL-10 
secretion was detected under the post-treatment condition (P = 0.08). Co-treatment with B. 
coagulans MTCC 5856 was noted to be more efficient compared with the post-treatment in 




Figure 3.5. Quantification of cytokines secreted in the supernatant of HT-29 cells after treatment with B. 
coagulans spores by Bioplex assay. Cytokines (A) IL-8, (B) IL-10 released by HT-29 cells (negative control), 
B. coagulans treated HT-29 cells, LPS-stimulated HT-29 cells (positive control) and LPS-stimulated and treated 
with probiotic B. coagulans (co- and post-treatment). Data are represented as mean ± SEM of three repeated 
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3.5 Discussion 
 
This study has investigated four functional aspects of the probiotic potential of B. 
coagulans MTCC 5856 spores: 1) ability to survive during simulated digestion, 2) adhesion 
capacity, 3) safety and 4) immunomodulation activity (Figure 3.1). The in-vitro simulated 
digestion process was conducted to mimic the conditions of the human gastrointestinal tract 
after food ingestion by sequentially exposing B. coagulans spores and L. acidophilus (control) 
to acidic pH, bile salts and digestive enzymes encountered during gastric transit. B. coagulans 
spores showed excellent resistance to the simulated digestion process with a higher survival 
rate (~ 92.4%) at the end of 240 min digestion compared with the L. acidophilus control (~ 
87.6%). The resistance to the digestion process is crucial since it ensures that the ingested 
dose actually reaches the gastrointestinal tract (GIT) where it essentially exerts its effects 
(458). The spores showed significant resistance to acidity (pH 3) and pepsin during their 
exposure in the gastric step of the in-vitro digestion. These results are in agreement with a 
recent study that reported good survival of B. coagulans MTCC 5856 in highly acidic pH (pH 
1.5 and 3) conditions and growth on MRS agar containing bile salts (0.3% and 0.5% w/v) 
(44). In addition to the affect of acidity and bile, our study also demonstrated the excellent 
resistance of B. coagulans spores to digestive enzymes. The exposure to digestive enzymes 
(pepsin and pancreatin) did not affect the spores, which remained at relatively the same 
population at the end of the simulated digestion process. These results collectively indicate 
that a relatively large proportion of ingested B. coagulans MTCC 5856 spores can reach the 
colon unaffected by gastric acids, bile salts and enzymes.  
 
A reduction in spore count of less than one logarithmic unit was observed in the 
intestinal phase of the simulation digestion (Figure 3.2). The possible reason for this small 
loss of spore count could be due to the acid activation of spore germination and subsequent 
killing of vegetative cells by simulated gastric and later by simulated intestinal fluids (459, 
460). A hardened coating primarily consisting of integument proteins, is thought to protect the 
spores against gastric acid and bile salts (45).  However, not all Bacillus spores are equally 
resistant to gastric transit (459). Hence, it is imperative to determine the survival of spores 
during digestion prior to their application as a probiotic. The greater than 90% survival of B. 
coagulans MTCC 5856 spores in our study emphasises the probiotic potential of this strain. 
Application of spores of B. coagulans MTCC 5856 for probiotic uses provides practical 
advantages as their incorporation does not require encapsulation or consideration of protection 
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the hostile GIT environment. Thus, B. coagulans spores can serve in formulating shelf-stable 
foods as well as products that require higher temperature processing.  
 
Adhesion to intestinal epithelium is a preferred attribute for a probiotic, as it will ensure, 
at least transiently, the colonisation of mucosal surfaces, thus facilitating interference with 
pathogen binding and bacterial interaction with immune cells (461). Similar to L. acidophilus 
control, B. coagulans spores used in our study displayed remarkable adhesiveness towards 
both human mucus-secreting colonic cells HT-29 (82.92%) and LS174T (79.34%). These 
results correlate with that of Ripamonti et al. (462) who reported adhesion of B. coagulans 
(isolated from calf faeces) to INT407 cell monolayers via microscopy following Giemsa 
staining. The substantial adhesion capacity of B. coagulans MTCC 5856 spores to intestinal 
cells therefore demonstrates that B. coagulans MTCC 5856 has an attribute that can enhance 
probiotic efficacy.  
 
Different studies have highlighted the suitability of human intestinal cell-lines including 
HT-29, LS174T and Caco-2 cells, as in-vitro model systems for examining the colonisation 
capacity of bacterial strains to colonic cells (452, 463-465). HT-29 and LS174T cells have 
been reported to possess substantial mucin secretion ability with significant Muc2 mRNA 
expression compared with Caco-2 cells (466). Previous studies showed preferred bacterial 
adhesion to Muc2 expressing cells suggesting a vital role of mucin in bacterial adhesion (467, 
468). The significant adhesion of B. coagulans spores to colonic HT-29 and LS174T cells in 
our study could be attributed to high adhesiveness to mucins present in the native human 
mucus layer covering the whole cell surface. 
 
It is known that both the spore coat and the exosporium main protein component of the 
spore have prominent roles in spore adhesion (469, 470). Probiotic spores of B. cereus were 
found to be more adhesive to Caco-2 cells and mucin than the vegetative cells by Sánchez et 
al. (471) suggesting the role of spore-coat–associated proteins in the interaction with intestinal 
epithelial cells within the gastrointestinal tract. Hydrophobicity of spores, as well as spore 
surface appendages, may also play an important role in their adhesive capacity to the 
hydrophilic intestinal mucus layer (472, 473). B. coagulans spores have been reported to 
exhibit 54% of hydrophobicity by Mohkam et al. (474). Therefore, high adhesion rates 
observed in our study for B. coagulans MTCC5856 spores could involve the role of several 
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Bacterial adhesion reflects the potential colonisation by the probiotic in the GIT that 
may prevent pathogens from attaching via specific obstruction on cell receptors or steric 
interactions (475). B. coagulans spores have been proven effective in reducing colonisation of 
vancomycin-resistant Enterococcus in mice (476). Recently, B. coagulans MTCC 5856 have 
been shown to exhibit inhibitory potential against E. coli (477, 478). Thus, the adhesion of B. 
coagulans to intestinal cells could be an important contribution in mediating competitive 
pathogen exclusion and communication with the immune system. In this study, the 
remarkable ability of B. coagulans MTCC 5856 to adhere to human colonic cells further 
corroborates their probiotic potential. 
 
The safety of probiotic strains is given prime importance in the selection process of 
probiotics (479). In terms of safety of Bacillus species, with the exception of Bacillus 
anthracis and Bacillus cereus, Bacillus species are not generally considered pathogenic (480). 
However, if the spores are to be consumed in large quantities on a regular basis as probiotics, 
a safety evaluation for each strain is vital. In our study, B. coagulans MTCC 5856 spores at a 
dose of 2 × 109 CFU/ mL, did not exhibit cytotoxic effects on HT-29 or LS174T cells as 
confirmed by LDH assay and Trypan blue exclusion test. This strengthens the probiotic 
grading of B. coagulans MTCC 5856 for food applications. The FDA (2015) confirmed a 
“generally regarded as safe” (GRAS) status to B. coagulans MTCC 5856 (LactoSpore®) spore 
preparation, further supporting its application in a variety of foods. Moreover, double-blind, 
placebo-controlled studies verified that 30-day and 90-day supplementation of B. coagulans 
MTCC 5856 (at a dose of 2 × 109 CFU spores/day) was evaluated as safe and tolerable in 
healthy human participants with supplementation (69) and improved quality of life and 
decreased irritable bowel syndrome symptoms (68).  
 
Immunomodulatory capacity of probiotic bacteria is also one of the vital criteria for the 
assessment of a probiotic strain (481) and for grading its probiotic potential. Even though the 
metabolically inactive nature of spores raises questions on their immunomodulatory capacity, 
a number of studies have demonstrated the ability of Bacillus spores to interact with immune 
system (381, 459, 482). Previous reports have also shown that the spore itself is 
immunomodulatory and can trigger a number of cellular immune responses in the GIT. This is 
consistent with the observations of our study (409, 482-484). B. coagulans MTCC 5856, 
which was in their spore form in our study, exhibited substantial immunomodulatory efficacy 
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Low-grade inflammation, loss of microbial diversity and outgrowth of Gram-negative 
bacteria are the hallmarks of inflammatory gastro-intestinal disorders including IBD. 
Therefore, the efficacy of B. coagulans MTCC 5856 spores to moderate the inflammatory 
reaction of the LPS–stimulated HT-29 cells was investigated in this study by evaluating the 
secretion of key anti-inflammatory and pro-inflammatory cytokines. Binding of LPS to Toll-
like receptors (TLRs), induces intestinal inflammation via generation and overproduction of 
pro-inflammatory cytokines including IL-8 (485, 486). In our study, under the influence of 
LPS, pro-inflammatory cytokine IL-8 was found to be secreted at comparatively higher levels 
but markedly reduced by co- and post-treatment with B. coagulans spores. The increase in 
pro-inflammatory cytokine secretion induced by LPS could be attributed to T cell 
proliferation and activation triggered by LPS-TLR interaction (487). The reduction in the pro-
inflammatory cytokine, IL-8 after treatment with B. coagulans MTCC 5856, could potentially 
be elicited by their ability to interfere with IL-8/LPS signalling and subsequently hindering 
the molecular events leading to T cell activation.  
 
Interestingly, B. coagulans MTCC 5856 spores in our study, showed a significant 
reduction in IL-8 secretion under both co- and post-treatment conditions (Figure 3.5A), with 
more effective reduction under co-treatment of LPS-stimulated HT-29 cells. This differential 
effect could possibly be attributed to different signalling pathways induced by probiotic 
spores under different inflammatory conditions. Moreover, this differential 
immunomodulatory effect highlights the prudence of time of application of probiotic spores to 
contain the colonic inflammation. This is in agreement with Azimirad et al. (394), who 
observed a similar differential immunomodulatory effect in a different strain of B. coagulans 
with substantial reduction in secretion and mRNA expression of IL-8 under pre-treatment, but 
no effect was observed under post-treatment in LPS-induced HT-29 cells. The inhibition of 
pro-inflammatory response by probiotic Bacillus spores could be associated with their 
capacity to interfere with IL-8/LPS signalling. Interaction of some spore-coat ligands of 
Bacillus probiotics with immune receptors (e.g. TLRs) on the intestinal epithelial cells could 
promote an immunomodulatory effect on the inflamed GIT in response to enteric pathogens 
or their antigens.  De Souza et al. (488) demonstrated the interaction of B. subtilis spores with 
TLRs. Interaction of Bacillus spore-specific ligands with TLRs during co-treatment condition 
may hinder the LPS-TLRs interaction, that in turn modulate the induction of IL-8 in intestinal 
cells. Such an antagonistic response, that benefits by inhibiting the bacterial-induced 
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The remarkable immunomodulatory capacity of B. coagulans MTCC 5856 spores is 
indicated by its ability to induce increased secretion of anti-inflammatory cytokine IL-10 
while concurrently reducing the secretion of pro-inflammatory cytokine IL-8. Our results 
appear to be consistent with findings of several other investigators who also reported 
considerable reduction in IL-8 (452, 455, 490-492) and increase in IL-10 (452, 455) using 
probiotic treatment under in-vitro conditions with different strains of lactic acid bacteria 
(LAB) and different inflammatory agents. Previously, LPS-stimulated peripheral blood 
mononuclear cells PBMCs from healthy elderly patients showed a 0.2 ng/mL increase in IL-
10 28 days after consumption of B. coagulans (409). In another study, cell wall and 
metabolite fractions of B. coagulans spores inhibited the polymorphonuclear leukocyte 
migration towards IL-8 as well as enhanced mitogen-induced expression of IL-10 in-vitro. 
Both components of B. coagulans modulated the production of cytokines in that they 
inhibited IL-2 production, improved production of IL-6, IL-4 and IL-10 (429).   
 
Under the non-LPS condition, that represented a normal physiological condition, B. 
coagulans spores showed remarkable efficacy to increase IL-10 secretion compared to the 
basal level of control HT-29 cells. In addition, contact with B. coagulans spores reduced the 
secretion of IL-8 relative to that of control HT-29 cells, making them excellent probiotic 
candidates for application in gut immune homeostasis. B. coagulans spores were found to be 
effective in elevating the secretion of anti-inflammatory IL-10 in colonocytes under non-
inflamed and LPS-stimulated-co-treated conditions in this study. However, under post-
treatment conditions, where LPS previously inflamed HT-29 cells, IL-10 levels could not be 
detected. The inability of B. coagulans spores to induce IL-10 secretion in already inflamed 
cells (post-treatment) strongly suggests that the time of probiotic treatment could influence 
the cytokine regulation in HT-29 cells. This is in agreement with Duary et al. (455) who also 
observed inability of Lactobacillus strains to increase the IL-10 gene expression levels during 
post-treatment of previously LPS-stimulated HT-29 cells relative to pre- and co-treatments. 
This effect was arbitrarily attributed to the involvement in different signal pathways triggered 
by the same probiotic strain under different conditions (455). Based on the analysis of IL-8 
and IL-10 secretions on the differently exerted immunomodulatory benefits under different 
(inflamed and non-inflamed) conditions in our study, the application of B. coagulans spores 
before (as prophylactic agent) or during (therapeutic) the onset of inflammation is critical in 
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To gain clear understanding of different immune signalling pathways utilised by 
probiotic spores under different conditions (co-, post-inflamed and non-inflamed) more in-
vitro and in-vivo studies focussing on these aspects are required. Pronounced ability of B. 
coagulans MTCC 5856 spores to induce the immunomodulatory effects showcased in our 




It can be concluded from this study, that Bacillus coagulans MTCC 5856 spores 
demonstrated considerable probiotic potential. These spores showed substantial ability to 
survive the gastric and intestinal conditions and then to colonize the intestine, at least 
temporarily, by effectively adhering to the colonic epithelium in equal comparison with a 
probiotic L. acidophilus control. Moreover, the spores did not show any cytotoxic effects 
towards HT-29 or LS174T cells but, did exhibit excellent immunomodulatory efficacy by 
downregulating the secretion of the key pro-inflammatory cytokine IL-8 while concomitantly 
promoting increased secretion of anti-inflammatory cytokine IL-10. More importantly, these 
spores also exhibited remarkable immunomodulatory and anti-inflammatory potential in HT-
29 cells under co-treatment relative to post-treatment condition highlighting the value of early 
application of these probiotic spores in order to suppress inflammation. By virtue of 
possessing these prophylactic and therapeutic attributes, applications of these probiotic spores 
can be explored as potential therapeutic agents in the management of intestinal inflammatory 
disorders including IBD and as adjunct therapeutics through their immune-stimulatory action. 
The excellent survival during digestion, adhesion capacity and marked immunomodulatory 
efficacy of B. coagulans MTCC 5856 spores coupled with their known ability to survive the 
food processing techniques and storage supports their incorporation into novel shelf stable 





    69 
Chapter 4 
Synbiotic supplementation containing whole 
plant sugar cane fibre and probiotic spores 
potentiates protective synergistic effects in 





IBD are chronic inflammatory disorders with increasing global incidence. Synbiotic 
supplementation, which is a two-point remediation approach carrying probiotic and prebiotic 
components for mitigating inflammation in IBD, is thought to be a pragmatic tactic owing to 
possible synergistic outcomes. In this study, the impacts of dietary supplementation with 
probiotic Bacillus coagulans MTCC5856 spores (B. coagulans) and prebiotic whole plant 
sugar cane fibre (PSCF) was assessed using a murine model of IBD. Eight-week-old C57BL/6 
mice were fed a normal chow diet supplemented with either B. coagulans, PSCF or its 
synbiotic combination. After seven days of supplementation, colitis was induced with dextran 
sulfate sodium (DSS) in drinking water for seven days during the continuation of the 
supplemented diets. Synbiotic supplementation ameliorated disease activity index and 
histological score (−72%, 7.38, respectively), more effectively than either B. coagulans 
(−47%, 10.1) and PSCF (−53%, 13.0) alone. Synbiotic supplementation also significantly (p < 
0.0001) prevented the expression of tight junction proteins and modulated the altered serum 
IL-1E (−40%), IL-10 (+26%), and C-reactive protein (CRP) (−39%) levels. Synbiotic 
supplementation also raised the short-chain fatty acids (SCFAs) profile more extensively 
compared to the unsupplemented DSS-control. The synbiotic health outcome effect of the 
probiotic and prebiotic combinations may be associated with a synergistic interaction of the 
direct immune-regulating efficacy of the components, their ability to protect epithelial 
integrity, stimulation of probiotic spores by the prebiotic fibre, and/or with stimulation of 
greater levels of fermentation of fibres releasing SCFAs that mediate the reduction in colonic 
inflammation. The model findings suggest synbiotic supplementation should be tested in 
clinical trials and supports the justification for their incorporation into functional foods for 





    70 
4.2 Introduction 
 
IBD are chronic relapsing inflammatory conditions of the gastrointestinal tract that 
comprises two partially overlapping but distinct clinical entities: Crohn’s disease (CD) that 
involves the entire gastrointestinal tract and ulcerative colitis (UC) that is limited to colon and 
rectum (19). The incidence of CD and UC has become of global significance with 
accelerating occurrence in countries adopting a Westernised diet, highlighting the urgent need 
for research into prevention and management of this complex and costly pathology (493). 
Although the aetiology and pathogenesis of IBD still remains unclear, emerging evidence 
supports the involvement of a recurrent tripartite pathophysiological circuit encompassing gut 
dysbiosis, altered epithelial integrity and defective immune responses (19). Therefore, 
preventive and therapeutic approaches that impede or break this inflammatory circuit by 
resolving one or more of the pathophysiological circuit components are highly sought.  
 
Dietary interventions are increasingly perceived as both preventive and corrective 
strategies to normalise the dysfunctional microbiome and altered immune and barrier integrity 
functions in IBD (27, 60, 494). In this regard, probiotic and prebiotic DFs are thought to be 
useful in mitigating the inflammatory circuit thereby resolving or preventing the severity of 
IBD. Both bioactive ingredients can improve inflammatory parameters in the gut by 
modifying microbiota composition and metabolites, regulating secretion of 
immunomodulatory molecules and protecting the colonic epithelial barrier (19, 26, 28, 495). 
Synbiotics, being a combination of probiotic and prebiotic ingredients that positively interact, 
potentially offer prophylactic and therapeutic effects that could function synergistically to 
confer health benefits to the host. 
 
DFs have shown particular promise in attenuating colonic inflammation in humans (11). 
The underlying mechanisms of effectiveness are likely to be multifactorial including dilution 
of toxins via stool bulking and the production of metabolites, particularly SCFAs, as a result 
of microbial fermentation. This later mechanism is frequently cited as a major potential 
contributor to the protective effect (23). DFs consist of edible plant parts that resist digestion 
and absorption in the small intestine and undergo complete or partial fermentation in the 
colon. It is an extremely complex group of substances, including non-starch polysaccharides, 
resistant starch, cellulose and hemicellulose, oligosaccharides, pectins, gums, lignin, and 
waxes (496). Much work on DFs, however, has examined various purified ingredients that 
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vegetables (52). Nevertheless, the biochemical complexity of DFs is recently being more 
appreciated to be a vital factor influencing the microbial complexity of the gut (52-54). This 
highlights the prudence of applications using prebiotic fibres that are representative of whole 
plant vegetables and fruits which retain fibre biochemical complexity compared to plant fibres 
that are extracted and potentially purified fractions. In this context, a process to produce sugar 
cane fibre by wet diffusion to remove most of the sucrose from cut cane, which is then dried 
and ground into a flour, has been reported to preserve the cell wall components (73, 74). Such 
fibre, in addition to retaining other intrinsic nutritional biologically active components, such 
as micronutrients and polyphenols, also contains both soluble and insoluble fibre benefits. 
These materials are comprised mainly of cell wall components and have a mix of rapid- and 
poor-fermentable fibres and at ratios that more accurately represent natural whole plant foods. 
In a recent study, such sugar cane fibre has been shown to impart positive effects on human 
gut microbiota in-vitro (75). The high content of total dietary fibre (87%) was accounted for 
with respect to its positive effect in this study. The relative similarity of the fibre components 
of this whole plant sugar cane fibre product to that in other whole plant foods, and the lack of 
any significant sugar or starch content, indicates its potential as a convenient supplementary 
dietary source of fibre. The availability of the cell wall components for fermentation in the 
lower bowel could alter microbial ecology and have a positive influence for IBD attenuation.  
 
Bacillus coagulans is a GRAS (generally recognised as safe) affirmed probiotic that can 
ferment a variety of plant substrates rich in insoluble cell wall components (64, 71) more 
efficiently than most members of gut microbiota (497, 498). It is also known to be capable of 
modulating the innate immune system by binding and interacting with the gastrointestinal 
tract epithelium (42, 432). This makes it a suitable probiotic for its synbiotic combination 
with prebiotic PSCF rich in insoluble cell wall fractions. Probiotic Bacillus coagulans MTCC 
(Microbial Type Culture Collection) 5856 spores, in addition to exhibiting excellent 
immunomodulatory effects in-vitro, have shown significant survival during simulated gastric 
transit with substantial adhesion capacity to human colonic epithelial cells (42). Based on the 
aforementioned findings, we hypothesised that preconditioning with probiotic B. coagulans 
MTCC 5856 spores, prebiotic PSCF or their synbiotic combination might repress the onset 
and/or severity of DSS-induced colitis in mice. This study therefore aimed to evaluate the 
efficacy of probiotic B. coagulans spores and PSCF, both alone and in combination, as a 
synbiotic dietary supplement to ameliorate the onset of experimental colitis in mice and 
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4.3 Materials and methods 
 
4.3.1 Probiotic Bacteria and Prebiotic Dietary Fibre 
 
LactoSpore® (Sabinsa Corporation, East Windsor, NJ, USA) containing the probiotic 
strain Bacillus coagulans MTCC 5856 (6 × 109 spores/gm) was produced by Sami Labs 
Limited (Bangalore, India) and supplied by Sabinsa Corporation (Australia). Kfibre, PSCF 




Fifty C57BL/6J (seven week old) mice of both sexes of average weight 19g were 
obtained from the University of Tasmania animal breeding facility and housed in a 
temperature-controlled environment with a 12-h day/night light cycle. Individual body 
weights were assessed daily including over an initial acclimation period of seven days. All 
mice had ad libitum access to radiation-sterilised rodent feed pellets (Barastoc Rat and 
Mouse, Ridley AgProducts, Australia, Appendix III) and autoclaved tap water for drinking 
during experiments. All animal experiments were approved by the Animal Ethics Committee 
of the University of Tasmania [ethics approval number: A0015840 (Appendix IV)] and 
conducted in accordance with the Australian Code of Practice for Care and Use of Animals 
for Scientific Purposes (8th Edition, 2013). All efforts were made to minimize animal 
suffering and to reduce the number of animals used.  
 
4.3.3 Study Design and Treatments 
 
Following one week of acclimation, mice at eight weeks of age were randomly allocated into 
the following five groups (n = 10 per group): (1) Healthy control (HC), (2) DSS-control, (3) 
probiotic B. coagulans MTCC 5856 spores (B. coagulans), (4) whole plant prebiotic sugar 
cane fibre (PSCF) supplement, and (5) synbiotic combined supplement (Synbiotic). Figure 4.1 
illustrates the experimental design of the mice feeding trial. Mice in HC and DSS-control 
groups received 4 g chow mash (standard chow pellet blended with water). The B. coagulans 
group received 4 g chow mash supplemented with probiotic B. coagulans MTCC 5856 spores 
(2 × 109 CFU/day/mouse). The PSCF group received 4g chow mash supplemented with 
Kfibre (200 mg/day/mouse). The Synbiotic treatment group mice received 4 g chow, each 
supplemented with B. coagulans MTCC 5856 spores (2 × 109 CFU/ day/mouse) and Kfibre 
(200 mg/day/mouse). The chow mash was prepared fresh each day. The mice were single-
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from prepared chow mash. The mice were fed these treatments for 14 days. Colitis was 
induced during the last seven days of the experimental period as previously described (499), 
by administering 2% dextran sulfate sodium (DSS; MP Biomedicals, colitis grade average 
molecular weight: 36,000–50,000) in the drinking water of all groups except for the non-
colitic DSS-control mice which received normal drinking water. Mice were sacrificed on day 
15 by CO2 asphyxiation.  
 
 
Figure 4.1. Experimental design of in-vivo feeding trial to analyse prophylactic efficacy of B. coagulans 
spores, PSCF and Synbiotic in DSS-induced acute colitis mice model. C57BL/6J mice (n = 10 per group) 
were fed chow supplemented with either  B. coagulans spores, PSCF or their Synbiotic combination for 14 days. 
Colitis was induced by administration of 2% DSS in drinking water for last seven days.  
 
4.3.4 Clinical Scoring and Histological Analysis 
 
A Disease Activity Index (DAI) was determined daily in all mice by scoring for body 
weight, hemocult reactivity or presence of gross blood and stool consistency during the week 
of DSS induction, as detailed in (500). Stool was collected from individual mice and tested for 
the presence of blood using Hemoccult II slides (Beckman Coulter Inc., Brea, CA, USA). 
Briefly, the following parameters were used for calculation: (a) body weight loss (score 0 = 
0%, score 1 = 1–5%, score 2 = 6–10%, score 3 = 11–15%); (b) stool consistency (score 0 = 
normal, score 1 = soft but still formed, score 2 = very soft/loose stool, score 3 = 
diarrhoea/watery stool); and (c) blood in stool (score 0 = negative hemoccult, score 1 = 
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determined by combining the scores from these three categories. Body weights were 
measured for each animal throughout the experiments and expressed as percent weight loss to 
the weight immediately before DSS treatment. Faecal samples were collected and stored at 
−80 °C on day 14 for metabolite analysis. 
 
After sacrificing the mice, the colons were removed from the caecum to the anus 
following the method of Perera et al. (501). The length of the colons from the ileocaecal 
junction to the rectum were recorded. The colon was subsequently opened along its 
longitudinal axis and the luminal (mucosal) contents were removed using sterilised 200 PL 
pipette tips prior to weighing the organ. The length and weight of colon and spleen were 
documented. Spleen weight, colon length, and colon weight/body weight ratio were calculated 
as macroscopic markers of inflammation. The contents of colon (mucosal-associated) and 
caecum were collected by scraping with sterile pipette tips for metabolite profiling and stored 
at −80 °C. The colon was bisected longitudinally, and one half was prepared using the Swiss 
roll technique (502) whereas the remaining colonic tissue was dissected out, segregated into 
proximal colon (PC) and distal colon (DC) and snap-frozen for molecular analyses. Swiss 
rolls underwent 24 h fixation in 10% (v/v) neutral-buffered formalin. Swiss rolls were 
subsequently transferred to 70% ethanol prior to progressive dehydration, clearing and 
infiltration with HistoPrep paraffin wax (Fisher Scientific, Philadelphia, PA, USA). Swiss 
rolls were then embedded in wax and 5 μm sections were cut using a rotary microtome. 
Sections were stained with haematoxylin and eosin (H and E; HD Scientific, Sydney, 
Australia). Slides stained with H&E (n = 8 per group) graded blindly for the severity of tissue 
damage at distal and proximal regions as described previously (503, 504). Briefly, frequency 
of distribution of inflammation graded 0-3, crypt architectural distortion and ulceration graded 
0–5, tissue damage graded 0-3, inflammatory infiltrate graded 0–3, goblet cell loss graded 0–
3, mucosal thickening (oedema) were graded 0–3. All images were captured on a Leica 
DM500 microscope using a Leica ICC50 W camera (Leica Microsystems, Wetzlar, 
Germany).  
 
4.3.5 Alcian Blue Staining 
 
DSS-induced alterations in goblet cells, and subsequent depletion in synthesis and 
secretion of mucin glycoprotein (MUC2) was analysed by Alcian blue staining (ab150662 
Alcian Blue, pH 2.5 (Mucin Stain), Abcam, Australia) following the manufacturer’s 
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Alcian blue, resulting in staining of the acidic sulphated mucin blue and the counterstained 
with Safranin O, staining the nuclei red following the method previously described (505). 
Computer-assisted image analysis was performed with a Leica DM500 microscope (Leica 
Microsystems, Wetzlar, Germany) and Leica ICC50 W camera (Leica Microsystems, 
Wetzlar, Germany). The staining intensity (IOD) was assessed using Image Pro Plus 7.0 
(Media Cybernetics, Inc., Rockville, MD, USA) and used for comparison among groups 
(506).  
 
4.3.6 Immunohistochemical Detection of Tight Junction Proteins 
 
Immunohistochemical detection of epithelial tight junction (TJ) proteins was performed 
using a Rabbit specific HRP/DAB (ABC) Detection IHC kit (ab64261, Abcam, Australia) 
following the manufacturer’s instruction, and as previously described (507). Following 
removal of paraffin and rehydration, the tissue sections were exposed to heat-induced epitope 
retrieval (4 min at 121 °C) in a sodium citrate buffer, pH 6 in a Decloaking chamber (Biocare 
Medical, Pachico, CA, USA). After washing the slides in 1× phosphate buffered saline (PBS) 
2 mins/wash, endogenous peroxidase activity was blocked by incubating the slides with 
hydrogen peroxide block for 10 min. Next, the slides were washed with PBS (2 × 2 min) 
washes and protein block was then applied for 30 min at room temperature to block non-
specific background staining. Following PBS (1 × 2 min) wash, colon sections were then 
incubated with primary antibodies: anti-ZO-1 (NBP1-85046, Novus Biologicals, Australia, 
1:400); anti-occludin (NBP1-87402, Novus, 1:600); anti-claudin-1 (NBP1-77036, Novus, 1 
Pg/mL) overnight at 4 °C. Sections were then washed with PBS (4 × 2 min) and biotinylated 
goat anti-rabbit IgG was applied and incubated for 10 min at room temperature. At the end of 
incubation, the slides were washed in PBS (4 × 2 min) and streptavidin peroxidase was 
applied to the sections which were further incubated for 10 min at room temperature. The 
slides were then thoroughly rinsed with PBS (4 × 2 min) before sections were covered with 
3,3’-diaminobenzidine (DAB) chromogen and substrate solution for 10 min. Tissue sections 
were subsequently counterstained with hematoxylin, dehydrated, and mounted with DPX 
media (Sigma-Aldrich, Sydney, Australia). 
 
Computer-assisted image analysis was performed with a Leica DM500 microscope 
(Leica Microsystems, Wetzlar, Germany), Leica ICC50 W camera (Leica Microsystems, 
Wetzlar, Germany), and Image Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, MD, USA) 
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blindly assessed by choosing random five fields on each slide (n = 4/group). Barrier TJ 
protein expressions and staining intensity in colonic epithelium was expressed as the 
percentage expression of a respective TJ protein.  
 
4.3.7 Myeloperoxidase Activity 
 
The extent of the inflammatory cell invasion in the colon was examined by the 
assessment of myeloperoxidase (MPO) activity (499). Weighed and snap frozen PC and DC 
specimens (n = 3) were analysed for MPO activity using a Myeloperoxidase Activity Assay 
kit (ab105136, colorimetric, Abcam, Cambridge, UK). Briefly, frozen tissue after washing in 
cold PBS, was resuspended in MPO assay buffer, before homogenisation with 10–15 passes 
using an Omni TH tissue homogeniser (Omni International, US) with 10–15 passes. The 
homogenate was then centrifuged at 13,000× g (10 min) and the supernatant assayed for MPO 
activity as per the manufacturer’s instructions. The values are expressed as MPO activity 
units/g tissue.  
 
4.3.8 Tissue Explant Culture and Cytokine Measurements 
 
PC and DC colon tissues of mice from each group were cut, weighed and washed with 
cold PBS before transferring to a 12-well plate containing 0.5 mL/well of RPMI1640 culture 
medium (In Vitro Technologies Pty Ltd, Melbourne, Australia) supplemented with 10% v/v 
foetal calf serum (Gibco, Life Technologies Pty Ltd, Melbourne, Australia), penicillin (100 
mU/L), and streptomycin (100 mg/L) (Sigma-Aldrich Pty Ltd, Sydney, Australia) as 
described previously (501). After 24 h of incubation, supernatant was collected from each 
well, centrifuged and stored at −80 °C until further analysis. Serum was collected from blood 
drawn by cardiac puncture at the end of the study for cytokine analysis. 
 
The cytokine levels in colon tissue (n = 3) and serum (n = 3) were determined by 
immunoassay using a Bio-Plex Pro Mouse Cytokine 23-plex kit (Bio-Rad #M60009RDPD, 
Bio-Rad Laboratories, Gladesville, NSW, Australia) following the manufacturer’s instructions 
and concentrations analysed using a Bio-Plex 200 instrument (Bio-Rad) and Bioplex Manager 
software, version 6 (Bio-Rad Laboratories) respectively. For tissues, the cytokine levels were 
normalized by dividing the cytokine results (pg/mL) by the measured biopsy weight (g). The 
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4.3.9 iNOS Activity 
 
The expression of inducible isoforms of nitric oxide synthase (iNOS) in colonic 
epithelial cells, in response to pro-inflammatory stimuli (508), was determined in PC and DC 
specimens using a Nitric Oxide Synthase Activity Assay kit (ab211084, Fluorometric, 
Abcam, Cambridge, UK). Snap frozen proximal and distal colonic tissues (n = 3) were 
washed in in cold PBS, resuspended in 200 PL NOS assay buffer, then homogenised by 10–
15 passes of an Omni TH tissue homogeniser (Omni International, Tulsa, OK, USA). The 
homogenate was then centrifuged at 10,000× g (10 min, 4 qC) and the supernatant then 
underwent iNOS activity assay activity assay as per the manufacturer’s instructions. The 
amount of protein in the lysate was determined using DC Protein Assay (Bio-Rad 
Laboratories, Australia). The results are expressed as iNOS activity mU/mg. 
 
4.3.10 Serum C-Reactive Protein Analysis 
 
The levels of C-reactive protein (CRP) in serum from respective groups (n = 3 
samples/group) were analysed using Mouse C-Reactive Protein/CRP Quantikine Elisa kit 
(MCRP00, R and D Systems, Australia) following the manufacturer’s instructions. The results 
are expressed as Pg/mL. 
 
4.3.11 Volatile SCFA Analysis 
 
Volatile SCFA profiling of caecal, mucosal-associated and faecal samples were 
performed using GC-MS analysis by Dr. David J. Beale (CSIRO), Dr. Avinash V. Karpe 
(CSIRO) and Dr. Shakuntala V. Gondalia (Swinburne university of Technology). Data 
analysis and interpretation was performed by the PhD candidate. For the GC-MS analysis, 
caecal, mucosal-associated and faecal samples (n = 5 per group) were prepared and 
derivatized following the protocol developed by Furuhashi et al. (509) with some 
modifications. Briefly, caecal, mucosal-associated and faecal samples of 100–150 mg fresh 
weight (stored at −80 °C) were weighed to ± 0.1 mg accuracy. These samples were added to a 
sterile 1.5 mL bead-beating tube (NAVY Rino Lysis tubes, Next Advance, Troy, NY, USA). 
A 1.0 mL aliquot isobutanol (10% MilliQ water), (LC-MS grade, Merck, Castle Hill, NSW, 
Australia) was added to each sample, followed by two 30 s, 4000 rpm homogenization pulses 
sandwiched between a 20-s pause interval (Precellys Evolution Homogenizer, Bertin 
Instruments, Montigny-le-Bretonneux, France). The samples were subsequently centrifuged at 
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The supernatant (675 µL) was transferred to a clean round bottomed 2 mL centrifuge 
tube (Eppendorf South Pacific Pty. Ltd., Macquarie Park, NSW, Australia) and NaOH (20 
mM, 125 µL, Merck Pty Ltd., Castle Hill, NSW, Australia) and chloroform (400 µL, LC-MS 
grade, Merck Pty Ltd.,) were added. The samples were briefly vortexed and centrifuged at 
16,000·g for 3 min. The aqueous phase (upper layer, 400 µL) was transferred to a new clean 
round bottomed 2 mL centrifuge tube (Eppendorf South Pacific Pty. Ltd., Macquarie Park, 
NSW, Australia) containing a boiling chip (Sigma Aldrich, Castle Hill, NSW, Australia). 
Pyridine (100µL), isobutanol (80 µL) (both LC-MS grade, Sigma Aldrich, Castle Hill, NSW, 
Australia), and MilliQ (Millipore Corporation) water (70 µL) were added and the samples 
were subjected to gentle hand vortexing (swirling action) followed by the addition of 50 µL 
isobutyl chloroformate (98% purity, Sigma Aldrich, Castle Hill, NSW, Australia). The tube 
was kept opened to release any generated gases and was allowed to stand for about one 
minute. Hexane (150 µL, LC-MS grade, Sigma Aldrich, Castle Hill, NSW, Australia) was 
then added to each tube, which was then capped and vortexed prior to centrifugation at 
15,700× g for 4 min. The upper phase (100 µL) was subsequently transferred to clean gas 
chromatography (GC) autosampler vial fitted with silanized low volume glass inserts; 
Malathion (1 µL, equivalent to 2.5 µg dry weight) was added as an internal standard. 
 
The GC-MS analysis was performed on an Agilent 6890B GC oven coupled to a 5977B 
mass spectrometer (MS) detector (Agilent Technologies, Mulgrave, VIC, Australia) fitted 
with an MPS autosampler (Gerstel GmbH & Co.KG, Mülheim an der Ruhr, Germany). The 
GC oven was fitted with two 15 m HP‐5MS columns (0.25 mm ID and 0.25 µm film 
thickness; 19091S-431 UI (Ultra Inert), Agilent Technologies, VIC, Australia) coupled to 
each other through a purged ultimate union (PUU) for the use of post-run backflushing.  The 
sample (1.0 µL) was introduced via a multimode inlet (MMI) operated in split mode (1:20). 
The column was maintained at 40 °C for 5 min, followed by an increase to 250 °C at a rate of 
10 °C/min. This was followed by a second increment to 310 °C at a rate of 60 °C/min. The 
column was held at 310 °C for 1 min. The mass spectrometer was kept in extractor ion mode 
(EI mode) at 70 eV. The GC-MS ion source temperature and transfer line were kept at 250 °C 
and 280 °C, respectively. Detector voltage was kept at 1054 V. The MS detector was turned 
off for the first 3 min and, at 4.0–4.8 min and 12.5–13.2-min time windows until the excess 
derivatization reagent (chloroformate/hexane solvents) were eluted from the column. This 
ensured that the source filament was not saturated and damaged. The scan range was kept in 
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performed as described in a previous study (510) and qualitative identification of metabolites 
was performed according to the Metabolomics Standard Initiative (MSI) chemical analysis 
workgroup (511) using standard GC-MS reference metabolite libraries (NIST 17, and an in-
house CF-based metabolomics library developed after Smart et al. (512) with the use of 
Kovats retention indices based on a reference n-alkane standard (C8-C40 Alkanes Calibration 
Standard, Sigma-Aldrich, Castle Hill, NSW, Australia). 
 
4.3.12 Metabolic Phenotyping Analysis 
 
Untargeted metabolomic profiling of faecal samples (n = 5 per group) were performed 
using GC-MS analysis by Dr. David J. Beale (CSIRO), Dr. Avinash V. Karpe (CSIRO) and 
Dr. Shakuntala V. Gondalia (Swinburne university of Technology) as described previously 
(510). Data analysis and interpretation was performed by the PhD candidate. The samples 
were subjected to derivatisation to increase volatility before subjecting to GC-MS analysis. 
Briefly, the samples (n = 5, weight = 40 mg) were freeze-dried and suspended in 1 mL 
methanol (LC-MS grade, Merck, Castle Hill, NSW, Australia), supplemented with 10 µg/mL 
adonitol (Analytical grade, Sigma Aldrich, Castle Hill, NSW, Australia) as an internal 
standard in a sterile 2 mL bead-beating tube. The samples were homogenized by bead beating 
for 30 s and then centrifuged at 570 g/4 °C for 15 min. The supernatant (50 µL) was 
transferred to a fresh centrifuge tube (1.5 mL) and dried in a vacuum evaporator centrifuge 
(LabGear, Brisbane, QLD, Australia) at 35 °C. Methoxyamine-HCl (20 mg/mL in Pyridine) 
(both, Analytical grade, Sigma Aldrich, Castle Hill, NSW, Australia) was added (40 µL) and 
samples were incubated at 30 °C/ 1400 rpm (ThermoMixer C, Eppendorf, Hamburg, 
Germany) for 90 min. This was followed by sialylation with 70 µL BSTFA at 37 °C/1400 
rpm for 30 min. Pre-derivatized 13C-stearic acid (10 µg/mL) was added (1 µL) as the QA/QC 
internal standard. The mixture was briefly vortexed and centrifuged at 15,700 g for 5 min. 
The aliquot was transferred to vials for GC-MS analysis.  
 
The GC-MS analysis was performed on an Agilent 6890B gas chromatograph (GC) 
oven coupled to a 5977B mass spectrometer (MS) detector (Agilent Technologies, Mulgrave, 
VIC, Australia) fitted with an MPS autosampler (Gerstel GmbH & Co. KG, Deutschland, 
Germany). The GC-MS conditions were as stated previously (513-515). Data acquisition and 
spectral analysis were performed using the Qualitative Analysis software (Version B.08.00) of 
MassHunter Workstation (Agilent Technologies). Qualitative identification of the compounds 
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workgroup (511) using standard GC-MS reference metabolite libraries (NIST 17, Fiehn 
Metabolomics RTL Library (G166766A, Agilent Technologies) and the Golm database) and 
with the use of Kovats retention indices based on a reference n-alkane standard (C8-C40 
Alkanes Calibration Standard, Sigma-Aldrich, Castle Hill, NSW, Australia). For peak 
integration, a 5-point detection filtering (default settings) was set with a start threshold of 0.2 
and a stop threshold of 0.0 for 10 scans per sample. Procedural blanks (n = 7) were analysed 
randomly throughout the sequence batch. The obtained data was processed on the 
Quantitative Analysis software of MassHunter Workstation and exported as a Microsoft Excel 
output file for statistical analysis. 
 
GC-MS data imported to Microsoft Excel platform was normalized with respect to the 
internal standard adonitol (relative standard deviation = 11.257%). The normalized data was 
further log-transformed and auto-scaled (mean-centred) before statistical analysis (516). For 
analysis of metabolome variations, partial least squares-discriminant analysis (PLS-DA) and 
orthogonal (O) PLS-DA were used. Because PLS-DA can overfit data, we used 1000 
permutations to validate these models. The OPLS-DA was used to identify discrimination 
between metabolites contributing to classification as previously described (510).  
 
4.3.13 Statistical Analysis 
 
The samples in the study were randomly chosen for all the analysis order to avoid bias. 
All data are presented as means ± standard error of the mean (SEM). The statistical analysis 
was performed with the use of GraphPad Prism Software (Version 7.0, San Diego, CA, USA). 
The data were evaluated using One-way analysis of variance (ANOVA) followed by Tukey’s 
post-hoc test to determine statistical differences between the groups against the DSS-control 
samples. For the analysis of DAI and body weight changes during the experimental period, 
two-way ANOVA followed by Tukey’s post-hoc test was used, setting treatment and the time 
as the variables. A P-value of < 0.05 was considered significant. A MetaboAnalyst (Version 
4.0, Wishart Research Group, University of Alberta) data annotation approach and Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) Pathway Database were used for the 
hierarchical clustering analysis and significance analysis for microarrays (SAM), along with 
the variable importance of projection (VIP) (517). The SAM and VIP methods are well-
established statistical methods for metabolites and were used to select the most discriminant 
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4.4 Results 
 
4.4.1 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
DAI and macroscopic inflammatory markers in DSS-induced mice 
 
In comparison with the HC group, the administration of probiotic, prebiotic and 
synbiotic treatments in the respective groups did not show any sign of toxicity, which was 
evaluated by body weight increase, food intake and general appearance of the animals. DAI 
(cumulative score for body weight change, stool consistency and blood in faeces) was 
evaluated to determine the efficacy of the treatments in reducing the severity of disease 
symptoms in DSS-induced colitis (Figure 4.2A). Compared with the DSS-control group that 
showed severe colitis symptoms, pre-conditioning with B. coagulans, PSCF and Synbiotic 
combination significantly reduced the DAI levels as early as day 2 until the end of 
experiment. At the end of the experiment, DAI of DSS-control group was significantly high 
(5.8 ± 0.5) (p ≤ 0.0001) compared with that of B. coagulans (3.1 ± 0.6, 47% reduction), PSCF 
(2.7 ± 0.5, 53% reduction), and Synbiotic (1.6 ± 0.2, 72% reduction) groups. DSS induction in 
DSS-control mice resulted in significant body weight loss until the end of experiment (−4.13 
± 1.4%). In contrast, mice maintained healthy body weight gain with Bacillus (2.84 ± 1.7%), 
PSCF (4.25 ± 1.0%), and synbiotic (4.7 ± 0.7%) treatments. Interestingly, PSCF was the more 
effective in reducing DAI starting from day 2 of DSS and in remediating the body weight loss 
as early as day 5 owing mainly to the impact of improvement in stool consistency on the DAI 
rating. 
 
The macroscopic evaluation of colonic segments determined the beneficial effects of all 
three treatments used in our study as evidenced by substantial reduction in colon weight/body 
weight ratio (B. coagulans, 7.68 ± 0.2; PSCF, 9.24 ± 0.3 and Synbiotic, 8.74 ± 0.3 mg/g) 
compared with DSS-control group (11.12 ± 0.3 mg/gm) (Figure 4.2C). Intestinal 
inflammation is associated with spleen enlargement (499) and, as expected, relative spleen 
weight of untreated DSS-control mice was significantly higher (0.076 ± 0.004 g) than that of 
HC mice (0.054 ± 0.003 g). PSCF (0.062 ± 0.003 g) and Synbiotic (0.063 ± 0.002 g) were 
equally significantly effective in reducing spleen weight while B. coagulans did not affect the 
relative spleen weight (Figure 4.2D). In contrast to shortening of colon length (Figure 4.2E, 
4.2F) in the DSS-control group (6.75 ± 0.3 cm), Synbiotic treatment proved effective in 
reducing this outcome by maintaining the colon length (8.12 ± 0.2 cm), which was 
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considered to be directly correlated to the severity of colonic damage in this experimental 
model of colitis (499). 
 
Figure 4.2. Effect of B. coagulans spores, PSCF and Synbiotic in DSS-induced colitis model. (A) Disease 
Activity Index (DAI), (B) % body weight change. Statistical significance among groups evaluated by two-way 
repeated-measures analysis of variance (ANOVA) followed by Tukey’s test. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 vs. DSS-control group and data expressed as mean ± SEM (n =10 per group). 
Colon weight/body weight ratio (C), Spleen weight (D), Colon length (E) and Macroscopic appearance of colon 
(F). Data expressed as mean ± SEM (n =10 per group), evaluated by one-way ANOVA followed by Tukey’s 
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4.4.2 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
histological alterations in DSS-induced mice 
 
Histological (H&E staining) examination of proximal colon (PC) and distal colon (DC) 
sections of DSS-induced mice showed altered erosion or destruction of epithelium, crypt 
distortion, depletion of goblet cells, submucosal oedema, and inflammatory cellular 
infiltration in the colon, mostly affecting the DC (Figure 4.3A). HC mice showed no signs of 
histological colon damage with score 0, while DSS induction in DSS-control mice resulted in 
a cumulative damage score of 10.5 ± 0.8 for the PC and 17.4 ± 0.5 for the DC (Figure 4.3B). 
Supplementation of DSS-induced mice with B. coagulans, PSCF and Synbiotic treatments 
induced protection and repair of the colonic mucosa. B. coagulans and Synbiotic in 
particular, were more effective in retention of colonic structure, protection of crypts and 
goblet cells and rescued infiltration of inflammatory cells. This resulted in a significant 
overall reduction of cumulative histological score of DC (10.1 ± 1.2 and 7.38 ± 0.7 
respectively). Relatively, PSCF also provided partial significant protection with 
histological score of 13.0 ± 1.0. In contrast, PCSF had no effect in PC (10.1 ± 0.5) with 
only B. coagulans and Synbiotic treatments being significantly successful in reducing 
damage to the PC with histological scores of 9.5 ± 0.7 and 7.8 ± 0.3 respectively. Unlike 
the DSS-control group, there was reduced polymorphic inflammatory infiltrate in the 
lamina propria and submucosa in probiotic, prebiotic and synbiotic supplemented group. 
This observation corroborates with the significantly reduced MPO activity in the colon of 
all three treatments (Figure 4.3C) compared with the DSS-control group. The attenuation 
of colonic inflammation in pre-conditioned mice (B. coagulans, PSCF and Synbiotic) is 
probably due to the anti-inflammatory properties of the functional dietary ingredients 
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Figure 4.3. Effect of B. coagulans spores, PSCF and Synbiotic treatments on DSS-induced colon injury 
and inflammation. (A) Histological images of proximal and distal colonic tissues stained with hematoxylin and 
eosin at 20× for each experimental group. (B) Histological score calculated after microscopic analyses of 
proximal and distal sections of the colon. (C) Myeloperoxidase (MPO) activity in colonic tissues was determined 
by colorimetric assay. Results expressed as mean ± SEM (n = 8 per group), evaluated by one-way ANOVA 
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4.4.3 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
goblet cells and colonic tight junction barrier 
 
Histological examination of distal colon from DSS mice showed a depletion of goblet 
cells when compared to HC and pre-conditioned mice. This suggested beneficial effects of 
probiotic and prebiotic ingredients on the intestinal epithelium potentially through stimulating 
mucus secretion by goblet cells. Specific staining with Alcian blue was therefore carried out 
to assess the mucus production following the administration of probiotic, prebiotic and 
synbiotic treatments. As depicted in Figure 4.4, in comparison with DSS-control group, there 
was a higher level of mucus staining with Alcian blue in supplemented mice samples. This 
implied that there had been an induction of higher levels of mucus secretion in the DSS-
challenged mice that received B. coagulans spores, Synbiotic, and PSCF supplementations. 
Unlike the DSS-controlled samples, where goblet cells were almost entirely destroyed, the 
mice supplemented with Synbiotic and B. coagulans showed protection of the goblet cells. 
PSCF also partially protected the goblet cells with mucus staining compared with DSS-
control.  
 
Immunohistochemical analysis was then performed to evaluate the assembly of the TJs 
and the integrity of the intestinal barrier. The presence of the TJ proteins-ZO-1, occludin, and 
claudin-1 on the tissue sections were analysed (Figure 4.5). In HC, ZO-1 (Figure 4.5A) 
staining was more intense in the apical tight junction complex both at the surface and in the 
crypts. In addition to showing their presence at the crypt surface, occludin (Figure 4.5B), and 
claudin-1 (Figure 4.5C) proteins stained more strongly at the basolateral membrane of crypts. 
As previously reported (519, 520) such signals were weak or totally absent on the epithelium 
of DSS-control sections resulting in very low percentage TJ protein expressions. Basolateral 
and partial apical staining of ZO-1, occludin and claudin-1 was maintained with B. coagulans 
and Synbiotic supplementation in DSS-treated animals. While PSCF was able to partially 
maintain ZO-1 and claudin-1 staining, such an effect was less evident for occludin. Synbiotic 
treatment was most effective in preserving the TJ protein expressions in DSS-induced mice 












PSCF B. coagulans 
 
Figure 4.4. Effect of B. coagulans spores, PSCF and Synbiotic on goblet cells. The paraffin embedded 
sections were stained with Alcian Blue to detect changes in goblet cells and in production of mucus in distal 
colonic tissue in each experimental group (40×) and staining intensity (IOD) of respective group is illustrated in 
the graph. Results expressed as mean ± SEM (n = 4 per group), evaluated by one-way ANOVA followed by 
















































































A.  ZO-1                                                                       
B.  Occludin  
C.  Claudin-1 
 
Figure 4.5 Effects of B. coagulans spores, PSCF and Synbiotic on expression of epithelial tight junction 
proteins. Immunohistochemical detection of (A) ZO-1, (B) Occludin and (C) claudin-1 and its respective 
percentage of expression in colon at 40×. Data expressed as mean ± SEM (n = 4 per group) and statistical 
significance among groups evaluated by one-way ANOVA followed by Tukey’s test *P < 0.05, **P < 0.01, 





    88 
A. B. C. 
D. F. E. 
G. H. I. 
J. K. 
4.4.4 Immunomodulatory effects of B. coagulans, PSCF, and Synbiotic 
supplementation on immune markers in DSS-induced mice 
 
Figure 4.6. Effect of B. coagulans spores, PSCF and Synbiotic on immune markers in colon tissues and 
blood serum. Protein levels of cytokines including (A) IL-1D, (B) IL-1E, (C) IL-6, (D) IL-12, (E) TNF-D, (F) 
IFN-J in proximal and distal colon explants as well as cytokine levels of (G) IL-1E, (H) IL-10, and (I) IL-12 in 
blood serum were analysed by Bio-plex. iNOS activity in colon tissues (J) measured by NOS activity assay and 
CRP levels in serum (K) by ELISA. Statistical significance among groups evaluated by one-way ANOVA 
followed by Tukey’s test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. DSS-colitic group and data 
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The cytokine analysis of the colonic segments and serum measured the intestinal 
immunomodulatory and anti-inflammatory effects of B. coagulans, PSCF and their synbiotic 
combination. A beneficial impact of ameliorating the altered immune response induced by 
DSS intake was noted. Overall, probiotic, prebiotic, and synbiotic treatments remarkably 
reduced the pro-inflammatory cytokine secretions of IL-1D, IL-1E, IL-6, IL-12, TNF-D, and 
IFN-J in proximal and distal colon segments compared with that of the DSS-colitic segments 
(Figure 4.6), while no significant effect of supplementations was noted on other cytokine 
levels (Supplementary Figure SF4.1). B. coagulans and Synbiotic treatments were equally 
effective in maintaining the levels of these altered cytokines relative to that of non-colitic 
mice while PSCF did not show significant effective reduction of IL-12 cytokine levels (Figure 
4.6D). Synbiotic treatment was statistically more potent in suppressing the elevated levels of 
IL-1D (−90.29%) and IL-12 (−67.42%) compared with B. coagulans (−85.94%, −52.20%, 
respectively) in the DC. No positive effect was observed in the PC segment for IL-6 and TNF-
D levels by PSCF treatment. However, the excellent immunomodulatory effect in the DC for 
respective cytokines was confirmed (Figure 4.6C, 4.6E), implicating its differential effects in 
these colonic segments.  
Serum cytokines IL-1E, IL-12, and IL-10 also showed immunomodulatory effects 
(Figure 4.6G–I), but no significant effect was observed for other serum cytokines 
(Supplementary Figure SF4.1). All three treatments substantially restored the IL-12 levels to 
values similar to HC mice, while Synbiotic treatment was significantly more efficacious in 
reducing pro-inflammatory IL-1E levels in serum. Moreover, B. coagulans and Synbiotic 
treatments increased the anti-inflammatory IL-10 levels in serum (181.2 ± 8.70, 184.7 ± 3.81 
pg/mL respectively) compared with the DSS-colitic group (143.8 ± 12.80 pg/mL) (Figure 
4.6H). iNOS activity which is known to be high in colitis in response to pro-inflammatory 
stimuli (508), was significantly suppressed in both colon segments by all treatments (Figure 
4.6J) compared with DSS-colitic levels. Serum CRP level (Figure 4.6K) was significantly 
higher in the DSS-control group (14.58 ± 0.45 Pg/mL) in comparison with HC animals (9.32 
± 0.45 Pg/mL). Bacillus, PSCF and Synbiotic remarkably normalised the CRP levels (9.67 ± 
0.34, 9.95 ± 0.65, 8.83 ± 0.59 Pg/mL, respectively) to that of the HC group. These results 
confirmed the notable anti-inflammatory efficacy of probiotic Bacillus spores, prebiotic PSCF 
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4.4.5 Effects of B. coagulans, PSCF, and Synbiotic supplementation on 
altered faecal metabolic profile in DSS-induced mice 
 
 
Figure 4.7. Effect of B. coagulans spores, PSCF and Synbiotic on metabolic modulations in DSS-induced 
colitic mice. (A) 2D-PLS-DA plot showing spatial division among groups that received different 
supplementations, DSS-control mice that received no supplementation and HC. (B) Key compounds separating 
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Faecal metabolites were analysed using GC-MS to gain an overview of changes induced 
by B. coagulans, PSCF and Synbiotic supplementation in DSS-treated mice. A total of 61 
metabolites of different functional groups such as sugars, amino acids, volatile fatty acids, and 
biogenic amines were detected. A supervised partial least squares-discriminant analysis (PLS-
DA) was performed to evaluate metabolic phenotyping of each experimental group as shown 
in Figure 4.7A. The samples from HC and DSS-control clusters were clearly divergent 
indicating marked distinction in metabolic patterns between the two groups. While, clusters of 
supplemented mice samples overlapped with that of HC and DSS-control, clear demarcation 
of the synbiotic and B. coagulans cluster was noted, with PSCF showing only partial 
divergence relative to that of DSS-control. This indicates substantial efficacy of B. coagulans 
to metabolise PSCF that, in turn, induced significant biochemical changes potentially owing 
to their synergistic effects as evidenced from synbiotic samples. Combination of PLS-DA 
(R2Y= 0.810 (P = 0.01), Q2 = 0.710), VIP scores (Figure 4.7B) and significance analysis for 
microarrays (SAM) enabled us to identify potential biomarkers. The results showed 61 
metabolites with 40 statistically significant compounds contributing to the clustering, with 
their SAM scores fold changes and International Chemical Identifiers (InChI) and standard 
InChI hashes (InChIKey IDs) listed in Supplementary Table ST4.1. Key metabolic markers 
making a significant contribution were identified by VIP analysis as displayed in Figure 4.7B. 
Among these identified metabolites, noticeable differences between DSS-control, and HC 
samples were noted particularly for succinic acid, stearic acid, and glycerol. Synbiotic 
supplementation was beneficial in minimising the metabolite alterations induced by DSS 
(Figure 4.7B and Supplementary Table ST4.1).  
 
4.4.6 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
SCFA levels in DSS-induced mice 
 
As shown in Figure 4.8, supplementation of DSS-induced mice with B. coagulans, 
PSCF, and Synbiotic treatments induced substantial modulations in the SCFA concentrations 
and their effects varied across caecal, luminal and faecal contents. Overall, the highest 
concentration of SCFA were noted in caecal contents compared to mucosal-associated and 
faecal contents. There were no significant differences between the concentration of acetate 
and propionate in DSS-control and HC mice. PSCF however, induced a significant increase in 
the acetate levels in caecal and mucosal-associated samples while, Synbiotic treatment was 
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supplementations were significantly effective in improving the propionate concentrations in 
caecal and mucosal-associated contents while, only synbiotic supplementation increased 
propionate levels in faecal samples. 
 
Butyrate levels were significantly decreased by DSS administration (2.05 ± 0.6 Pg/g) 
compared with that of HC mice (7.91 ± 1.1 Pg/g) in the caecum. The decrease in butyrate 
induced by DSS was maintained at control levels with all three supplements in the caecum 
with PSCF (13.2 ± 2.4 Pg/g) being significantly more effective than B. coagulans (11 ± 0.9 
Pg/g) and Synbiotic (10.4 ± 1.0 Pg/g). Similarly, in faecal content, PSCF significantly 
improved butyrate (13.6 ± 1.6 Pg/g compared with 3.72 ± 0.1 Pg/g for DSS-colitic followed 
by Synbiotic (8.15 ± 0.6 Pg/g) while B. coagulans (6.69 ± 0.1 Pg/g) had no effect. Synbiotic 
supplementation resulted in marked increase in mucosal-associated valerate while, PSCF 
caused elevation in its concentration in faecal content. Similarly, Synbiotic was more efficient 
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Figure 4.8. Effects of B. coagulans spores, PSCF and Synbiotic in modulating SCFA concentrations in 
caecal, mucosal-associated and faecal contents in DSS-induced colitis. Caecal- acetate (A), propionate (D), 
butyrate (G), valerate (J), succinate (M); mucosal-associated acetate (B), propionate (E), butyrate (H), valerate 
(K), succinate (N) and faecal- acetate (C), propionate (F), butyrate (I), valerate (L), succinate (O). Statistical 
significance among groups evaluated by one-way ANOVA followed by Tukey’s test. *P < 0.05, **P < 0.01, 
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4.5 Discussion 
 
Dietary strategies involving probiotic and prebiotic fibre components that function by 
modulating immune responses, colonic epithelial integrity and microbial composition and 
related metabolites are being widely investigated for the prevention or reduction of severity of 
IBD (521, 522). The present study clearly supported the premise that conditioning of the gut 
with synbiotic supplementation containing compatible probiotic and prebiotic fibre can be 
greatly beneficial to reducing the symptoms and severity of DSS-induced acute colitis in 
mice. The observations confirmed substantial anti-inflammatory efficacy by synbiotic 
supplementation containing B. coagulans and PSCF. This was evidenced by the improvement 
of clinical symptoms, macroscopic, histological, biochemical, metabolic and immune 
parameters in the DSS-induced colitic mice model. 
 
The addition of 2% (w/v) DSS to drinking water for seven days without ameliorating 
treatments resulted in a progressive rise in DAI (Figure 4.2A), owing to both body weight loss 
(Figure 4.2B) and excretion of diarrheic/bleeding faeces. However, the supplementation of 
DSS-induced mice with B. coagulans, PSCF, and their synbiotic combination significantly 
attenuated the severity of the DSS damage and improved DAI and macroscopic markers of 
inflammation (Figure 4.2C–F). The ability of PSCF to show early effects on DAI and body 
weight could be related to its high content of insoluble hemicellulose. This fraction has a large 
water-holding capacity and thus could appropriately contribute to regulating the faecal water 
content in colitic mice (288, 289). The anti-diarrheal effect of B. coagulans has been 
previously confirmed (48). The increased beneficial effects of synbiotic supplementation in 
reducing the disease severity could be related to the synergistic actions between the probiotic 
and prebiotic components. 
 
A potentiated synbiotic effect relative to that of B. coagulans and PSCF individually 
was also evident from the histology of the colon compared with DSS-control mice (Figure 
4.3A,B). Synbiotic supplementation showed substantial protection to the colonic epithelial 
architecture by mitigating crypt disruption, loss of goblet cells, submucosal oedema and 
epithelial structure damage induced by DSS. Synbiotic supplementation also induced 
suppression of infiltration of activated neutrophils as evidenced by significant reduction in 
MPO activity in DSS-induced mice (Figure 4.3C). The infiltration of activated neutrophils is 
one of the most prominent histological features observed in IBD and is directly proportional 
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leads to tissue necrosis and mucosal dysfunction in IBD (520). The reduction in MPO activity 
suggests that synbiotic supplementation imparted an anti-inflammatory effect, in addition to 
histological protection. 
 
Disruption of intestinal epithelial TJs and impaired epithelial barrier function is a central 
event in the pathogenesis of IBD and may lead to persistent aberrant immune reactions, thus 
accelerating gut inflammation and the inflammatory circuit (99). Synbiotic treatment in our 
study was the most effective followed by B. coagulans and PSCF in protecting the expression 
level of TJ proteins (ZO-1, occludin and claudin-1) in DSS-induced mice (Figure 4.5). TJs 
create a semi-permeable barrier against paracellular penetration of harmful substances from 
the gut lumen (99). Bacillus subtilis intake has been recently confirmed to upregulate the 
expressions of TJ proteins for improved barrier function in colitic mice (392) and corroborates 
with these results. Moreover, Synbiotic and B. coagulans protected the goblet cells and mucin 
production more effectively than PSCF alone (Figure 4.4). This indicates the possible ability 
of the B. coagulans MTCC 5856 spores to benefit goblet cell structure and function, and 
needs further investigation to determine the mechanism of this effect. Some Bacillus species 
have been shown to upregulate mucin glycoproteins and protect colonic mucus layer integrity 
and goblet cell function (523). Although we could not confirm if Synbiotic supplementation 
had a stimulating effect on TJ proteins and/or localisation or, instead, if it avoided TJ 
degradation by DSS, we observed that Synbiotic supplementation significantly maintained the 
TJ patterns similar to that of animals in HC. This is indicative that Synbiotic supplementation 
significantly preserved the integrity of the epithelium. The synergy between B. coagulans and 
PSCF could have imparted excellent protection and/or maintenance of epithelial integrity on 
DSS-induced mice, thus supporting its application in IBD to reinforce intestinal barrier 
integrity. 
 
Alterations in the barrier integrity in IBD leads to aberrant immune responses resulting 
in an inflammation cascade and tissue damage (91). Although B. coagulans and PSCF 
supplementations alone were able to modulate the tested cytokines (IL-1D, IL-1E, IL-6, IL-12, 
TNF-D, and IFN-J), a more profound anti-inflammatory effect was observed with Synbiotic 
supplementation in both the colon and serum (Figure 4.6A–I). A spike in the levels of IL-1E, 
IL-6, and TNF-D have been implicated in human IBD pathogenesis (118). Such pro-
inflammatory cytokines are secreted at high levels by activated lamina propria antigen 
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D, and IL-1E are being targeted by therapeutic approaches to curb the aberrant inflammatory 
response in IBD due to their roles in the pathogenesis of the disease (524-526). TNF-D is 
reported to exert its pro-inflammatory effect through elevated production of IL-6 and IL-1E 
(527). This is in line with the present study, where DSS-induction caused elevated secretions 
of these cytokines in DSS-control group relative to that of HC (Figure 4.6). Upregulation of 
pro-inflammatory cytokine levels has also been reported to upregulate iNOS expression and 
secretion of nitric oxide that causes tissue damage in IBD (528). The anti-inflammatory 
effects of Synbiotic, B. coagulans and PSCF in suppressing the levels of these pro-
inflammatory cytokines as well as reducing iNOS activity in colonic tissues, indicates their 
immunomodulatory potentials. B. coagulans MTCC 5856 spores in our previous study 
showed excellent immunomodulatory effect in-vitro (42). Marked reduction in pro-
inflammatory cytokines in the colon of DSS-induced mice in the current study further 
supports its excellent immunomodulatory efficacy in IBD application.  
 
Synbiotic supplementation was the most effective in demonstrating noticeable anti-
inflammatory effects by significantly reducing the serum levels of pro-inflammatory IL-1E 
and IL-12 while concurrently elevating anti-inflammatory IL-10 in the serum. IL-10 plays a 
prominent role in counterbalancing Th1 and Th17 immune activity in IBD towards a Th2 
response by downregulating antigen presentation and subsequent release of proinflammatory 
cytokines thereby attenuating mucosal inflammation (527). IL-10 has been reported to play a 
role in maintaining intestinal barrier integrity possibly owing to effects on zonulin pathway 
(529). The ability of B. coagulans spores to elicit IL-10 levels in inflammatory condition has 
been determined in-vitro and in human subjects. Thus, the anti-inflammatory efficacy of 
Synbiotic supplementation could be related to major immune-regulating capability of B. 
coagulans MTCC 5856 spores, thereby supporting its application in synbiotic therapies for 
IBD. Furthermore, Synbiotic treatment also reduced the increased CRP levels in the serum of 
DSS-induced mice. In the inflammatory state, circulating IL-6 promotes CRP production in 
the liver and its release into the bloodstream (530). Elevated levels of CRP has been 
implicated in human IBD patients (531). The reduction in overall pro-inflammatory mediators 
by synbiotic supplementation may be due to either direct immune-regulating effect of the B. 
coagulans and PSCF on cytokine secretion, or it could be owing to their indirect affect on the 
protection of intestinal barrier integrity. In either case this leads to reduction in luminal 
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DNA extracted from caecal, faecal and mucosal-associated contents from DSS-induced 
mice in the present study, failed amplification before 16s rRNA sequencing. This was caused 
by the presence of DSS in the samples that inhibited the PCR amplification as known earlier 
(532). The microbiota profiling of DSS samples could therefore not be performed and is a 
limitation of the study. The levels of microbiota-derived untargeted metabolites and SCFAs 
were therefore alternatively analysed as signatures of the gut microbiota that contribute to 
modulating the immune activity of the intestinal mucosa (533, 534). The untreated DSS-
control mice exhibited distinct faecal metabolic phenotype relative to that of HC. This was 
reflective of clinical and animal IBD studies that confirmed significant differences in 
metabolic profiles between healthy and IBD patients (217, 220, 221). The metabolic analysis 
of supplemented mice in our study resulted in considerable normalization of metabolic profile 
indicating the positive effects of synergistic combination of B. coagulans and PSCF that 
induced marked improvement in metabolic pattern. Notably, for mice supplemented with 
PSCF, there was not much distinction observed from DSS-control group, but the synbiotic 
combination with B. coagulans resulted in an improved metabolic pattern. This marked 
synergism could be associated with the acceleration of fermentation of insoluble plant cellular 
materials, such as hemicellulose in PSCF, by the supplemented B. coagulans (71). The 
resulting higher levels of fermentation metabolites would thus, in turn, influence other 
beneficial microbial metabolic activities. This further supports the application of compatible 
synbiotic components to generate maximum benefits through increased SCFA production.  
 
Increased levels of microbiota-derived SCFAs are inversely associated with dysbiosis in 
IBD (229). Of particular interest are higher levels of acetate, propionate and butyrate, which 
results from fermentation of indigestible carbohydrate components of fibre-rich diets. The 
effects of SCFAs have been studied to in animal models of colitis (288) and clinical UC 
(235). Each type of SCFA is likely to contribute to host health (535). In this study we 
determined the SCFA profile along the GIT, analysing samples across caecal, mucosal-
associated, and faecal contents (Figure 4.8). The concentration of SCFAs varied along the 
length of the gut, with most abundant levels in the caecum and PC, while it declined towards 
the DC (535). In line with a recent study (536), caecum showed the highest levels of all the 
SCFAs tested in our study irrespective of the supplementation. Caecum is considered the 
major site for fermentation in the rodent gut and contains the largest pool of microbiota. It 
therefore generates the most SCFAs. However, some recent studies have also reported 
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GIT (215, 536, 537). Therefore, the overall gastrointestinal profile is of importance when 
associating the gut microbiome and metabolites with health outcomes.  
 
All three supplementations caused a substantial increase in concentrations of measured 
SCFAs compares with that of DSS-control group. However, the potentiated effect of 
Synbiotic supplementation is evidenced by induction of SCFA production along the entire 
length of the colon compared to B. coagulans supplementation alone where the additional 
SCFA production capacity was absent past the caecum. This effect highlights the advantage 
of using a compatible prebiotic fibre as synbiotic companion with a particular probiotic that 
can metabolize it. The high total dietary fibre content of PSCF (87%) (75) would contribute to 
this effect. PSCF supplementation resulted in increased butyrate levels line with an in-vitro 
study with human gut microbiota utilizing sugar cane fibre (75).The effect of additional 
SCFA production in caecum by B. coagulans would not extend to the proximal or distal parts 
of the colon. In the current study, the elicited extra SCFAs with synbiotic supplementation 
from caecum to the faecal pellets, indicated the ability of B. coagulans to utilize the PSCF to 
also generate SCFAs after the caecum. The ability of B. coagulans to metabolize a variety of 
plant fibres for fermentation, including cranberry fibre (478) and fenugreek seeds (477), to 
produce SCFAs and hemicellulose (71) for lactic acid production has been previously 
demonstrated.  
 
PSCF supplementation also resulted in increased butyrate levels, correlating with results 
of an in-vitro study with human gut microbiota utilizing sugar cane fibre (75). This ability of 
synbiotic supplementation for eliciting butyrate levels along the entire length of colon could 
contribute to the beneficial effect observed in the current study. Butyrate is the preferred 
energy source for colonocytes and has the ability to regulate cytokines thus showing 
protection against inflammation in UC and colorectal cancer (535). Butyrate has been 
demonstrated in in-vitro (538, 539) and in-vivo (540) studies to increase epithelial integrity 
and mucus secretion, consistent with the immunohistological and mucus staining analysis in 
the present study. The substantial increase in butyrate levels in the caecum by B. coagulans 
supplementation may be due to ability to support the growth and activity of butyrate 
producers probably via cross-feeding of the lactic acid production. B. coagulans are known to 
be efficient at producing lactic acid through fermentation of various plant substrates, 
including hemicellulose (64, 71). Lactic acid is reported to be utilized by strictly anaerobic 
butyrate-producing bacteria of clostridial clusters XIVa for the production of high 
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prebiotic fibre that directly or indirectly influence butyrate production may help to restore 
intestinal barrier integrity in diseased state. This effect was evidenced by the significant 
reduction in DSS-induced colonic epithelial damage (Figure 4.3) by Synbiotic 
supplementation in our study. 
 
Acetate and propionate have also been studied to benefit epithelial integrity via binding 
with certain metabolite-sensing G-protein-coupled receptors (such as GPR43, GPR109A) and 
modulating immune response (227, 239, 542). Valerate was increased by Synbiotic 
supplementation. It that has been determined to stimulate intestinal growth and attenuate 
inflammatory pathogenesis in colitis and cancer (222). Besides their positive effect in colon, 
SCFAs have also been exhibited to mediate improved host metabolism and modulate the 
activity of the enteric nervous system (535), thus providing benefits beyond GIT. The high 
levels of immuno-modulatory effects observed in the present study could also possibly be 
correlated to high SCFA levels induced by Synbiotic supplementation owing to the 
synergistic combination. SCFAs by engaging with engage with GPRs are known to induce 
immune-modulation leading to a direct local and systemic anti-inflammatory effects (227, 
543). This further supports the application of synergistic synbiotic combinations to achieve 




This is a detailed study highlighting the site-specific inflammatory and SCFA changes 
in a mice model of IBD as a result of synbiotic supplementation of the normal diet with 
prebiotic whole plant fibre and probiotic spores. The Synbiotic pre-supplementation resulted 
in a substantial anti-inflammatory effect, reducing disease severity, colonic damage, and 
inflammatory mediators while modulating the metabolite and SCFA profiles of DSS-induced 
gut damage. The research has clearly demonstrated that the supplementation of whole plant 
PSCF and B. coagulans spores produced a synergistic combination that protected mice against 
acute damage induced by DSS in mice. The results underscore the significant efficacy of 
synbiotic applications to increase the beneficial and preventive effects on the host by targeting 
different mechanistic approaches to resolving the inflammation cycle. However, the 
differences in the evolved biology of humans compared to mice requires caution in translation 
of the results to impacts on human disease (219). While mice models do allow the changes in 
gut microbiota, as a result of pre- and probiotic combinations, to be studied in a controlled 




    100 
actions of probiotic B. coagulans spores and prebiotic PSCF in mouse model of IBD provides 
support for investigating their therapeutic and preventive effects in human IBD. However, the 
ability to reduce the severity of DSS-induced colitis was demonstrated using pre-
supplementation. Human trials should be aimed at testing proactive prevention, or efficacy 
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4.7 Supplementary data 
 
Figure SF4.1. Non-significant effect of B. coagulans spores, PSCF and Synbiotic on immune markers in 
colon tissues and blood serum. Protein levels of cytokines including (A) IL-10 (B) IL-17, (C) MIP-1D, (D) 
MIP-1E, (E) GM-CSF in proximal and distal colon explants as well as cytokine levels of (F) IL-1D, (G) IL-6, 
(H) TNF-D, (I) IL-17, (J) IFN-J, (K) MIP-1D, (L) MIP-1E, (M) GM-CSF  in blood serum were analysed by 
Bio-plex. Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test. Non-




    102 
 
Table ST4.1 Most significant compounds identified by OPLS-DA and SAM analysis in HC, DSS-control, 
B. coagulans (BC), PSCF and synbiotic groups (*First 40 compounds are identified by SAM).  
Compound 























































































































































-QWWZWVQMSA-N 1.2402 1.3004 1.1307 1.2202 1.1702 
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UWTATZPHSA-N 0.23877 0.2287 0.17023 0.2314 0.52183  
L-serine 
MTCFGRXMJLQNBG-
REOHCLBHSA-N 0.90573 0.80824 1.1704 0.7656 0.72921  
Thymine 
RWQNBRDOKXIBIV-
UHFFFAOYSA-N 0.2904 0.60831 0.13184 0.6657 0.85964  
Malonic acid 
OFOBLEOULBTSOW-
UHFFFAOYSA-N 0.91188 0.81386 0.88259 0.7758 0.74087  
Methionine 
FFEARJCKVFRZRR-























UHFFFAOYSA-N 0.41256 0.68247 0.15453 0.7494 1.0804  
Lyxose 
SRBFZHDQGSBBOR-




GASJEMHNSA-N 0.77237 0.79383 0.65727 0.7932 0.7504  
xylitol 
HEBKCHPVOIAQTA-
NGQZWQHPSA-N 0.5054 0.63101 0.41881 0.6327 0.65337  
Galactose 
WQZGKKKJIJFFOK-
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Tyramine 
DZGWFCGJZKJUFP-
UHFFFAOYSA-N 0.69223 0.82033 0.59041 0.8402 0.79394  
Lysine 
KDXKERNSBIXSRK-
YFKPBYRVSA-N 0.42108 0.69937 0.49143 0.6578 0.6221  
Tyrosine 
OUYCCCASQSFEME-
QMMMGPOBSA-N 0.79626 0.71207 0.74887 0.6674 0.63055  
Allo-inositol 
CDAISMWEOUEBRE-
UHFFFAOYSA-N 1.194 1.1 1.3715 1.0443 1.0161  
Sucrose 
CZMRCDWAGMRECN
-UGDNZRGBSA-N 0.58274 0.52774 0.69347 1.0782 1.026  
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Chapter 5 
Prebiotic green banana resistant starch and 
probiotic Bacillus coagulans spores synbiotic 
supplementation ameliorates gut inflammation 





The research goal is to develop dietary strategies to help address the growing incidence 
of IBD. This study has investigated the effectiveness of green banana resistant starch (GBRS) 
and probiotic B. coagulans MTCC5856 spores for amelioration of dextran-sulfate sodium 
(DSS)-induced colitis in mice. Eight-week-old C57BL/6 mice were fed normal chow diet 
supplemented with either B. coagulans, GBRS or synbiotic combination. After 7-days 
supplementation, colitis was induced by adding 2% DSS in drinking water for 7 days while 
continuing the supplemented diets. Animal health was monitored and after the 14 days all 
animals were sacrificed to measure the biochemical and histochemical changes associated 
with each supplement type. Synbiotic supplementation alleviated the disease activity index 
(DAI) and histological damage score (-67%, 8.8 respectively) more adequately than B. 
coagulans (-52%, 10.8 respectively) or GBRS (-57%, 13.6 respectively) alone. Compared to 
DSS-control Synbiotic supplementation significantly (P<0.0001) maintained expressions of 
tight junction proteins. Moreover, synbiotic effects accounted for ~ 40% suppression of IL-1E 
and ~29% increase in IL-10 levels in serum while, also reducing C-reactive protein (-37%) to 
that of DSS-control. While, B. coagulans alone could not induce additional levels of short-
chain fatty acid (SCFA) production beyond the caecum, the synbiotic combination with 
GBRS resulted in substantial increased SCFA levels across the whole length of the colon. The 
amelioration of overall inflammatory parameters in this experimental IBD model by synbiotic 
supplementation with B. coagulans and GBRS supports researching its application in 
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5.2 Introduction 
 
Although the pathogenesis of IBD that encompasses CD and UC, still remains unclear, 
emerging evidence substantiates the role of interaction of genetic, environmental and 
immunological factors. Perturbations in the composition of the gut microflora (dysbiosis) are 
associated with the pathogenesis of IBD (88, 91, 544). As diet is a major factor influencing 
the enteric microflora, numerous research projects have considered the role of specific 
nutrients in the development of IBD. The western diet, characterised by low intake of dietary 
fibre, has been linked with increased risk of IBD in several studies (9) and implicated in 
leading to gut dysbiosis that further aggravates gut inflammation. In this regard, prebiotic 
dietary fibre and probiotics are considered as critical components of dietary improvements in 
the context of IBD as both bioactive agents function to suppress inflammation via a number of 
proposed mechanisms (26, 242, 545). Hence, various probiotic and prebiotic agents are being 
increasingly explored to treat IBD in humans (242, 546, 547).  
 
A number of factors influence the beneficial effects of probiotics. Their survival in 
delivery formats, including functional foods, is required as well as during gastric transit in 
order to exert health effects of the live organism (548). In this context, Bacillus species are a 
growing research focus due to the ability of their heat-stable spores to survive gastric transit, 
harsh manufacturing and storage temperatures and delivery formats that potentially involve 
hot foods (355, 425). Furthermore, Bacillus strains are known to exert therapeutic effects 
owing to their ability to induce immune responses and to produce antimicrobial peptides that 
help mitigate inflammation (425). Bacillus coagulans MTCC 5856 spores, specifically, have 
been shown to survive during harsh processing and storage conditions of functional foods 
(43), survive gastric transit, induce excellent immunomodulatory effects in-vitro (42) and 
exhibit beneficial effects in therapeutic management of clinical diarrhea (48).  
 
An additional factor that may influence the beneficial effects of probiotics are their 
ability to generate fermentation products that influence the composition of the gut 
microbiome and thus potentially the health of the host. Bacteriocin and organic acid 
production are two possible characterized antimicrobial products of probiotics that can 
influence and stabilize the gut microbiome (549, 550). Other intermediate metabolites, 
including short-chain fatty acids (SCFAs) produced as a consequence of bacterial 
fermentation of prebiotic in the gut, have been affirmed to exert beneficial effects on the host 
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prebiotic dietary fibre that can be metabolised and fermented by the administered probiotic, as 
well as by beneficial microflora in the gut, to direct the shift of immune markers from pro-
inflammatory to anti-inflammatory phenotype (552). This combination of probiotic and 
prebiotic factors can be referred to as synbiotic and potentially offers greater success of 
colonisation and survivability of the beneficial bacteria owing to the synergy than either 
probiotic or prebiotic alone (442). B. coagulans MTCC5856 are known to ferment variety of 
plant fibres. This therefore makes them a candidate for probiotics in synbiotic combination 
with plant prebiotic fibres.  
 
Resistant starch (RS) is now classified as a type of dietary fibre (553). RS is defined as 
the sum of starch and the degradation products of starch that, on average, reaches the large 
intestine of healthy adult humans. Numerous clinical studies have successfully demonstrated 
the beneficial effects of RS in colonic health (553, 554). RS, derived as a ground flour from 
dried green banana (GB), has been demonstrated to prevent intestinal inflammation (76) and 
modulate oxidative stress (77) in animal models of colitis and impart anti-diarrhoeal effects in 
children (78, 79). Due to high RS content and nutrition value, GB flour is being increasingly 
incorporated in food products to increase functional  properties such as stabilising emulsions 
(555-557). Synbiotic functional foods, targeted towards improving gut health by carrying both 
probiotic and prebiotic, could be of high interest for health food applications such as for 
mitigating inflammation in IBD patients. However improved knowledge on possible health 
effects, dosage response and mechanisms is needed to support such developments. 
 
 For this research it was hypothesised that supplementing the diet with probiotic B. 
coagulans MTCC5856 spores, prebiotic green banana resistant starch (GBRS) flour and its 
synbiotic combination may ameliorate the severity of DSS-induced colitis in mice model of 
IBD. This is the first report to investigate the anti-inflammatory potential of GBRS flour 
prepared from green lady finger bananas. This flour has all the fibre from green banana fruit. 
The fibre levels are very high being greater than 50% w/w owing to high RS content in 
addition to other nutritional components such as 5-hydroxytryptophan (5-HTP) (72). This 
study aimed to investigate the efficacy of pre-conditioning the gut with diet supplemented 
with B. coagulans spores, GBRS, both individually and in synbiotic combination prior to 
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5.3 Materials and methods 
 
5.3.1 Probiotic Bacteria and Prebiotic Dietary Fibre 
 
LactoSpore® containing probiotic strain Bacillus coagulans MTCC 5856 (6 × 109 
spores/gm) was produced by Sami Labs Limited (Bangalore, India) and supplied by Sabinsa 
Corporation (Australia). Prebiotic green banana resistant starch (GBRS) was supplied by 




Fifty C57BL/6J (seven week old) mice of both sexes of average weight 19g were 
obtained from the University of Tasmania animal breeding facility and housed in a 
temperature-controlled environment with a 12-h day/night light cycle. Individual body 
weights were assessed daily including over an initial acclimation period of seven days. All 
mice had ad libitum access to radiation-sterilised rodent feed pellets (Barastoc Rat and 
Mouse, Ridley AgProducts, Australia, Appendix III) and autoclaved tap water for drinking 
during experiments. All animal experiments were approved by the Animal Ethics Committee 
of the University of Tasmania [ethics approval number: A0015840 (Appendix IV)] and 
conducted in accordance with the Australian Code of Practice for Care and Use of Animals 
for Scientific Purposes (8th Edition, 2013). All efforts were made to minimize animals’ 
suffering and to reduce the number of animals used.  
 
5.3.3 Study Design and Treatments 
 
Following 1 week of acclimation, mice at 8 weeks of age were randomly allocated into 
following 5 groups (n = 10 per group): (1) Healthy Control (HC), (2) DSS-control, (3) 
Probiotic B. coagulans MTCC 5856 (B. coagulans), (4) Prebiotic green banana resistant 
starch (GBRS) and (5) Synbiotic.  The experimental design of the mice feeding trial is 
illustrated in Figure 5.1. Mice in HC and DSS-control groups received 4g chow mash 
(standard chow pellet blended with water). The B. coagulans group received 4 g chow mash 
supplemented with probiotic B. coagulans MTCC 5856 spores (2 × 109 CFU/day/mouse). The 
GBRS group received 4g chow mash supplemented with GBRS (400 mg/day/mouse). The 
Synbiotic group received 4 g chow each supplemented with B. coagulans MTCC 5856 spores 
(2 ×109 CFU/ day/mouse) and GBRS (400 mg/day/mouse). The chow mash was prepared 
fresh each day. The mice were single-caged throughout the experiment to measure the defined 
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treatments for 14 days. Colitis was induced during the last 7 days of the experimental period 
by administering 2% dextran sulfate sodium (DSS; MP Biomedicals, colitis grade average 
molecular weight: 36,000-50,000) in drinking water of all groups except for non-colitic 
control mice which received normal drinking. Mice were sacrificed on day 15 by CO2 
asphyxiation. 
 
Figure 5.1. Experimental design of in-vivo feeding trial to analyse prophylactic efficacy of B. coagulans 
spores, GBRS and Synbiotic in DSS-induced acute colitis mice model. C57BL/6J mice (n = 10 per group) 
were fed chow supplemented with either  B. coagulans spores, GBRS or their Synbiotic combination for 14 
days. Colitis was induced by administration of 2% DSS in drinking water for last seven days.  
 
 
5.3.4 Clinical Scoring and Histological Analysis 
 
A Disease Activity Index (DAI) was determined daily in all mice by scoring for body 
weight, hemoccult reactivity or presence of gross blood and stool consistency during the week 
of DSS induction. DAI was determined by combining the scores from these three categories 
as detailed in Section 4.3.4 of Chapter 4 (552). Faecal samples were collected on day 14 and 
stored at −80 °C for metabolite analysis. After sacrificing the mice, the colons were dissected 
from the caecum to the anus as described previously. The mucosal and caecal contents were 
collected for metabolite profiling and stored at −80 °C. The collection, preparation and storage 
of colonic tissues for molecular analyses and histological staining as detailed previously in 
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group) were stained with H&E stain and graded blindly for the severity of tissue damage at 
distal and proximal regions as described previously (552).  
 
5.3.5 Alcian Blue Staining 
 
DSS-induced alterations in goblet cells, and subsequent depletion in synthesis and 
secretion of mucin glycoprotein (MUC2), were analysed by Alcian blue staining (ab150662 
Alcian Blue, pH 2.5 (Mucin Stain), Abcam, Australia) following the manufacturer’s 
instructions as previously described in Chapter 4 (4.3.5). The staining intensity (IOD) was 
assessed using Image Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, MD, USA) and used 
for comparison among groups (506).  
 
5.3.6 Immunohistochemical Detection of Tight Junction Proteins 
 
Immunohistochemical detection of epithelial tight junction (TJ) proteins : ZO-1, 
occludin and claudin-1 was performed using a Rabbit specific HRP/DAB (ABC) Detection 
IHC kit (ab64261, Abcam, Australia) following the manufacturer’s instruction and as 
previously described (552). Antibodies anti-ZO-1 (NBP1-85046, Novus Biologicals, 
Australia, 1:400); anti-occludin (NBP1-87402, Novus, 1:600) and anti-claudin-1 (NBP1-
77036, Novus, 1 Pg/mL) were used for incubating the colonic sections overnight at 4 °C. 
Computer-assisted image analysis was performed with a Leica DM500 microscope (Leica 
Microsystems, Wetzlar, Germany), Leica ICC50 W camera (Leica Microsystems, Wetzlar, 
Germany), and Image Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, MD, USA) software. 
The expression of tight junction (TJ) proteins: ZO-1, occludin and claudin-1 was blindly 
assessed by choosing random five fields on each slide (n = 4/group). Barrier TJ protein 
expressions and staining intensity in colonic epithelium was expressed as the percentage 
expression of a respective TJ protein.  
 
5.3.7 Myeloperoxidase Activity 
 
The extent of the inflammatory cell invasion in the colon was examined by the 
assessment of myeloperoxidase (MPO) activity (499). Weighed and snap frozen PC and DC 
specimens (n = 3) were analysed for MPO activity using a Myeloperoxidase Activity Assay 
kit (ab105136, colorimetric, Abcam, Cambridge, UK) as described previously  (552). The 
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5.3.8 Tissue Explant Culture and Cytokine Measurements 
 
PC and DC colon tissues of mice from each group were cut, weighed and washed with 
cold PBS before transferring to a 12 well plate containing 0.5 mL/well of RPMI1640 culture 
medium (In Vitro Technologies Pty Ltd, Melbourne, Australia) supplemented with 10% v/v 
foetal calf serum (Gibco, Life Technologies Pty Ltd, Melbourne, Australia), penicillin (100 
mU/L), and streptomycin (100 mg/L) (Sigma-Aldrich Pty Ltd, Sydney, Australia) as 
described previously (501). After 24 h of incubation, supernatant was collected from each 
well, centrifuged and stored at −80 °C until further analysis. Serum was collected from blood 
drawn by cardiac puncture at the end of the study for cytokine analysis. 
 
The cytokine levels in colon tissue (n = 3) and serum (n = 3) were determined by 
immunoassay using a Bio-Plex Pro Mouse cytokine 23-plex kit (Bio-Rad #M60009RDPD, 
Bio-Rad Laboratories, Gladesville, NSW, Australia) following the manufacturer’s instructions 
and concentrations analysed using a Bio-Plex 200 instrument (Bio-Rad) and Bioplex Manager 
software, version 6 (Bio-Rad Laboratories) respectively. For tissues, the cytokine levels were 
normalized by dividing the cytokine results (pg/mL) by the measured biopsy weight (g). The 
most significantly altered cytokines are presented as pg/g of tissue. 
 
5.3.9 iNOS Activity 
 
The expression of inducible isoforms of nitric oxide synthase (iNOS) in colonic 
epithelial cells in response to pro-inflammatory stimuli (508) was determined in PC and DC 
specimens using a Nitric Oxide Synthase Activity Assay kit (ab211084, Fluorometric, 
Abcam, Cambridge, UK), following the previously described method (552). The results are 
expressed as iNOS activity mU/mg. 
 
5.3.10 Serum C-Reactive Protein Analysis 
 
The levels of C-reactive protein (CRP) in serum from respective groups (n = 3 
samples/group) were analysed using Mouse C-Reactive Protein/CRP Quantikine Elisa kit 
(MCRP00, R and D Systems, Australia) following the manufacturer’s instructions. The results 
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5.3.11 Volatile SCFA Analysis 
 
GC-MS analysis of 100–150 mg fresh weight (stored at −80 °C) of caecal, mucosal-
associated and faecal samples (n = 5 per group) each was conducted for volatile SCFA 
profiling following the method described previously (510, 552). The GC-MS analysis was 
performed by Dr. David J. Beale (CSIRO), Dr. Avinash V. Karpe (CSIRO) and Dr. 
Shakuntala V. Gondalia (Swinburne University of Technology). Data analysis and 
interpretation was performed by the PhD candidate. 
 
5.3.12 Metabolic Phenotyping Analysis 
 
Untargeted metabolomic profiling of faecal samples (n = 5 per group) were performed 
using GC-MS analysis by Dr. David J. Beale (CSIRO), Dr. Avinash V. Karpe (CSIRO) and 
Dr. Shakuntala V. Gondalia (Swinburne University of Technology) as described previously 
(510, 552). Data analysis and interpretation was performed by the PhD candidate. 
 
5.3.13 Statistical Analysis 
 
The samples in the study were randomly chosen for all the analyses to avoid bias. All 
data are presented as means ± standard error of the mean (SEM). The statistical analysis was 
performed with the use of GraphPad Prism Software (Version 7.0, San Diego, CA, USA). The 
data were evaluated using One-way analysis of variance (ANOVA) followed by Tukey’s 
post-hoc test to determine statistical differences between the groups against the DSS-control 
samples. For the analysis of DAI and body weight changes during the experimental period, 
two-way ANOVA followed by Tukey’s post-hoc test was used, setting treatment and the time 
as the variables. A p-value of < 0.05 was considered significant. A MetaboAnalyst (Version 
4.0) data annotation approach and Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
Pathway Database were used for the hierarchical clustering analysis and significance analysis 
for microarrays (SAM), along with the variable importance of projection (VIP) (517). The 
SAM and VIP methods are well-established statistical methods for metabolites and were used 
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5.4 Results 
 
5.4.1 Effects of B. coagulans, GBRS and Synbiotic supplementation on 
clinical manifestations and macroscopic inflammatory markers  
 
DSS-induction resulted in a progressive increase in colonic inflammation demonstrated 
by severe body weight loss and high DAI (Figure 5.2A, 5.2B). However, supplementation of 
B. coagulans, GBRS and Synbiotic treatments, started 7 days prior DSS-induction, attenuated 
the impact of the DSS damage and boosted the recovery of the treated animals. This is 
evidenced by the significant reduction in body weight loss and by lower incidences of 
diarrheic/bloody faeces, resulting in lower DAI values throughout the experiment in the 
treated groups when compared to untreated DSS-control group. At the end of the experiment 
on day 8, DAI was significantly (P < 0.0001) higher for DSS-control group (6.1 ± 0.5) 
compared to B. coagulans (2.9 ± 0.4, 52% reduction), GBRS (2.6 ± 0.4, 57% reduction) and 
Synbiotic (2.0 ± 0.2, 67% reduction) mice (Figure 5.2B). Moreover, probiotic, prebiotic and 
synbiotic supplementation significantly (P < 0.0001) reduced the loss of body weight 
compared to that of DSS-control group starting from day 6.  
 
The macroscopic evaluation of colonic segments affirmed the remedial effects of all 
three treatments used in our study, as indicated by a substantial reduction in colon 
weight/body weight ratio (B. coagulans, 7.70±0.2; GBRS, 9.32±0.3 and Synbiotic, 8.32±0.3 
mg/g) compared with DSS-control group (11.16±0.2 mg/gm) (Figure 5.2C). Relative spleen 
weights of DSS-control mice were markedly higher (0.08±0.004 g) than that of GBRS 
(0.063±0.002 g) and Synbiotic (0.062±0.003 g) mice (Figure 5.2D). B. coagulans had no 
effect on spleen weight reduction (0.068±0.004 g). B. coagulans (7.80±0.3 cm), GBRS 
(7.91±0.2 cm) and Synbiotic (8.09±0.2 cm) supplementation effectively prevented the colon 
shortening compared with the DSS-control group (6.80±0.3 cm) (Figure 5.2E, 5.2F). 
Additionally spleen enlargement, increased colon weight/body weight ratio and colon 
shortening was directly associated with intestinal inflammation and disease severity in 
experimental colitis models (499).  
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Figure 5.2. Effect of B. coagulans spores, GBRS and Synbiotic in DSS-induced colitis model. (A) Disease 
Activity Index (DAI), (B) % body weight change. Statistical significance among groups evaluated by two-way 
repeated-measures analysis of variance (ANOVA) followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 vs. DSS-control group and data expressed as mean ± SEM (n =10 per group). Colon 
weight/body weight ratio (C), Spleen weight (D), Colon length (E) and macroscopic appearance of colon (F). 
Data expressed as mean ± SEM (n =10 per group), evaluated by one-way ANOVA followed by Tukey’s Test. 
NS = non-significant. 
 
A.                                                                        B.                                                                        
C.                                                                        D. 
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5.4.2 Effects of B. coagulans, GBRS and Synbiotic supplementation on 
histological alterations in colon 
 
Histological (H&E staining) examination of proximal colon (PC) and distal colon (DC) 
sections of DSS-induced mice displayed histological damage with erosion or destruction of 
epithelium, crypt distortion, depletion of goblet cells, submucosal oedema and inflammatory 
cellular infiltration in the colon, mostly affecting distal section (Figure 5.3A). While, HC 
showed no signs of histological colon damage (score 0), DSS resulted in a cumulative damage 
score of 9.38±0.8 for PC and 17.1±0.4 for DC (Figure 5.3B). Supplementation with 
Synbiotic and B. coagulans induced protection against the damage, as evidenced by 
substantial retention of colonic structure, protection of crypts and goblet cells, and reduced 
infiltration of inflammatory cells which resulted in a significant overall reduction of 
cumulative histological scores of DC (8.8±0.5, 10.8±1.0 respectively). GBRS provided a 
partial but significant protection with a histological score of 13.6±0.7. In contrast, 
histology scores for PC demonstrated no statistically significant protection by the three 
treatments. MPO assay however, showed a substantial reduction in neutrophil infiltration 
in PC by synbiotic and B. coagulans compared with that of the DSS-colitic group.  In DC, 
all three supplementations were successful in reducing the inflammatory cell infiltrate as 
determined by decreased MPO activity (Figure 5.3C) with B. coagulans and Synbiotic 
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Figure 5.3. Effect of B. coagulans spores, GBRS and Synbiotic treatments on DSS-induced colon injury 
and inflammation. (A) Histological images of proximal and distal colonic tissues stained with hematoxylin and 
eosin at 20× for each experimental group. (B) Histological score calculated after microscopic analyses of 
proximal and distal sections of the colon. (C) Myeloperoxidase (MPO) activity in colonic tissues was determined 
by colorimetric assay. Results, expressed as mean ± SEM (n = 8 per group), were evaluated by one-way 
ANOVA followed by Tukey’s test (*P < 0.05, **P < 0.01, ****P < 0.0001). 
B.  C.      
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5.4.3 Effects of B. coagulans, GBRS and Synbiotic supplementation on 
goblet cells and colonic tight junction barrier 
 
 
Figure 5.4. Effect of B. coagulans spores, GBRS and Synbiotic on goblet cells. The paraffin embedded 
sections were stained with Alcian Blue to detect changes in goblet cells and in production of mucus in distal 
colonic tissue in each experimental group (40×) and staining intensity (IOD) of respective group is illustrated in 
the graph. Results expressed as mean ± SEM (n = 4 per group), evaluated by one-way ANOVA followed by 



















































































C.  Claudin-1 
 
 
Figure 5.5. Effects of B. coagulans spores, GBRS and Synbiotic on expression of epithelial tight junction 
proteins. Immunohistochemical detection of (A) ZO-1, (B) Occludin and (C) Claudin-1 and its respective 
percentage of expression in colon at 40×. Data expressed as mean ± SEM (n = 4 per group) and statistical 
significance among groups evaluated by one-way ANOVA followed by Tukey’s test *P < 0.05, **p < 0.01, 
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Staining with Alcian blue was performed to examine the effect of supplementation on 
DSS-induced alterations in the mucus secretion by goblet cells. Significantly high mucus 
staining with Alcian blue was detected in colon sections of mice supplemented with B. 
coagulans and Synbiotic with moderate capacity of GBRS suggesting induction of high 
secretion levels of mucus in DSS-challenged mice that received supplementations (Figure 
5.4). In comparison, in DSS-control colon sections, the goblet cells were almost entirely 
destroyed.    
 
Immunohistochemical analysis was performed to investigate the impact of 
supplementation on assembly of the TJs and the integrity of the intestinal barrier. The 
presence of the TJ proteins- ZO-1, occludin and claudin-1 were analysed for on the colonic 
tissue sections (Figure 5.5). In HC sections, ZO-1 staining (Figure 5.5A) was more intense in 
the apical tight junction complex, both at the surface and in the crypts. Occludin (Figure 5.5B) 
and claudin-1 (Figure 5.5C) proteins stained more strongly at the basolateral membrane of the 
crypts, and also showed their presence at the crypt surface. In DSS-control sections however, 
such signals were weak or totally absent in line with previous reports (519, 520), indicating a 
low percentage  of  TJ protein expression. B. coagulans and Synbiotic supplementation, 
however, effectively maintained the basolateral and partial apical staining of ZO-1, occludin 
and claudin-1 in DSS-induced mice. GBRS only displayed partial maintenance of ZO-1 
staining, although the effect was less noticeable for occludin and claudin-1. In contrast, 
Synbiotic supplementation significantly maintained the TJ patterns similar to that of HC 
sections, indicating a high level of protection of the integrity of the epithelium.  
 
5.4.4 Immunomodulatory effects of B. coagulans, GBRS and Synbiotic 
supplementation on immune markers  
 
B. coagulans, GBRS and Synbiotic supplementation improved the altered immune 
responses induced by DSS supporting their immunomodulatory and anti-inflammatory effects 
(Figure 5.6). In comparison with the DSS-control group, all three treatments substantially 
reduced the tested pro-inflammatory cytokine levels of IL-1D, IL-1E, IL-6, IL-12, TNF-D, 
IFN-J in PC and DC segments. However, no significant effect of supplementations was noted 
on levels of the other cytokines (Supplementary Figure SF5.1). Supplementation with B. 
coagulans alone and Synbiotic proved effective in reducing the levels of all the cytokines 
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of IL-1E (-60%), IL-6 (-62%), TNF-D (-66%) and IFN-J (-73%) levels by B. coagulans 
supplementation in comparison with that of GBRS (IL-1E: -36%, IL-6: -35%, TNF-D: -46%, 
IFN-J: -57%). However, GBRS had no significant effect on the levels of IL-1D, IL-12 and 
TNF-D in DC. The Synbiotic supplementation proved effective in reducing the levels of all 
pro-inflammatory cytokines, in comparison with elevated cytokine levels in the DSS-control 
but, displayed greater reduction in the levels of IL-6 (-78%), IL-12 (-56%) and IFN-J (-71%) 
compared with GBRS supplementation and greater suppression in the level of IL-1E (-75%) 
compared to B. coagulans.  
 
Serum cytokines indicative of immunomodulatory effects also followed a similar trend 
(Figure 5.6G-I). Synbiotic significantly decreased pro-inflammatory serum cytokine levels of 
IL-1E (50.1±4.6 pg/mL) and IL-12 (146.4±7.4 pg/mL) while, concomitantly increasing anti-
inflammatory IL-10 (181.7±6.1 pg/mL) levels compared with the DSS-control group (IL-1E: 
82.8±4.1 pg/mL, IL-12:  246.6±6.0 pg/mL and IL-10: 140.5±6.5 pg/mL). While, B. 
coagulans and GBRS supplementations alone were not effective in reducing increased serum 
IL-1E (66.1±7.0 and 59.38±5.0 pg/mL respectively), significant reduction in IL-12 
(179.3±12.3 and 169.5±11.1 pg/mL respectively) was achieved relative to that of the DSS-
control. No significant effect was observed for other serum cytokines (Supplementary Figure 
SF5.1). DSS-induction elevated iNOS activity in both PC and DC in response to the pro-
inflammatory stimulus, in line with the previous report (508). Synbiotic and B. coagulans 
lowered the iNOS activity significantly, while GBRS had no effect. Moreover, compared to 
high CRP levels in DSS-control (14.81±0.6 Pg/mL), B. coagulans (10.31±0.3Pg/mL), GBRS 
(10.61±0.7 Pg/mL) and Synbiotic (9.4±0.2 Pg/mL) reduced the serum CRP levels. Synbiotic 
and B. coagulans supplementations induced normalisation of CRP levels and were 
statistically similar to that of HC levels (8.3±0.5 Pg/mL). These observations indicate that a 
combination of probiotic spore and prebiotic GBRS resulting a desirable level of 
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Figure 5.6. Effect of B. coagulans spores, GBRS and Synbiotic on immune markers in colon tissues and 
blood serum. Protein levels of cytokines including (A) IL-1D, (B) IL-1E, (C) IL-6, (D) IL-12, (E) TNF-D, (F) 
IFN-J in proximal and distal colon explants as well as cytokine levels of (G) IL-1E, (H) IL-10, and (I) IL-12 in 
blood serum were analysed by Bio-plex. iNOS activity in colon tissues (J) measured by NOS activity assay 
and CRP levels in serum (K) by ELISA. Statistical significance among groups evaluated by one-way ANOVA 
followed by Tukey’s test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. DSS-colitic group and data 
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5.4.5 Effects of B. coagulans, GBRS, and Synbiotic supplementation on 
alteration of faecal metabolic profile  
Figure 5.7 Effect of B. coagulans spores, GBRS and Synbiotic on metabolic modulations in DSS-induced 
colitic mice. (A) 2D-PLS-DA plot showing spatial division among groups that received different 
supplementations, DSS-control mice that received no supplementation and HC. (B) Key compounds separating 
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Faecal samples were analysed by GC-MS platform to gain an untargeted overview of 
alterations in dominant gut metabolites induced by B. coagulans, GBRS and Synbiotic 
supplementations in DSS-treated mice. The analysis detected a total of 61 metabolites 
belonging to different functional groups such as sugars, amino acids, volatile fatty acids and 
biogenic amines. A supervised partial least squares-discriminant analysis (PLS-DA) was 
performed to evaluate metabolic phenotyping of each experimental group (Figure 5.7A). The 
remoteness between the samples from HC and DSS-control indicates a clear distinction in 
metabolic patterns between the groups. Among the supplemented groups, samples from B. 
coagulans and GBRS clusters overlapped with each other, and with that of HC, and partially 
with DSS-control. Synbiotic cluster showed clear divergence relative to that of DSS-control 
samples suggesting its potential to induce marked changes in the metabolic profile. 
Combination of PLS-DA (R2Y= 0.803 (P = 0.01), Q2 = 0.521), VIP scores (Figure 5.7B) 
and SAM enabled us to identify potential biomarkers. The results showed 61 metabolites 
with 28 statistically significant compounds contributing to the clustering, with their 
significance analysis for microarrays (SAM) scores fold changes and International 
Chemical Identifiers (InChI) and standard InChI hashes (InChIKey IDs) listed in 
Supplementary Table ST5.1. Key metabolic markers making a significant contribution 
were identified by VIP analysis as displayed in Figure 5.7B. Among these identified 
metabolites, substantial differences in the patterns between DSS-control and HC were 
particularly noted for allantoin, threitol, arabitol, uracil, aspartic acid, palmitic acid, 
myristic acid, hypoxanthine and 6-deoxy-D-glucose. Synbiotic supplementation generated 
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Figure 5.8. Effects of B. coagulans spores, GBRS and Synbiotic in modulating SCFA concentrations in 
caecal, mucosal-associated and faecal contents in DSS-induced colitis. Caecal- acetate (A), propionate (D), 
butyrate (G), valerate (J), succinate (M); mucosal-associated acetate (B), propionate (E), butyrate (H), valerate 
(K), succinate (N) and faecal- acetate (C), propionate (F), butyrate (I), valerate (L), succinate (O). Statistical 
significance among groups evaluated by one-way ANOVA followed by Tukey’s test. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 vs. DSS-colitic group and data expressed as mean ± SEM (n = 5 per group). ns = 
non-significant. 
A. B. C. 
D. F. E. 
G. H. I. 
J. K. L. 








Application of dietary strategies to prevent the onset or reduce severity of IBD is 
gaining momentum. The mechanisms that contribute to managing IBD appear to act through 
modulating cytokine responses, epithelial integrity and gut microbiota (521, 522). The results 
of the present study clearly indicated that pre-conditioning of gut with synbiotic 
supplementation carrying probiotic and prebiotic components, prior to DSS-induction, 
markedly reduced the symptoms and severity of DSS-induced colitis in the mouse model. The 
results supported the anti-inflammatory potentials of both the probiotic B. coagulans 
MTCC5856 and GBRS supplement ingredients. However, the effect was noted to be more 
profound with synbiotic supplementation as illustrated by its ability to prevent the clinical 
manifestations, macroscopic, histological, biochemical, metabolic and immune parameter 
changes in the DSS-induced mice. Synergistic action between the two bioactive components 
could account for such the enhanced beneficial effect.  
 
During feeding the supplementation of DSS-induced mice with B. coagulans, GBRS 
and Synbiotic significantly (P < 0.0001) lowered the DAI scores observed by the marked 
reduction in body weight loss and lower incidences of diarrheic/ bleeding faeces compared to 
that of DSS-control mice (Figure 5.2). Green banana-supplemented diets (79) and B. 
coagulans spores (48) have each previously been shown to reduce clinical diarrheal episodes 
in line with the observations on DDS-induced mice in the current study. The anti-diarrheic 
effect of GBRS could be due to its high RS content that, upon reaching the caecum/colon, is 
metabolized by bacteria to SCFAs (77). These in turn, stimulate salt and water absorption, 
provide energy and induce a trophic effect on the colon (79). The ability of B. coagulans to 
elicit an anti-diarrheic effect could be via several proposed mechanism that include 
suppression and binding of pathogenic bacteria, improvement of the epithelial barrier function 
and alteration of the immune activity of the host (48). Synbiotic supplementation that 
combines these effects should stimulate more profound efficacy outcomes against 
manifestations of IBD, as supported by the observations in the current study. 
 
The animal study allowed other observations not easily possible in clinical trials. A 
potential synbiotic outcome was demonstrated from improvement in histology of the colon 
(Figure 5.3A, 5.3B) compared to the DSS-control as well as to the B. coagulans and GBRS 
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colonic epithelial architecture by alleviating crypt disruption, loss of goblet cells, submucosal 
oedema and inflammatory infiltrates induced by DSS. In other biomarkers of IBD activity 
synbiotic supplementation caused significant reduction (P < 0.0001) in MPO activity (Figure 
5.3C) especially in the DC section compared to that of DSS-control. Neutrophil-
myeloperoxidase is an enzyme that catalyses production of reactive oxygen species and is 
increased in the mucosa of patients with IBD (558). The level of MPO activity is directly 
proportional to the neutrophil concentration and thus is an index of neutrophil infiltration and 
inflammation (520). MPO activity may cause oxidative damage to host tissue and induce or 
perpetuate inflammation. MPO is an important diagnostic and prognostic tool in assessing 
IBD status (558). This current research found that colonic MPO activity was markedly 
increased in DSS-control mice, and that synbiotic supplementation significantly reduced this 
effect in both PC and DC. This suggest that synbiotic supplementation has an anti-
inflammatory effect that in analogous to the histological evidence of protection.  
 
Synbiotic supplementation in this study, followed in efficacy by B. coagulans and 
GBRS alone, were also effective in protecting the TJ proteins (ZO-1, occludin and claudin-1) 
in DSS-induced mice (Figure 5.5). Disruption of intestinal epithelial TJs and impaired 
epithelial barrier function is a prominent event in the pathogenesis of clinical colitis that 
further promotes dysregulated immune reactions, thus aggravating gut inflammation. TJs 
maintain the epithelial barrier function by sealing the intracellular spaces between adjoining 
epithelial cells, thus restricting paracellular movement of harmful substances across intestinal 
mucosa (99). Our data shows that synbiotic supplementation exerted a marked protective 
effect on the barrier integrity by maintaining the expressions of the TJ proteins, thereby 
reducing the severity of gut inflammation. Moreover, Synbiotic and B. coagulans 
supplementations were most effective in protecting goblet cells and mucin production, with 
GBRS also demonstrating a considerable effect compared to the DSS-control (Figure 5.4). A 
recent study (392) has demonstrated the ability of a Bacillus probiotic to upregulate the 
expression of TJ proteins in colitic mice, in line with these observations with B. coagulans.  
 
The barrier integrity protection efficiency of  GBRS supplementation could also be 
correlated to the ability of its RS component to induce SCFA production that in turn nourishes 
the colonic mucosa (77). The results of the current study suggest that a synergy between B. 
coagulans and GBRS combination imparted a substantial protection and/or maintenance of 
epithelial integrity in DSS-induced mice. While the efficacy of the synbiotic combination to 
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investigation taken together the results support the ability of the prebiotic and probiotic 
combination to reinforce intestinal barrier integrity and help prevent the manifestation of IBD. 
 
The breach of epithelial integrity in IBD also triggers aberrant inflammatory responses 
resulting in increased accumulation of pro-inflammatory mediators and thus further 
exacerbating the inflammation cascade and tissue damage (91). B. coagulans alone, and in 
synbiotic combination, demonstrated excellent immunomodulatory and anti-inflammatory 
efficacy as evidenced by reduction in colonic pro-inflammatory cytokine levels of IL-1D, IL-
1E, Il-6, IL-12, TNF-D, and IFN-J in both PC and DC segments. The results were similar to 
our previous study (42) that demonstrated marked immunomodulatory effects of B. coagulans 
MTCC 5856 spores in-vitro with colonic cell cultures. Levels of IL-1E, IL-6 and TNF- D 
were reported to be elevated in IBD patients (118).  These cytokines are mainly secreted by 
activated lamina propria antigen presenting cells (APC) in response to the inflammation. 
APC’s are part of the mechanism that maintains intestinal immune tolerance in the steady 
state but also prevent inappropriate responses to components of the gut microbiota that 
contribute to pathology in IBD (559). TNF-D, plays a pivotal role in triggering the 
accumulation and activation of leukocytes in colitis and hence is an important therapeutic 
target (524). Blockade of IL-6 signalling with monoclonal antibodies was also reported to be 
effective in reducing chronic intestinal inflammation in a mouse model. This effect was 
associated with the activation of T cell apoptosis and the suppressed production of pro-
inflammatory IFN-J (525). In contrast to a previous study (77), using green dwarf banana 
flour, that reported no effect on colonic cytokines, in the current study there was a noticeable 
reduction in levels of IL-1E, IL-6 and IFN-J as well as reduction in serum IL-12 levels 
detected with GBRS supplementation. However, the respective immune-regulatory effects 
were less pronounced compared to that with Synbiotic supplementation, while there was no 
effect on levels of colonic IL-1D, IL-12, TNF-D and serum IL-10. Furthermore, in serum, 
Synbiotic supplementation induced marked reduction in pro-inflammatory IL-1E while, 
concomitantly increasing anti-inflammatory IL-10 indicating a synergistic effect.  
 
B. coagulans MTCC 5856 spores have been demonstrated to impart excellent 
immunomodulatory effects to colonic cells in-vitro in an inflammatory state (42). This 
observation highlights the potential for application of probiotics with substantial 
immunomodulatory capacity, in conjunction with prebiotic with average immune-regulating 
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responses in IBD. IL-10 plays a prominent role in counterbalancing Th1 and Th17 immune 
activity in IBD towards a Th2 response by downregulating antigen presentation and 
subsequent release of pro-inflammatory cytokines thereby attenuating mucosal inflammation 
(527). IL-10 deficiency has been demonstrated to exacerbate colitis in the DSS-induced colitis 
model and IL-10−/− knockout mice have been shown to develop spontaneous colitis (560). 
Moreover, IL-10 administration has been determined to ameliorate colitis in mice by 
suppressing intestinal inflammation and reducing pro-inflammatory cytokine production 
(561). The anti-inflammatory potential of the synbiotic supplementation in the current study 
therefore warrants its application to human IBD trials to confirm the ability to regulate the 
exacerbated immune responses. 
 
The supplementations also affected other indicators of the inflammatory response. The 
B. coagulans and Synbiotic supplementations suppressed increased colonic inducible nitric 
oxide synthase (iNOS) activity. Th1 and Th17 cytokines upregulate the iNOS expression and 
production nitric oxide (NO) in IBD that causes oxidative stress related inflammation and  
tissue damage (528). Elevated levels of CRP has been determined in human IBD (531). When 
inflammation is triggered, circulating IL-6 (partly induced by IL-1E and TNF-D) stimulate the 
production of CRP in the liver and subsequent release into the bloodstream (530). In the 
present study, elicited colonic IL-6 and serum CRP levels induced by DSS-induction were 
mitigated effectively by supplementation. Synbiotic, B. coagulans and GBRS 
supplementations displayed potent immune regulating efficacies to normalise the elevated 
serum CRP levels indicative of inflammation. Synbiotic was the most effective statistically (P 
< 0.0001) compared to DSS-control (Figure 5.6K). The combined immunomodulatory effect 
of B. coagulans and GBRS could be accounted for a potentiated synergistic efficacy of 
synbiotic supplementation in mitigating the pro-inflammatory cytokines in the current study. 
These findings indicate that the modulation of DSS-induced aberrant inflammatory responses 
by components of Synbiotic could potentially be owing to either a direct effect via 
suppression of pro-inflammatory cytokine, or to an indirect effect imparted by maintenance of 
epithelial integrity. Boost to the epithelial barrier functions would result in reduction of entry 
of foreign luminal antigens and thus lessen full activation of the innate immune system. There 
are therefore multiple mechanisms by which the action of synbiotic ingredient 
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The microbiota-derived metabolites and SCFAs, which are the signatures of the gut 
microbiota and modulate immune activity in the gut, are important indicators of dysbiotic 
pattern in IBD (533, 534). The profiling for potential microbiota-derived untargeted 
metabolites in the present study, revealed distinct patterns between DSS-control and HC 
samples that are in agreement with previous reports (220, 221), that confirmed significant 
difference in faecal metabolic profiles IBD subjects compared to that of their healthy 
counterparts. The Synbiotic supplementation in the current study demonstrated excellent 
ability to modulate faecal metabolic profile of DSS-induced mice compared with that of the 
DSS-control. B. coagulans and GBRS supplementations alone could not mediate the same 
modulations in the metabolic profiles as observed by their synbiotic combination. This 
suggests the importance of application of the synbiotic strategy to achieve the most 
pronounced beneficial effects. A similar trend in effects was observed, in terms of SCFA 
profiles, where B. coagulans alone was not very effective in inducing SCFAs along the colon 
past the caecum. The  Synbiotic and GBRS supplementations elicited elevated SCFA 
production along the entire length of colon. This indicated that, while the probiotic could 
induce increased fermentation in the caecum, the limiting factor post the caecum was the 
presence of fermentable substrate.  
 
SCFAs made in the colon are active metabolites that function to reduce inflammatory 
mediators and increasing epithelial barrier function (562). The most abundant SCFAs in the 
colon are acetate, propionate and butyrate. These are produced by gut microbiota via 
fermentation of indigestible fibres. The concentrations of SCFAs vary along the length of the 
gut. The caecum and proximal colon show the highest levels that then decline towards distal 
colon segment (535). Moreover, in the caecum and colon 95% of SCFAs are absorbed by the 
colonocytes while only 5% are excreted  in the faeces (563). Hence, determining the SCFA 
levels along entire length of colon including caecum is more instructive when assessing 
possible health effects than just measuring faecal SCFA levels. In this study the caecum 
showed the most abundant levels of SCFAs tested with all three supplementations confirming 
the findings of a previous study (536). However, this effect declined in the mucosal-
associated and faecal samples with B. coagulans supplementation. Furthermore, a noticeable 
increase in SCFAs levels with GBRS and Synbiotic supplementations were observed along 
the entire length of the colon (caecal, mucosal-associated and faecal contents). The 
observation implied that B. coagulans alone could induce extra SCFA either directly, by 
metabolising available chow fibre, or indirectly by stimulation of metabolism of SCFA-
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could be limited. This conclusion is further supported by the ability of Synbiotic 
supplementation showing the higher levels of SCFAs production detected beyond caecum in 
mucosal-associated and faecal contents. Also, similar levels of SCFA produced by both 
GBRS alone and Synbiotic suggest the potential role of native microbiota, and possibly a 
limited role of the administered spore probiotic, in mediating greater SCFA levels. It is 
concluded that applying B. coagulans, along with GBRS could potentiate SCFAs production 
along the entire length of colon to mediate trophic beneficial effects in IBD. However clinical 
trials would be needed to determine if the mouse results also applied to the activity of the 
human gut microbiome.  
 
There is good evidence that shows that reduced SCFAs concentrations, particularly 
butyrate, and its direct effect on microbial perturbations, results in defects in colonic barrier 
function and is associated with the related aberrant immune responses in IBD (551). In-vitro 
(538, 539) and in-vivo (540) studies have determined the effectiveness of butyrate in 
increasing epithelial integrity and mucus secretion. In the results of this study the considerable 
increase in butyrate levels by Synbiotic, GBRS and B. coagulans supplementation could be 
related to the positive effects observed on the histology of the colon, barrier integrity and 
reduction in disease severity in DSS-induced mice. Butyrate is the preferred energy source for 
colonocytes, and has the ability to regulate cytokines, thus showing protection against 
inflammation in UC and colorectal cancer (535). The improved expression of TJ proteins and 
mucus staining in goblet cells could be partially attributed to the elevated butyrate levels 
associated with Synbiotic supplementation in the present study. Acetate and propionate, that 
were found to elevate with Synbiotic supplementation along the entire colon length have also 
been found to benefit epithelial integrity via binding with certain metabolite-sensing G-
protein-coupled receptors (such as GPR43, GPR109A) and modulating immune response 
(227, 239, 542).Valerate, that has been determined to stimulate intestinal growth and attenuate 
inflammatory pathogenesis in colitis (222), was increased by Synbiotic supplementation in 
this study. Therefore, a prebiotic component of synbiotic combination, that directly or 
indirectly influences SCFA production capacity of administered probiotic and gut beneficial 
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5.6 Conclusions 
 
The research has highlighted a substantial efficacy of synbiotic supplementation 
carrying GBRS and B. coagulans spores in reducing the clinical manifestations and severity 
of DSS-induced colitis in a mouse model. The probiotic and prebiotic components 
complement each other to potentiate the beneficial effects.  A substantial anti-inflammatory 
effect of the Synbiotic supplementation was generated by suppressing aberrant immune 
responses and colonic damage induced by DSS.  The combination of the probiotic B. 
coagulans MTCC5856 and GBRS also improved the production of  the metabolites and 
SCFAs that could similarly function to modulate the inflammatory parameters and ameliorate 
the disease severity. The observed synergistic functioning ameliorating or preventing the 
disease severity in DSS-induced mice model supports its further investigation for mitigating 
inflammation in human IBD. Furthermore, synergistic combinations of these synbiotic 
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5.7 Supplementary data 
 
Figure SF5.1. Non-significant effect of B. coagulans spores, GBRS and synbiotic on immune markers in 
colon tissues and blood serum. Protein levels of cytokines including (A) IL-10 (B) IL-17, (C) MIP-1D, (D) 
MIP-1E, (E) GM-CSF in proximal and distal colon explants as well as cytokine levels of (F) IL-1D, (G) IL-6, 
(H) TNF-D, (I) IL-17, (J) IFN-J, (K) MIP-1D, (L) MIP-1E, (M) GM-CSF  in blood serum were analysed by 
Bio-plex. Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test. Non-
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Table ST5.1. Most significant compounds identified by OPLS-DA and SAM analysis in HC, DSS-control, 
B. coagulans (BC), GBRS and Synbiotic groups (*First 28 compounds are identified by SAM).  
Compound 




































V-UHFFFAOYSA-N 1.1377 0.98485 
0.2037























5 0.54117 0.017213 
Stearic acid* 
QIQXTHQIDYTFR
H-UHFFFAOYSA-N 1.1904 1.1258 
0.0895




UHFFFAOYSA-N 0.97012 0.97602 1.2616 1.0181 0.97063 0.022131 
L-alanine* 
MUBZPKHOEPUJK













N 0.93638 0.98458 1.2561 1.0268 0.93831 0.038033 
Oleic acid* 
ZQPPMHVWECSIR
J-KTKRTIGZSA-N 0.90587 0.82736 1.1791 
0.8141




N 0.76788 1.2614 1.0012 1.316 1.2004 0.042459 
Altrose* 
WQZGKKKJIJFFOK




3 0.8301 0.060164 
Glucose* 
WQZGKKKJIJFFOK




9 1.0548 0.068689 
Urea* 
XSQUKJJJFZCRTK-
UHFFFAOYSA-N 1.8628 2.1847 2.4975 2.2657 2.0866 0.072787 
Talose* 
WQZGKKKJIJFFOK

















3 0.95198 0.096721 
Cholic acid* 
BHQCQFFYRZLCQ
Q-OELDTZBJSA-N 0.86044 0.76698 1.105 
0.7897













ABXHMFFYSA-N 0.51337 0.66024 
0.2917

















A-UHFFFAOYSA-N 1.18 1.0594 
0.8938
















6 0.98415 0.17377 
Allose* 
WQZGKKKJIJFFOK




8 0.79865 0.17557 
Name 
(unidentified
) - 1.5577 1.3491 
0.0490
86 1.4048 1.2883  
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Chapter 6 
Efficacy of sugar cane fibre and probiotic spore 
synbiotic combination in attenuating chronic colonic 





The efficacy of using prebiotic whole plant sugar cane fibre (PSCF) in combination 
with probiotic Bacillus coagulans MTCC5856 spores (B. coagulans) was investigated alone, 
and in synbiotic combination, for ameliorating chronic colitis in the spontaneous colitic 
Winnie (Muc2 mutant) mice model of IBD. Seven-week-old Winnie colitic mice were fed 
normal chow diet supplemented with either B. coagulans, PSCF or its synbiotic combination 
for 21 days. All three supplementations improved diarrheic stools, as well as prevented body 
weight loss. Synbiotic supplementation significantly ameliorated histological scores in both 
proximal (p<0.0001) and distal (p=0.0443) colon sections more effectively than either B. 
coagulans and PSCF alone. Moreover, Synbiotic supplementation substantially modulated the 
altered colonic and serum cytokine levels and lowered serum C-reactive protein (CRP) level 
compared to the unsupplemented Winnie-control. All three supplementations also resulted in 
noticeable modulation in the microbiota composition in caecal, mucosal-associated and faecal 
samples. While, PSCF favoured the abundance of Akkermansia, Synbiotic was effective in 
restabilising the depleted levels of Prevotella in Winnie colitic mice. Synbiotic was also 
significantly effective in elevating and normalising the levels of short-chain fatty acids along 
the length of the colon compared to that in unsupplemented Winnie-control mice. The 
augmented synbiotic effect could potentially be due to a combination of direct immune-
modulating abilities of the components, their capability to improve epithelial integrity and/or 
modulation of the microbiota. Additionally, the symbiotic effect could also be a result of the 
increased levels of fermentation products elicit mitigation of inflammation. The beneficial 
effects in ameliorating the inflammation in spontaneous chronic colitic Winnie mice model of 
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6.2 Introduction 
 
IBD, including UC and CD are chronic inflammatory conditions of the gastrointestinal 
tract and have multifactorial aetiologies (564). A three part  pathophysiological circuit 
involving aberrant immune response, dysbiotic intestinal microbiota (and the associated 
metabolic pathways) and aberrant intestinal barrier function have been considered leading 
factors for causing ongoing chronic inflammation (19). The interaction of genetic, 
environmental and immunological factors is also believed to play prominent roles in the 
development and course of IBD. Additionally changes in the composition of the gut 
microflora have been associated with the pathogenesis of IBD (19, 138, 141, 143). The 
incidence of CD and UC is rising worldwide (493) despite the current medical treatments that 
focus primarily on immunosuppression (19). Treatments that hinder multiple factors involved 
in the recurrent inflammatory cascade would be a more pragmatic approach for mitigating the 
chronic inflammation associated with IBD.  
 
Dietary interventions are being sought as adjuvant therapeutic treatments (9, 10, 23, 
535). Dietary components can influence the composition of gut microbiota and the associated 
bacterial metabolic pathways, as well as interact with the immune system.  In this context, a 
synergistic combination of prebiotic dietary fibre (DF) and probiotic bacteria are considered a 
potential approach to resolving the inflammatory cascade in the gut. Mechanistically this can 
be achieved by modifying the microbiota composition, the microbial metabolites, regulating 
secretion of immunomodulatory molecules and through protecting the colonic epithelial 
barrier (26, 28). The westernised diet, low in dietary fibres from fruits and vegetables, has 
also been linked to the surge in IBD incidence (9, 23). The biochemical complexity of DF is 
being regarded as a logical factor in influencing microbial complexity (52-54). Prebiotic 
fibres that are representative of whole plant vegetable and fruits, retain biochemical 
complexity and cell wall structures. Whole plant PSCF is made by grinding the dried, sucrose 
depleted cane. It therefore has 87% total dietary fibre content made up of both soluble and 
insoluble as well as rapid-and slow-fermentable fibres at ratios similar to that of whole plant 
foods (72, 73, 74). Moreover, to achieve potentiated synergistic beneficial outcomes, 
application of compatible probiotic that can metabolise these fibre fractions would be 
desirable.  
 
B. coagulans can metabolise a variety of plant substrates rich in insoluble cell wall 
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demonstrated to confer substantial immunomodulatory, anti-inflammatory and anti-diarrhoeal 
effects (42, 48). It is therefore a candidate for synbiotic combination with prebiotic dietary 
fibres to augment its beneficial effects via SCFA production. Moreover, besides maintaining 
its stability during processing and storage of functional foods (43),  B. coagulans spores have 
been shown in-vitro to survive during gastric transit and adhere to human colonic epithelial 
cells (42).   
 
In the previous study (Chapter 4), pre-conditioning of mice PSCF and B. coagulans 
spores, prior to chemical induction of colitis using DSS, resulted in effective attenuation of 
acute colitis in DSS-colitic mice. The study clearly demonstrated that pre-conditioning of the 
gut with the synbiotic supplementation resulted in improvement in the severity of the clinical 
manifestations, histopathological features, immune markers and bacterial short-chain fatty 
acid production. The positive results may have been specific to the acute DSS model of colitis 
and changes in the microbiome could not be reliably measured due to interference of the DSS 
with PCR reaction. Therefore, the efficacy of the synbiotic combination carrying whole plant 
PSCF and B. coagulans in ameliorating chronic colitis was also tested using the well-
established Winnie spontaneous chronic colitis mouse model.  
 
Winnie mice are raised from a C57BL/6 background and demonstrate symptoms closely 
resembling to that of clinical IBD (565). Inflammation is evident by 6 weeks of age and 
progresses over time, leading in severe colitis, by the 16th week (566). The chronic intestinal 
inflammation results from a primary intestinal epithelial defect conferred by a missense 
mutation in the Muc2 mucin gene (109, 566). Disruption of Muc2 biosynthesis initiates 
depletion of mucus layers, increasing intestinal permeability and leading to increased 
vulnerability to luminal antigens (109). The decrease in Muc2 production and secretion in 
active UC patients (567) and reduced expression of Muc2 in CD (568) are comparable to the 
variation in Winnie Muc2 aberration (565). Moreover, colitis in Winnie is chronic with 
periods of remission and relapse similar to human IBD (569). The inflammation in the distal 
region of the Winnie colon shows histopathological features of crypt elongation, neutrophilic 
infiltrates, goblet cell loss, crypt abscess formation, limited mucus secretion and focal 
epithelial erosions with an ulcerative colitis-type phenotype (109). Moreover, microbial gut 
dysbiosis and disruption in metabolomic profile in Winnie has been recently confirmed to be 
comparable to that in clinical IBD (217). Winnie mice have been shown to respond well to 
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572). However, the influence of dietary components such as probiotic or prebiotic on the 
disease pathogenesis in chronic spontaneous colitic Winnie mice is lacking.  
 
It was hypothesised, based on the DSS model results (Chapter 4), that synergism 
between the whole plant PSCF and B. coagulans MTCC 5856 (B. coagulans) spores, would 
confer beneficial effects in attenuating chronic inflammation in spontaneous colitic Winnie. 
This study therefore aimed to investigate the therapeutic efficacy of the supplementations, 
alone and in combination, in the Winnie mice model of IBD and further examine its 
underlying mechanisms. The observations of this study would be useful in appreciating the 
effects of dietary components on the health of chronic colitic Winnie mice. This aspect has 
not been previously reported for this spontaneous colitic model. The Winnie model also 
offered the additional advantage of being able to extract DNA to profile the microbiome 
without the interference from DSS. This interference prevented good DNA extraction and 
profiling of microbiome changes in the DSS induced colitis model.  
 
6.3 Materials and methods 
 
6.3.1 Probiotic Bacteria and Prebiotic Dietary Fibre 
 
LactoSpore® (Sabinsa Corporation, East Windsor, NJ, USA) containing the probiotic 
strain Bacillus coagulans MTCC 5856 (6 × 109 spores/gm) was produced by Sami Labs 
Limited (Bangalore, India) and supplied by Sabinsa Corporation (Australia). Kfibre, 
prebiotic whole plant sugar cane fibre (PSCF) was supplied by KFSU Pty Ltd., Queensland, 




Thirty-two, six-week-old Winnie mice (homozygous Muc2 mutant; C57BL/6J 
background) of both sexes and eight, six-week-old C57BL/6J wild type (WT) were obtained 
from the University of Tasmania animal breeding facility and housed in a temperature-
controlled environment with a 12-hour day/night light cycle. Individual body weights were 
assessed daily including over an initial acclimation period of 7 days. All mice had access to 
radiation-sterilised rodent feed pellets (Barastoc Rat and Mouse, Ridley AgProducts, 
Australia, Appendix III) and autoclaved tap water for drinking ad libitum during experiments. 
All animal experiments were approved by the Animal Ethics Committee of the University of 
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with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes (8th 
Edition 2013). All efforts were made to minimize animals' suffering and to reduce the number 
of animals used.  
 
6.3.3 Study Design and Treatments 
 
Figure 6.1. Experimental design of in-vivo feeding trial to analyse therapeutic efficacy of B. coagulans 
spores, PSCF and Synbiotic in chronic spontaneous colitis Winnie mice model. Colitic Winnie mice (n = 8 
per group) that received normal drinking water were fed chow supplemented with either  B. coagulans spores, 
PSCF or their Synbiotic combination for 21 days.  
 
Following 1 week of acclimation, Winnie mice at 7 weeks of age were randomly 
allocated into the following 4 groups (n = 8 per group): (1) Winnie-control, (2) Probiotic B. 
coagulans MTCC 5856 (B. coagulans), (3) Whole plant prebiotic sugar cane fibre (PSCF) and 
(4) Synbiotic supplement. The experimental design of the mice feeding trial is illustrated in 
Figure 6.1. Mice in the Winnie-control group received 4g chow mash (standard chow pellet 
blended with water). The B. coagulans group received 4 g chow mash supplemented with 
probiotic B. coagulans MTCC 5856 spores (2 × 109 CFU/day/mouse). The PSCF group 
received 4g chow mash supplemented with Kfibre (200 mg/day/mouse). Synbiotic mice 
received 4 g chow, each supplemented with B. coagulans MTCC 5856 spores (2 × 109 CFU/ 
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4g normal chow mash. The chow mash was prepared fresh each day. The mice were single-
caged throughout the experiment to measure the defined daily intake of respective treatments 
from prepared chow mash. The mice were fed these treatments for 21 days. Mice were 
sacrificed on day 22 by CO2 asphyxiation.  
 
6.3.4 Clinical Scoring and Histological Analysis 
 
Body weight and  disease activity index (DAI) was determined daily in all Winnie 
mice by scoring for changes in body weight, hemoccult reactivity, presence of gross blood in 
stool or at the anus and stool consistency, throughout the experiment, as detailed previously 
(501). DAI was determined by combining the scores from two parameters - stool consistency 
and presence of blood in the stool. These parameters were graded according to the scoring 
system as described previously in Chapter 4 (Section 4.3.4). Body weights were calculated for 
each animal throughout the experiments and weight calculated as percent weight change to 
the weight immediately before administration of supplemented chow (day 0). Faecal samples 
from Winnie and WT mice were collected on day 21 for short-chain fatty acid (SCFAs) and 
microbiota analyses. During faecal sample collection, mice were placed in cages with no 
bedding for approximately 2 hours to avoid contamination. At least 4 pellets (200-400 mg) 
were collected fresh from each mouse and transferred to microcentrifuge tubes using sterile 
forceps before storage at -80°C.  
 
Following the sacrifice of mice, the measurement of macroscopic markers of 
inflammation (colon length and weight, spleen weight), collection of mucosal-associated and 
caecal contents for SCFA and microbiota profiling, collection of colonic tissues for cytokine 
analyses and preparation of proximal and distal colonic sections for histological staining by 
haematoxylin and eosin (H&E) was performed as detailed previously in Chapter 4 (Section 
4.3.4). Slides stained with H&E (n = 6 per group) were graded blindly for the severity of 
tissue damage at distal and proximal regions based on the previously described scoring system 
(501, 504). Briefly, frequency of inflammatory infiltrate graded 0-3, goblet cell loss graded 0-
3, crypt architectural distortion graded 0-3, frequency of crypt abscess graded 0-3, crypt 
hyperplasia graded 0-3, muscle thickening (oedema) graded 0-3, ulceration graded 0-3. The 
histological inflammation score for each proximal and distal colon region was derived from 
the sum of the score for each aforementioned criterion. All images were captured on a Leica 
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6.3.5 Tissue Explant Culture and Cytokine Measurements 
 
The cytokine levels in colon tissues (n = 3) and serum (n = 3) were determined by 
immunoassay using a Bio-Plex Pro Mouse cytokine 23-plex kit (Bio-Rad #M60009RDPD, 
Bio-Rad Laboratories, Australia) following the manufacturer’s instructions and concentrations 
analysed using a Bio-Plex 200 instrument (Bio-Rad) and Bioplex Manager software, version 6 
(Bio-Rad Laboratories) respectively as detailed in Chapter 4 (Section 4.3.8) (552). For tissues, 
the cytokine levels were normalized by dividing the cytokine results (pg/mL) by the measured 
biopsy weight (g) and the cytokines are presented as pg/g of tissue. 
 
6.3.6 Serum C-Reactive Protein Analysis 
 
The levels of C-reactive protein (CRP) in serum from respective groups (n = 3 
samples/group) were analysed using Mouse C-Reactive Protein/CRP Quantikine Elisa kit 
(MCRP00, R and D Systems, Australia) following the manufacturer’s instructions. The results 
are expressed as Pg/mL. 
 
6.3.7 Volatile SCFA Analysis 
 
GC-MS analysis of 100–150 mg fresh weight (stored at −80 °C) of caecal, mucosal-
associated and faecal samples (n = 5 per group) each was conducted for volatile SCFA 
profiling following the method described previously (510, 552) in Chapter 4 (Section 4.3.11). 
The GC-MS analysis was performed by Dr. David J. Beale (CSIRO), Dr. Avinash V. Karpe 
(CSIRO) and Dr. Shakuntala V. Gondalia (Swinburne University of Technology). Data 
analysis and interpretation was performed by the PhD candidate. 
 
6.3.8 Microbiota analysis by 16s rRNA high-throughput sequencing 
 
The total DNA was extracted from caecal, mucosal-associated and faecal samples (n = 5 
per group) of Winnie and WT mice using the QIAamp DNA Stool Mini Kit (Qiagen, 
Melbourne, VIC, Australia). The samples underwent high-throughput sequencing on the 
Illumina MiSeq platform at the Australian Genome Research Facility (University of 
Queensland, Brisbane, QLD, Australia). Polymerase chain reaction (PCR) amplicons 
spanning the 16S rRNA V1-V3 hypervariable region with 27F forward primer (5’-
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GWATTACCGCGGCKGCTG-3’) were sequenced. Paired-end reads were assembled by 
aligning the forward and reverse reads using PEAR1 (version 0.9.5). Primers were identified 
and trimmed. Trimmed sequences were processed using Quantitative Insights into Microbial 
Ecology (QIIME 1.8) 4 USEARCH 2.3 (version 8.0.1623) and UPARSE software (573). 
Using USEARCH tools, sequences were quality filtered; full-length duplicate sequences were 
removed and sorted by abundance. Singletons or unique reads in the data set were discarded. 
Sequences were clustered followed by chimera filtering using "rdp_gold" database as a 
reference (574). To obtain several reads in each Operational taxonomic units (OTUs), reads 
were mapped back to OTUs with a minimum identity of 97%. Using QIIME, taxonomy was 
assigned using Greengenes database5 (Version 13_8, Aug 2013) (575). Image analysis was 
performed in real time by the MiSeq Control Software (MCS) v2.6.2.1 and Real-Time 
Analysis (RTA) v1.18.54, running on the instrument computer. RTA performs real-time base 
calling on the MiSeq instrument computer. The Illumina bcl2fastq 2.20.0.422 pipeline was 
used to generate the sequence data (574, 575). 16S rRNA gene sequences were analysed using 
MEGAN6 (Community edition version) (576), Microbiome analyst (577) and QIIME. 
Statistical analysis of Bray-Curtis dissimilarities was calculated using the relative abundances 
of bacterial genera using Adonis function in R (version 3.2).  
 
6.3.9 Statistical Analysis 
 
All data are presented as means ± SEMs. The statistical analysis was performed using 
GraphPad Prism Software (Version 7.0) The data were evaluated using One-way analysis of 
variance (ANOVA) followed by Tukey’s post-hoc test to determine statistical differences 
between the groups against Winnie-control samples.  For the analysis of DAI and body weight 
changes during the experimental period, Two-way ANOVA was used followed by Tukey’s 
post-hoc test, setting treatment and the time as the variables. A P-value of < 0.05 was 
considered significant. To determine overall microbial variation in the five groups, a principal 
coordinate analysis (PCoA) was used with Bray-Curtis ecological indexing and Euclidean 
distances as the similarity measure and Ward’s linkage as a clustering algorithm (510). Two 
bacterial alpha (D-) biodiversity indices were evaluated, i.e. the Inverse Simpson Index and 
the Shannon Index. for both indices, an increased value indicates greater diversity (578). The 
data were evaluated with one-way analysis of variance (ANOVA) and using Tukey’s test for 
multiple comparisons with a statistical significance of P < 0.05. For comparative microbial 
analysis, a linear discriminant effect size (LEfSe) analysis was performed (α = 0.05), 
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6.4 Results 
 
6.4.1 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
clinical manifestations in Winnie mice 
 
DAI (stool consistency and blood in faeces) and body weight changes were evaluated to 
determine the efficacy of the treatments in reducing the severity of disease symptoms in 
Winnie chronic spontaneous colitic mice (Figure 6.2). Compared with the Winnie-control 
group, that showed severe colitis symptoms (loss of body weight and diarrheic/bloody 
faeces), supplementation with B. coagulans, PSCF and Synbiotic significantly reduced the 
DAI levels as well as prevented body weight loss throughout the experiment (Figure 6.2A). 
At the end of the experiment, DAI of Winnie-control group was significantly higher 
(4.38±0.2) compared with that of B. coagulans (1.38±0.2, -69%), PSCF (1.75±0.3, -60%) 
and Synbiotic (1.37±0.3, -69%). Noticeably, PSCF was most effective in reducing DAI as 
early as day 3 mainly owing to improvement in stool consistency in comparison with B. 
coagulans and Synbiotic. In contrast to Winnie-control mice on day 21 (Figure 6.2B), Winnie 
mice supplemented with Bacillus, PSCF and Synbiotic treatments recovered body weight loss 
by 73.89%, 33.23% and 49.79% respectively.  
 
The macroscopic evaluation of colonic segments revealed the beneficial effects of all 
three supplementations used in the study, as evidenced by marked reduction in colon 
weight/body weight ratio (B. coagulans, 21.01±1.7; PSCF, 23.57±1.0 and Synbiotic, 
19.79±1.2 mg/g) compared with Winnie-control group (32.29±1.2 mg/g) (Figure 6.2C). None 
of the supplementations were effective in reducing the spleen enlargement (Figure 6.2D) that 
is also associated with colonic inflammation (499). Synbiotic supplementation was also 
significantly effective in reducing the colon length shortening (9.5±0.4) compared to the 
shorter colon length of Winnie-control mice (8.4±0.2 cm) (Figure 6.1E-F). The above markers 
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Figure 6.2. Effect of B. coagulans spores, PSCF and Synbiotic on clinical  manifestations in chronic colitic 
Winnie mice. (A) Disease Activity Index (DAI), (B) % body weight change. Statistical significance among 
groups evaluated by two-way repeated-measures analysis of variance (ANOVA) followed by Tukey’s test. *P < 
0.05, **P < 0.01, ***P< 0.001, ****P< 0.0001 vs. DSS-control group and data expressed as mean ± SEM (n = 8 
per group). Colon weight/body weight ratio (C), Spleen weight (D), Colon length (E) and macroscopic 
appearance of colon (F). Data expressed as mean ± SEM (n = 8 per group), evaluated by one-way ANOVA 
followed by Tukey’s Test. NS = non-significant, PSCF- Prebiotic sugar cane fibre. 
A.                                                                              B.                                                                                
C.                                                                             D.           
E.  F.  
Winnie-
control 
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6.4.2 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
histological alterations in chronic colitic Winnie mice 
Figure 6.3. Effect of B. coagulans spores, PSCF and Synbiotic treatments on colon injury and 
inflammation in chronic colitic Winnie mice. (A) Histological images of proximal and distal colonic tissues 
stained with hematoxylin and eosin at 10x for each experimental group. (B) Histological score calculated after 
microscopic analyses of proximal and distal sections of the colon. Results expressed as mean ± SEM (n = 6 
per group), evaluated by one-way ANOVA followed by Tukey’s test (*P < 0.05, **P < 0.01, ****P < 
0.0001). 
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Histological examination showed severe surface epithelial damage, crypt abscesses, 
crypt loss, distortion of crypt architecture, crypt hyperplasia and increased inflammatory 
infiltrate mostly affecting the distal colon (DC) section (Figure 6.3A) of Winnie-control 
compared with that of supplemented mice. Supplementation of Winnie with synbiotic (11, P 
< 0.0001), B. coagulans (13, P = 0.0003) and PSCF (13.8, P = 0.0014) displayed significant 
improvements in the histology of the colon, particularly in the distal section compared with 
the marked histological alterations score of 19.7 in untreated Winnie-control mice (Figure 
6.3B). The comparative histological score for proximal colon (PC) was also statically lower 
(P = 0.0443) in Winnie supplemented with synbiotic (6.83) compared to that of Winnie-
control (10). B. coagulans (7.83, P = 0.2377) and PSCF (8, P = 0.3002) alone were not 
statistically effective in reducing the histological score in PC, thus supporting the necessity of 
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6.4.3 Immunomodulatory effects of B. coagulans, PSCF, and Synbiotic 
supplementation on colonic immune markers  
 
Figure 6.4. Effect of B. coagulans spores, PSCF and Synbiotic on immune markers in colon tissues. Protein 
levels of cytokines including (A) IL-1D, (B) IL-1E, (C) IL-6, (D) IL-10, (E) IL-12, (F) Il-17, (G) GM-CSF, (H) 
IFN-J, (I) MIP-1D,  (J) MIP-1E and (K) TNF-D in proximal and distal colon explants were analysed by Bio-
plex. Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001, ns-non-significant vs. Winnie-control and data expressed as mean 
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Cytokine analysis of the colonic tissue explants was used to ascertain the intestinal 
immunomodulatory and anti-inflammatory effects of B. coagulans, PSCF and their synbiotic 
combinations showing beneficial effects on the altered immune responses in spontaneous 
chronic colitic Winnie mice (Figure 6.4). The mucosal explants isolated from the colon of the 
untreated Winnie-control group showed marked secretion of a number of pro-inflammatory 
cytokines (IL-1D,  IL-1E, IL-6, IL-12, IL-17, GM-CSF, IFN-J, TNF-D) and chemokines 
(MIP-1D, MIP-1E) and a drop in anti-inflammatory IL-10 levels in both PC and DC sections. 
Supplementation of Winnie with synbiotic markedly suppressed the level of the elevated pro-
inflammatory mediators, particularly in the DC section compared with that of the B. 
coagulans and PSCF supplementations alone. In PC the B. coagulans, PSCF and Synbiotic 
groups showed significant reduction in levels of MIP-1E and TNF-D. While PSCF was 
effective in suppressing the levels of IL-1D (P = 0.0242), IFN-J (P = 0.0179), GM-CSF (P = 
0.0168), MIP-1D (P = 0.0204), MIP-1E (P = 0.0054), and TNF-D (P = 0.0022) in DC no 
substantial reduction was noted for secretions of IL-1E (P = 0.1867), IL-6 (P = 0.1065), IL-12 
(P = 0.0644), or IL-17 (P = 0.1044). Synbiotic and B. coagulans alone were statistically 
equivalent in suppressing the secretions of IL-1D (P = 0.0203, 0.0198 respectively), IL-1E (P 
= 0.0195, 0.0229 respectively), IL-6 (P = 0.0173, 0.0116 respectively), IL-12 (P=0.0225, 
0.0198 respectively), GM-CSF (P = 0.0139, 0.0148 respectively), MIP-1D (P = 0.0012, 
0.0014 respectively), and MIP-1E (P = 0.0020, 0.0027 respectively) in DC. However, 
Synbiotic compared to B. coagulans supplementation was more potent in reducing the levels 
of IL-17 (P = 0.0304, 0.1044 respectively), IFN-J (P = 0.0084, 0.0292 respectively), and 
TNF-D (P = 0.0007, 0.0023 respectively). Moreover, Synbiotic supplementation elevated the 
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6.4.4 Immunomodulatory effects of B. coagulans, PSCF, and Synbiotic 
supplementation on systemic immune markers  
 
Figure 6.5. Effect of B. coagulans spores, PSCF and synbiotic on immune markers in serum. Protein levels 
of cytokines including (A) IL-1D, (B) IL-1E, (C) IL-6, (D) IL-10, (E) IL-12, (F) IL-17, (G) GM-CSF, (H) IFN-J, 
(I) MIP-1D and (J) MIP-1E and (K) TNF-D in serum were analysed by Bio-plex. CRP levels in serum (L) 
measured by ELISA. Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s 
test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = non-significant vs. Winnie-control and data 
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None of the three supplementations were effective in reducing the serum levels of IL-1D, IL-
17, GM-CSF and MIP-1D. However, substantial immune regulatory effects of the 
supplementations in Winnie were noted for other serum cytokines tested (Figure 6.5A-K). B. 
coagulans and PSCF supplementations alone suppressed the elevated serum levels of IL-1E 
(P = 0.0094, 0.0110 respectively), IL-6 (P = 0.0015, 0.0045 respectively), IFN-J (P = 0.0156, 
0.1739 respectively), MIP-1E (P=0.246, 0.0288 respectively) and TNF-D (P = 0.0384, 0.0338 
respectively) in chronic spontaneous colitic Winnie. In addition to suppressing these 
cytokines, Synbiotic supplementation showed relatively more profound suppression in the 
levels of IL-6 (P = 0.0004) and IFN-J (P = 0.0099) further supporting the existence of 
synergetic beneficial effects. Moreover, compared to Winnie-control, synbiotic 
supplementation significantly elevated the anti-inflammatory IL-10 levels in serum (P = 
0.0233). It was more effective than B. coagulans (P = 0.4021) and PSCF (P = 0.9481) 
supplementations alone. Marked systemic immunomodulatory outcome effects of the 
supplementations in chronic colitic Winnie was also evidenced by the ability of B. coagulans, 
PSCF and its synbiotic combination to reduce the elevated CRP in the serum (11.32±0.58, 
12.91±0.57 and 12±0.32 Pg/mL respectively) compared to that in unsupplemented Winnie-
controls (16.81±0.80 Pg/mL) as depicted in Figure 6.5L. These observations, together with 
the prior DSS model results, further corroborate the substantial immunomodulatory and anti-
inflammatory efficacies of the supplementations used in the study to reduce colonic and 
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PC2: 26.7% 
PC1: 33.6% PC3: 14.1% 
6.4.5 Effects of B. coagulans spores, PSCF and Synbiotic 
supplementation on microbial diversity in chronic colitic Winnie mice 
 
Table 6.1. Comparison of Alpha (D) diversity indices evaluated in caecal, mucosal-associated and faecal 
samples obtained from wild-type (WT), Winnie-control, B. coagulans spores, PSCF and Synbiotic mice.  
 
Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test. *P < 0.05, **P 
< 0.01, ***P < 0.001 Versus Winnie-control group and $P < 0.05, $$P < 0.01, $$$P < 0.001 versus WT group. 
Data expressed as mean ± SEM (n = 5 per group). 
 
 
Figure 6.6. Principal component analysis (PCoA) plot based on Bray-Curtis distances calculated in caecal 
(C-), mucosal-associated (M-) and Faecal (F-) contents of wild-type (WT), Winnie-control (Win), B. 
coagulans (Bc) spores, PSCF and Synbiotic (Syn) groups; (n = 5 per group). 
Sample site Group Shannon Index Inverse Simpson 
Index 
Caecal WT 3.8 (±0.03) 11.7 (±0.25) 
 Winnie-control 3.9 (±0.09) 12.3 (±0.45) 
 B. coagulans 4.2 (±0.06)$ 14.0 (±0.35)$$, * 
 PSCF 4.17 (±0.10)$ 13.1 (±0.25) 
 Synbiotic 4.2 (±0.06)$, * 14.6 (±0.45)$$$, ** 
Mucosal WT 3.9 (±0.01) 11.85 (±0.29) 
 Winnie-control 4.1 (±0.01)$ 13.53 (±0.17)$$ 
 B. coagulans 4.2 (±0.02)$$ 13.68 (±0.23)$$$ 
 PSCF 4.1 (±0.04) 13.47 (0.34)$$ 
 Synbiotic Undetermined Undetermined 
Faecal WT 3.7 (±0.14) 10.5 (±0.34) 
 Winnie-control 3.8 (±0.17) 10.7 (±0.27) 
 B. coagulans 4.0 (±0.06) 12.23 (±0.37)$,* 
 PSCF 3.9 (±0.04) 12.19 (±0.29)$,* 
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Taxonomic and functional profiles of 75 samples (n = 5 per group), including the caecal, 
mucosal-associated and faecal samples of WT and Winnie groups, were generated using the 
16S rRNA gene sequencing-based method. In the experiment, 3 out of 5 synbiotic mucosal-
associated samples collected did not generate the required 30,000 minimum sequencing raw 
read outputs hence the effect of synbiotic in modulating microbial diversity in mucosal-
associated samples could not be determined. The effect of supplementation of diet with B. 
coagulans, PSCF and synbiotic in modulating microbial alpha and beta diversities in chronic 
colitic Winnie across caecal, mucosal-associated and faecal contents were assessed (Table 
6.1). The Shannon index and inverse Simpson index, which are indices of alpha diversity, did 
not significantly differ between WT and Winnie-control mice samples except for in the 
mucosal-associated sample. The supplementations however, caused substantial increases in 
alpha diversity indices and the effect varied across the sample types. Compared with that of 
Winnie-control, synbiotic supplementation resulted in increased Shannon and Simpson 
indices in caecal and faecal samples. B. coagulans and PSCF supplementations alone 
however, resulted in significant modulation only in the Simpson index but had no effect on 
the Shannon-index. To evaluate beta diversity, PCoA plots of phylogeny with Bray-Curtis 
ecological indexing using ward clustering was used (Figure 6.6). The clustering showed 
distinct demarcation of samples (caecal, mucosal-associated and faecal) of WT group from 
that of Winnie groups (both supplemented and unsupplemented) with three distinct clusters at 
the operational taxonomic units (OTU) level among the 5 groups. This indicated clear 
differences in the microbial patterns between the healthy WT and the inflamed Winnie colitic 
mice. However, the microbial communities (irrespective of the sample types) of 
unsupplemented Winnie-control and supplemented Winnie groups were scattered, with no 
clear distinction between groups. This suggested high inter-individual variability among the 
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Figure 6.7. Relative abundances (%) of caecal (C)-, mucosal (M)- and Faecal (F)- associated microbiota at 
(A) phylum, (B) genus and (C) species level observed in wild-type (WT), Winnie-control (Win), B. coagulans 
(Bc) spores, PSCF and Synbiotic (Syn) groups; (n = 5 per group). 
 
Figure 6.7A indicates the phylum-level changes in the caecal, mucosal-associated and 
faecal samples of WT and Winnie mice, which are dominated by Bacteroidetes and 
Firmicutes and moderately by Verrucomicrobia. Around 99% of the total microbial 
abundance was classified into seven major phyla (Bacteroidetes, Cyanobacteria, 
Deferribacteres, Firmicutes, Proteobacteria, TM7 and Verrucomicrobia) in all sample types, 
while the rest were allocated as unclassified or others. Although Winnie mice shared most of 
the same phyla as healthy WT, levels of their abundance varied. While WT caecal and faecal 
samples showed 43% and 16% respectively of relative abundance of Firmicutes, their levels 
were reduced in Winnie-control to only 16% in caecal and 8% in faecal samples. Similarly, 
the phylum Bacteroidetes was also reduced in Winnie-control (19%) caecal samples 
compared to that of WT (54%). Though B. coagulans and PSCF supplementations resulted in 
elevation of Firmicute levels (28% and 22% respectively), no effect was observed for relative 
abundance of Bacteroidetes (19% and 20% respectively). Synbiotic supplementation 
however, increased Firmicutes (25%) and Bacteroidetes (36%) levels relative to that of 
Winnie-control in the caecum. Also, in faecal samples, Synbiotic supplementation was 
effective in inducing modulations in the levels of Firmicutes (25%) and Bacteroidetes (36%) 
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samples in Winnie groups showed increased abundance of Verrucomicrobia. As shown by 
LEfSe analysis (Figure 6.8A), among the Winnie experimental groups, PSCF 
supplementations caused substantial increase in Verrucomicrobia levels in caecal (52%) 
followed by in mucosal-associated (42%) and faecal (13%) samples. Similarly, compared to 
the spike in the level of Proteobacteria phylum in Winnie-control faecal samples (20.5%), 
Synbiotic suppressed the level (1.9%) similar to that in WT (1.1%). Among the other minor 
phyla, TM7 (0.32% in Winnie-control mice) in caecum was suppressed by synbiotic (0.057%) 
and B. coagulans (0.022%) and were closer to the levels observed in WT (0.036%). PSCF 
however, increased TM7 levels in caecal samples (1.39%). 
 
At the genus level, the distribution of microbial populations of Winnie-control mice was 
markedly different when compared to WT, in caecal, mucosal-associated and faecal 
microbiota (Figure 6.7B). While WT caecal samples showed the presence of Oscillospira, it 
was undetected in Winnie-Control. B. coagulans supplementation increased the abundance of 
Oscillospira in caecum, Akkermansia in faeces while modulating Bacteroides in faecal 
samples compared to that of Winnie-control. PSCF supplementation markedly enriched 
Akkermansia in caecal, faecal and mucosal-associated samples compared with that of in 
Winnie-control. Synbiotic supplementation in Winnie not only favoured the abundance of 
Bacteroides in faeces as revealed by LEfSe analysis (Figure 6.B), it was also observed to 
increase Oscillospira in caecal and faecal samples. While Prevotella showed its presence in 
caecal, mucosal-associated and faecal samples of WT, their levels were undetected in caecal 
and mucosal-associated samples of Winnie-control, while very low levels were detected in 
faecal samples. B. coagulans, PSCF and Synbiotic supplementations however, was able to 
induce appreciable increase in Prevotella levels in Winnie colitic mice. At the species level 
(Figure 6.7C), while WT samples showed the presence of Ruminococcus gnavus in all sample 
types, it was at very low levels in unsupplemented Winnie-control and supplemented Winnie 
groups. Compared to WT samples, Winnie samples showed increased prevalence of 
Akkermansia muciniphila. The ability of PSCF to substantially elevate the abundance of 
Akkermansia muciniphila in caecal samples was confirmed by LEfSe analysis (Figure 6.8B). 
PSCF also modulated their levels in mucosal-associated and faecal samples, while Synbiotic 
was effective in increasing their level in faecal samples the most. High levels of Desulfovibrio 
C21_c20 in faecal samples of WT and Winnie-control were greatly reduced with B. 
coagulans, PSCF and Synbiotic supplementations. Compared to WT, Winnie-control samples 
showed increased Bacteroides uniformis, while its level was suppressed by Synbiotic. 
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A. 
detected in Winnie-control samples. The levels of these species were reduced marginally by 
Synbiotic supplementation in caecal samples while B. coagulans suppressing their level in 
faecal samples minorly. Additionally, Eubacterium dolichum, that were at undetectable levels 
in samples from WT mice, had a notable prevalence in the samples of Winnie-control but 














Figure 6.8. Biomarker analysis with Linear Discriminant Analysis (LDA) Effect Size (LEfSe) scoring plot 
using Kruskal-Wallis rank sum test (p = 0.01 and log LDA threshold cut-off value = 1.0). Wild-type (WT), 
Winnie-control (Win), B. coagulans (Bc) spores, PSCF and synbiotic (Syn) groups at phylum (A), genus (B) and 
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6.4.7 Effects of B. coagulans, PSCF and Synbiotic supplementation on 
SCFA profile in chronic colitic Winnie mice 
 
Figure 6.9. Effects of B. coagulans spores, PSCF and Synbiotic in modulating SCFA concentrations in 
caecal, mucosal-associated and faecal contents in Winnie vs. Wild-type (WT) mice. Statistical significance 
among groups evaluated by one-way ANOVA followed by Tukey’s test. *P < 0.05, **P < 0.01, ***P < 0.001, ns 
vs. Winnie-control group and $P < 0.05, $$P < 0.01, $$$P < 0.001, $$$$P < 0.0001, ns vs. WT group. Data 
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As shown in Figure 6.9, feeding Winnie chronic colitic mice with PSCF, Synbiotic and 
to a lesser extent B. coagulans supplementations induced substantial modulations in the SCFA 
concentrations and their effects varied across caecal, mucosal-associated and faecal contents. 
Overall, higher concentrations of SCFA were noted in caecal contents than in mucosal-
associated and faecal contents. Compared to the SCFAs concentration in the samples from 
WT mice, unsupplemented Winnie-control mice exhibited marked reductions in acetate, 
propionate and butyrate while, valerate and succinate were at undetectable levels. Although 
the supplementations were not statistically effective in normalising the whole SCFAs profile 
in range with that of WT, the supplementations substantially induced elevation in the tested 
SCFAs concentration relative to that of Winnie-control.  While B. coagulans supplementation 
was ineffective in elevating the plummeted SCFAs levels in Winnie chronic colitic mice, 
PCSF supplementation alone showed ability to increase acetate (0.93±0.4 vs 2.98 Pg/g), 
propionate (0.83±0.3 vs 2.62±0.3 Pg/g), valerate (0.034±0.02 vs 0.118±0.02 Pg/g) and 
succinate (0.022±0.01 vs 0.218±0.08Pg/g) in faecal contents. Synbiotic supplementation was 
markedly effective in elevating the declined levels of acetate, propionate and butyrate in 
caecal and faecal contents indicating its synergetic functioning. In caecal contents, Synbiotic 
supplementation compared to the unsupplemented Winnie-control resulted in a significant 
increase in concentrations of acetate (5.07±0.9, 1.45±0.3 Pg/g respectively), propionate 
(3.29±0.7, 1.15±0.3 Pg/g respectively) and butyrate (3.16±0.5, 0.707±0.2 Pg/g 
respectively). Moreover, Synbiotic supplementation in faecal contents, exhibited the excellent 
ability to not only increase the levels of acetate (2.19±0.4 Pg/g), propionate (1.87±0.3 Pg/g) 
and butyrate (2.15±0.4 Pg/g) in Winnie colitic mice, the levels were equivalent to that of WT 
mice (2.06±0.4, 1.09±0.2, 3.25±0.3  Pg/g respectively). Furthermore, only Synbiotic 
supplementation was effective in elevating butyrate levels along the entire length of colon (in 
caecal and faecal samples) relative to PSCF and B. coagulans supplementations alone. This 
finding indicates the prudence of application of synergetic Synbiotic components to provide 
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6.5 Discussion 
 
In the current study, a dietary strategy involving the supplementations of B. coagulans, 
PSCF and their synbiotic combination was investigated in ameliorating chronic colitis in the 
spontaneous chronic colitic mice model Winnie. The findings indicate substantial efficacy of 
synbiotic supplementation in attenuating colonic inflammation in Winnie as evidenced by the 
improvement in clinical manifestations; colonic histopathology, colonic and systemic immune 
parameters. Additionally modulations of the microbiota and SCFAs fermentation products 
were induced by synbiotic supplementations more effectively and consistently than B. 
coagulans or PSCF alone.  
 
In Winnie mice, spontaneous chronic colitis results from a primary intestinal epithelial 
defect conferred by a missense mutation in the Muc2 mucin gene, leading to symptoms of 
diarrhoea, ulcerations, rectal bleeding and weight loss similar to those in clinical IBD (565). 
In the current study, the gradual rise in DAI, body weight loss and excretion of 
diarrheic/bleeding faeces in Winnie was attenuated with B. coagulans, PSCF and Synbiotic 
supplementations compared to that in unsupplemented Winnie-control. The marked efficacy 
of PSCF in improving faecal consistency, leading to early improvements in DAI, may be 
associated with its high content of insoluble hemicellulose fractions. The hemicellulose 
fraction of plant fibre is known to possess large water-holding capacity and thus, contribute to 
regulating the faecal water content in colitic mice (288, 289). In a previous study (565), 
diarrhoea in Winnie mice, evidenced by a long size of the faecal mass moving from caecum to 
the anus, was associated with altered gastrointestinal transit times and disturbed colon motility 
compared with the wild-type (WT) mice. Similarly, alterations in the gastrointestinal transit 
times have been reported in IBD patients (579). PSCF supplementation has been confirmed to 
reduce diarrheic faeces resulting in improved DAI in DSS-induced colitic mice (552). B. 
coagulans have been reported in clinical studies to impart an anti-diarrheal effect (48). The 
beneficial effect imparted by synbiotic supplementation in the current study could be related 
to the synergistic actions between the bioactive components and supports its potential 
application in reducing diarrheal episodes in clinical IBD.  
 
Synbiotic supplementation was also effective in escalating the improvement in DAI as 
well as macroscopic markers of inflammation (colon length and colon weight:body weight 
ratio), reinforcing evidence of ability to ameliorate disease severity and associated clinical 
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effects of the synbiotic application, compared to that of B. coagulans and PSCF alone, was 
evidenced by its ability to decrease the histological change scores in both proximal and distal 
colon sections of the Winnie mice (Figure 6.3B). The development of colitis in Winnie, with 
colonic histological damage mostly to the distal region, has been previously shown (109, 
501).  The ability of synbiotic treatment in reducing the colonic surface epithelial damage, by 
abating crypt loss, crypt abscesses, crypt hyperplasia, loss of goblet cells, submucosal edema 
and inflammatory infiltrate (Figure 6.3A), could be correlated with the improvement in the 
clinical manifestations in chronic colitic Winnie. Such synergetic beneficial outcomes of the 
B. coagulans and PSCF in synbiotic combination could be accounted for by the reinforcing of 
weakened colonic barrier integrity in chronic colitis.  
 
Disruption in the colonic barrier integrity in IBD exacerbates dysregulated immune 
responses leading in an inflammation cascade and tissue damage (91). Disruption of Muc2 
biosynthesis in Winnie colitic mice, is comparable to the reduction in production and 
secretion of Muc2 observed in human IBD (567, 568). This is known to trigger depletion of 
the mucus barrier, thus heightening intestinal permeability and increasing vulnerability to 
luminal antigens (109). The mucosal barrier dysfunction in the Winnie mice leads to colitis 
mediated by multiple cytokines (566, 580).  The intestinal inflammation in IBD is marked by 
a Th1 and Th17-mediated responses with heightened expression of TNF-α, IFN-γ, IL-1β, IL-
12, IL-6 and IL-17 (581). In the current study, unsupplemented Winnie-control colon 
segments were determined to secrete elevated levels of pro-inflammatory IL-1α, IL-1β, IL-6, 
IL-12, IL-17, GM-CSF, IFN-γ, MIP-1α, MIP-1β and TNF-α (Figure 6.4). This is in 
agreement with a recent study, that reported significantly increased levels of the pro-
inflammatory cytokines in Winnie colon compared to that of wild-type (WT) mice (501). 
B. coagulans and PSCF treatment alone were able to reduce most of these elevated 
cytokines, however Synbiotic supplementation exhibited more consistent effects in 
suppressing the secretion levels of these pro-inflammatory cytokines in chronic colitic 
Winnie colon. IL-1β has been implicated to play a vital role in the pathogenesis of clinical 
IBD. In patients suffering from either acute or chronic gastrointestinal inflammation, 
increased levels of IL-1β cytokine have been reported (582). A number of clinical reports 
have confirmed the correlation of the increased IL-1β secretion from colonic tissues and 
macrophages of IBD patients with the severity of the disease (583-585).  TNF- α is 
reported to incite a pro-inflammatory effect by inducing increased production of IL-6 and 
IL-1β (527). Similarly, increased levels of cytokines, such as IL-17, IFN- γ and IL-12, are 
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mucosa, accumulation of GM-CSF is associated with the delay of neutrophil apoptosis 
(586).  Chemokines MIP-1α (also known as CCL3) and MIP-1β (also known as CCL-4), 
that induce pro-inflammatory cytokine production, are also observed to be highly 
expressed in IBD patients (587). The excellent ability of Synbiotic supplementation in the 
current study, was evidenced by its potentiated synergistic immune-modulatory efficacy in 
reducing the secretion levels of these pro-inflammatory cytokines and chemokines in the 
inflamed Winnie colonic tissue.  
 
Increase in systemic pro-inflammatory cytokines are associated with IBD. At the 
systemic level, increased concentrations of IL-1β, IL-6, IFN- γ, and TNF-D were confirmed 
in IBD patients compared to healthy individuals (588). Such pro-inflammatory cytokines are 
secreted mainly by activated lamina propria antigen presenting cells in response to the 
inflammation (118). The capability of Synbiotic for imparting beneficial systemic anti-
inflammatory effects was evidenced by its ability to suppress the levels of pro-inflammatory 
cytokines and chemokines in serum while also increasing anti-inflammatory IL-10. IL-10 
plays a vital role in downregulating antigen presentation and subsequent release of 
proinflammatory cytokines, leading to attenuation of mucosal inflammation (527). B. 
coagulans spores have been confirmed to modulate IL-10 levels under in-vitro inflammatory 
conditions (42) and in humans (409). Furthermore, B. coagulans, PSCF and Synbiotic 
supplementations were effective in reducing the elevated serum CRP levels in Winnie further 
corroborating their immuno-modulatory capacities. High levels of CRP are reported in human 
IBD patients (531). CRP production in the liver and its release in the blood stream is 
stimulated by circulating IL-6 during inflammation (530). The marked ability of the 
supplementations in our study to reduce serum IL-6 and CRP levels supports their potential 
application in IBD to induce anti-inflammatory and immunomodulatory effects to hinder the 
inflammatory cascade. The amplified ability of Synbiotic for improving the overall pro-
inflammatory profile of Winnie, could be attributed to either a direct immune-regulating 
effect of B. coagulans and PSCF, and/or due to their effect on improvement of colonic barrier 
integrity. Either of these effects could lead to a decrease in luminal antigen load and full 
activation of innate immune system. Our findings support the potential of synbiotic 
supplementations to be applied in clinical IBD to effectively mitigate the aberrant 
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Human clinical studies on the changes in microbiota associated with IBD are normally 
restricted to faecal sampling only. The dysbiosis associated with IBD however, may not be 
limited only to the faecal microbiota as the microbial numbers and composition vary along the 
gastrointestinal tract (139, 215). Mounting evidence has indicated that there is a distinction 
between the microbial dysbiotic pattern in different locations along the gastrointestinal tract 
of IBD patients, leading to the alterations in metabolic and immune responses (215, 589, 590). 
Therefore, the present study aimed to analyse site-specific profiles of microbiota and SCFA 
levels in caecal, mucosal-associated and faecal samples utilizing 16S rRNA gene sequencing 
and GC-MS for SCFA analysis. Besides the differences in the WT, unsupplemented Winnie-
control and supplemented Winnie groups, this study confirmed microbial and SCFA shifts 
along the caecal, mucosal-associated and faecal samples. Although the indices of alpha-
diversity did not significantly differ between the WT and Winnie-control samples, 
supplementation of chronic colitic Winnie with synbiotic was most effective in increasing the 
alpha diversity indices in caecal and faecal samples (Table 6.1). No significant difference in 
alpha indices between Winnie and WT faecal samples had been reported earlier by Robinson 
et al. (217). This may be attributed to the high inter-individual variability among Winnie mice 
suggesting, use of higher sample size for future analysis. Principal component analysis 
however, revealed a clear distinction in beta-diversity between WT and Winnie mice groups, 
further indicating the inflammatory status of the mice model (Figure 6.6). Notable differences 
in the caecal, mucosal-associated and faecal microbiota of WT and Winnie mice were evident 
at levels of bacterial taxonomical classification, including the phylum, genus and species. 
These observations agree with previous reports that confirmed distinct microbial patterns in 
faecal samples of inflamed Winnie and healthy WT mice (217). Although Winnie mice shared 
most of the same phylum as healthy WT mice, levels of their abundance were markedly 
different. In general, the abundance of members from Proteobacteria, Cyanobacteria and 
Verrucomicrobia in Winnie-control samples was greater, whereas reduced levels of 
Firmicutes and Bacteroidetes were evident compared to that of WT (Figure 6.7A).  
 
Dysbiosis of gut microbial communities has been well recognized as one of the 
hallmarks of pathogenesis in IBD patients and animal models of colitis (138, 141, 214, 217, 
591). Consistent with our results, Robinson et al. (217) also reported reduction in 
Bacteroidetes in Winnie-control compared with WT. Depletion of commensally associated 
bacteria, notably members of the phyla Bacteroidetes and Firmicutes, has been linked with 
IBD in several clinical reports (143, 214, 592). Compared with unsupplemented Winnie-
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caecal and faecal samples of chronic colitic Winnie. The genus Prevotella, belonging to 
phylum Bacteroidetes, was also significantly declined in the Winnie-control with only a low 
presence only in faecal samples, but its prevalence was enhanced by synbiotic 
supplementation in both the caecum and faeces. A high fibre diet has been linked to increased 
prevalence of Prevotella in healthy human subjects (593) and in African children consuming 
high-fibre, low-fat diets (10). Prevotella is a well-known dietary fibre fermenter for 
production of SCFAs (594). Prevotella species are also known to possess enzymes for 
degradation of an array of polysaccharides including cellulose, hemicellulose and xylans (10, 
595). From this view, the increase in Prevotella levels in PSCF-supplemented Winnie could 
be correlated to the high content of plant cell wall fractions available for degradation. The 
ability of B. coagulans supplementation to also influence the abundance of Prevotella 
indicates a potential beneficial effect of the probiotic. The combined beneficial effect of 
increasing the prevalence of Prevotella and elevation of SCFA levels in Winnie by synbiotic 
supplementation suggests synergistic functioning. B. uniformis was detected in the biopsies of 
active UC patients (596). Synbiotic supplementation also decreased the level of Bacteroides 
uniformis (phylum Bacteroidetes) in faeces compared to that in the Winnie-control (Figure 
6.7C). 
 
The decreased prevalance of butyrate-producing Firmicutes is often associated with IBD 
(597, 598). Members of genus Oscillospira of Firmicutes are butyrate-producers (593). They 
were detected in WT but there was a complete absence in Winnie-control. The Oscillospira 
level was found to be severely decreased in IBD patients (597, 599). Synbiotic 
supplementation effectively recovered the altered levels of Oscillospira in caecum and faeces 
to that of WT. Synbiotic supplementation also influenced the level of Blautia of Fimicutes 
Phylum (Figure 6.8B) that has been reported in healthy Chilean individuals (593) and is one 
of the butyrate-producing bacteria in the human gut (214). In contrast to the previous IBD 
study in humans, that reported an increased prevalence of mucolytic Rumicococcus gnavus 
(112), Winnie mice showed complete depletion of R. gnavus (Figure 6.7B and 6.7C). None of 
the supplementations from this present research were able to restore its level. However, 
mucolytic activity of R. gnavus was shown in-vitro, to effectively degrade human Muc2 and 
porcine mucin (112). It also has an increased abundance in CD compared to that of UC in the 
intestinal mucosa of IBD patients. The increased population shift in R. gnavus was most 
apparent in non-inflamed histologically normal intestinal biopsies of IBD patients and there 
were lower levels of these mucolytic bacteria in inflamed UC tissue. It was hypothesized that 
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cells, reduced Muc2 expression and decreased mucin secretion in Winnie colitis model, 
similar to that reported in human UC (109), could be correlated to the decline of this 
mucolytic species in the current study.  
 
Increased prevalence of Proteobacteria is considered a potential diagnostic signature of 
dysbiosis and risk of inflammation (600, 601). Relative to Winnie-control, Synbiotic was also 
more effective in reducing the abundance of phylum Proteobacteria in caecal and faecal 
samples compared with either B. coagulans or PSCF supplementation. B. coagulans and 
PSCF had no effect on Proteobacteria level in mucosal-associated samples. A significant 
increase in members of Proteobacteria phylum has been previously reported in faeces and in 
the caecal lymphoid patch of Winnie (217). Abundance of Desulfovibrio C21_c20 species of 
Proteobacteria phylum were also reduced in Winnie supplemented with Synbiotic. The rates 
of hydrogen sulfide production were higher among the sulfate-reducing bacteria isolated from 
patients with UC compared to those in healthy volunteers (602). Species of genus 
Desulfovibrio are known to inhibit epithelial butyrate metabolism via release of hydrogen 
sulfide (603). These observations could be related to the decline in butyrate-producing 
bacteria and reduced butyrate production in inflamed colitic Winnie-control mice (Figure 6.9). 
The increased abundance of Proteobacteria in European children consuming a low-fibre, 
high-fat diet, compared to African children consuming high-fibre, low-fat diet, was reported 
by De Filippo et al. (10). In this context, the influence of Synbiotic in lessening the increased 
prevalence of Proteobacteria in Winnie mice in the current study, could be attributed to the 
high whole plant fibre content of PSCF.  
 
High abundance of Verrucomicrobia members (Akkermansia) has been reported in 
healthy Chilean subjects (604) while its decreased abundance is noted in IBD patients (112, 
178, 179). Interestingly, compared to that of WT, increased abundance of Verrucomicrobia 
was evident in all Winnie groups irrespective of supplementation/non-supplementation and 
the sample types. PSCF was most potent in inducing the bloom of Verrucomicrobia phylum, 
particularly in the caecum (Figure 6.7A and 6.8A). Members of genus Akkermansia and 
species A. muciniphila of Verrucomicrobia phylum were also elevated by PSCF 
supplementation in this research, specifically in the caecum. Additionally, in faecal samples 
all the three supplementations caused a moderate increase in Akkermansia genus level. The 
efficient colonisation of A. muciniphila in the caecum is attributed to the high mucin 
production (185). The increased ability of PSCF to induce growth of Akkermansia could be 
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growth of Akkermansia, and was strongly correlated with the improvement of inflammation in 
DSS-induced colitis (605) and high-fat diet fed mice (606, 607). A. muciniphila uses mucin as 
nutrients (185). The increased prevalence of Akkermansia in Winnie mice, relative to that in 
WT mice, is surprising considering the less mucin being secreted, owing to the point mutation 
in Muc2 gene of Winnie (109). The bloom in the members of genus Akkermansia in Winnie 
could be partially related to its ability to metabolize the fatty acid hexadecenoic acid, which 
has been reported earlier to be heightened 2-3 fold compared with that in WT mice (217). 
Also, the aerotolerant ability of some species of Akkermansia confers resistance to the 
oxidative environment in the inflammatory colon (607, 608). In substantiation with our 
observation, increased abundance of Akkermansia was also reported in DSS mice model of 
colitis (180-182). Therefore there seems to be no clear consesus on the role of Akkermansia in 
chronic gut inflammation in IBD. In contrast however, A. muciniphila is known as a 
modulator for gut homeostasis (185) and is abundantly present in healthy human intestinal 
tract making up 1-4% of the bacterial population in the colon (183, 184). A recent study has 
demonstrated improvement in metabolic parameters in over-weight and obese human subjects 
by supplementation with A. muciniphila (609). Decline in its abundance is reported in human 
IBD patients suggesting its potential anti-inflammatory role (112, 178). A beneficial effect of 
Akkermansia on colitis however, is effected by its extracellular vesicles that were found to 
protect against DSS-induced colitis (186). Moreover, besides being able to degrade mucins, 
Akkermansia was also found to increase mucus layer thickness in prebiotic treated diet-
induced obese mice, suggesting its potential ability to stimulate mucin synthesis (610). 
Akkermansia has additionally been demonstrated in-vitro to adhere to and restore the integrity 
of the epithelial cell layer, while no adherence was observed to human mucus thus, suggesting 
that the beneficial role of this bacterium in the gut is not exclusively associated with mucus 
layer physiology (608). Considering that the attenuation of colitic inflammatory parameters 
induced by PSCF and synbiotic supplementations was associated with a significant increase in 
Akkermansia in Winnie, a beneficial affect on gut inflammation is indicated. The ability of B. 
coagulans to enhance barrier integrity and mucus secretion (552), could be related to its 
influence on this mucosa-associated bacterium. While, PSCF increased abundance of minor 
phylum TM7 in the caecum, Synbiotic declined its level. High relative abundance of  TM7 
has been reported in the IBD patients (611) and IBD mice model (612). The efficacy of 
Synbiotic in reducing its level indicates a potential mechanism for its beneficial effect.  
 
The Synbiotic supplement showed marked efficacy for modulating the altered SCFA 
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mucosal-associated and faecal samples were analysed to better understand the efficacy of B. 
coagulans, PSCF and their synbiotic combination in influencing the immune response and 
microbiota in Winnie colitic mice. Dysregulation in microbiota-derived SCFA production is 
often implicated with dysbiosis in IBD and therefore, has gathered considerable research 
interest (229). Of particular note are acetate, propionate and butyrate, each of which is likely 
to contribute to the host health (535). These SCFA, that are solely metabolized by gut bacteria 
from indigestible carbohydrates from fibre-rich diets,  have been affirmed to attenuate disease 
severity in animal models of colitis (288) and in clinical UC (235). Consistent with the 
previous Winnie report (217), significant decline in the SCFA levels were detected in samples 
from unsupplemented Winnie-control mice compared to that in healthy WT mice. This has 
further confirmed the significant inflammatory and dysbiotic status of the Winnie colon. The 
altered SCFA production in Winnie could be associated with the decline in the abundance of 
SCFA producing bacteria belonging to genus Oscillospira and Prevotella as observed in 
Winnie-control group in the current study (Figure 6.7).  
 
Reduced SCFA levels are an important indicator of dysbiosis in IBD. The consistently 
high ability of synbiotic supplementation to address the pathology caused by the Winnie 
mutation could be evidenced by its ability to elicit SCFA production in caecal and faecal 
samples thus, mediating a trophic effect along the entire length of the colon. This observation 
could potentially be correlated with the increased butyrate-producing Oscillospira genus with 
Synbiotic but was not detected in Winnie-control mice. Additionally, the ability of Synbiotic 
supplementation to promote the abundance of SCFA-producing Prevotella genus could be 
associated with the elevation in the SCFA levels. Butyrate is the preferred energy source for 
colonocytes and mediates regulation of cytokines further, imparting protection against 
inflammation in UC and colorectal cancer (535). Although, B. coagulans supplementation 
alone could not confer any substantial mediation in the SCFA production compared to 
Winnie-control, PSCF supplementation triggered elevations in the level of acetate and 
propionate in the faeces. However, this effect was not observed for the butyrate level. The 
propionate boosting effect of PSCF alone, could be correlated to its ability in inducing bloom 
in relative abundance of Akkermansia in Winnie (Figure 6.7). In in-vitro organoid testing, A. 
muciniphila was shown to induce substantial concentrations of propionate and acetate but not 
butyrate (613), in alignment with the observations of the current study. Its mucin degrading 
activity is known to mediate the production of propionate and acetate (614). Butyrate has been 
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consistent with the improvement in histological and immune-regulatory observations induced 
by Synbiotic in the present study. 
 
The employment of a suitable probiotic bacteria targeted at metabolising the compatible 
prebiotic fibres to elevate SCFA production is a pragmatic synbiotic strategy towards 
resolving IBD inflammation. In the current study, relative to the individual supplementations, 
the synergistic synbiotic supplementation, not only induced increased levels of acetate, 
propionate and butyrate along the entire colon length, but the SCFA levels in the faecal 
samples were considerably restored to a level similar to that in WT mice. The inability of B. 
coagulans to modulate the SCFA production in this Winnie chronic colitic model, indicates 
two possible inferences: Firstly a possible lack of available fermentable fibre in normal chow 
diet to be directly metabolized by this probiotic and secondly, its compromised efficiency in 
promoting microbial growth of SCFA producers in chronic colitic inflamed Winnie colon. 
The ability of B. coagulans in inducing SCFA production in the caecum suggests the 
beneficial effects of pre-conditioning of the mice gut before colitis induction using DSS as 
previously demonstrated in Chapters 4 (552) and 5.  This finding also indicates the need for 
early application of this probiotic spore in order to achieve the maximum benefit, as 
demonstrated in an in-vitro study in Chapter 3 (42). The excellent SCFA induction efficacy of 
B. coagulans in synbiotic combination with PSCF, suggests its ability to metabolise the fibre 
fractions to induce beneficial modulatory outcomes. The B. coagulans is known to ferment a 
variety of plant fibre including cranberry fibre (478), fenugreek seeds (477) and hemicellulose 
(71). Thus, the efficacy of B. coagulans in fermenting plant hemicellulose, such that present 
in whole plant PSCF, makes them an ideal bioactive combination for synbiotic application in 
conferring trophic effects of SCFAs in IBD along the entire colon length. 
 
Acetate and propionate are also known to benefit the epithelial integrity via binding with 
certain metabolite-sensing G-protein-coupled receptors (such as GPR43, GPR109A) and 
modulating the immune response (227, 239, 542). Valerate, that has been determined to 
stimulate intestinal growth and attenuate inflammatory pathogenesis in colitis and cancer 
(222), was increased by PSCF supplementation. In addition to conferring benefits in the colon, 
SCFAs have also been confirmed to facilitate enhanced host metabolism and modulate the 
activity of the enteric nervous system (535), thus rendering extra-intestinal metabolic benefits. 
The excellent immuno-modulatory effects observed in the present study could possibly be 
correlated to high SCFA levels induced by Synbiotic supplementation in Winnie colitic mice 
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engaging with GPRs, leading to direct local and to systemic anti-inflammatory effects (227, 
543) as evidenced by the improved cytokine profile in the current study. These observations 
merit the application of synergistic synbiotic combination to achieve potentiated benefits in 




The findings of this study highlight a significant efficacy of synbiotic probiotic and 
prebiotic supplementation in ameliorating the chronic colitis as evidenced by attenuation of 
spontaneous colitis in mice model of IBD. The results have demonstrated potentiated anti-
inflammatory outcome effects of synbiotic treatment supplementation carrying whole-plant 
PSCF and B. coagulans spores by reducing clinical manifestations, colonic damage and 
inflammatory mediators while, modulating the gut microbiota and SCFA profiles of chronic 
colitic mice. The observations support the hypothesis that supplementation of whole plant 
PSCF and B. coagulans spores together produced a synergistic combination that augmented 
the beneficial outcome effects against the damage induced by chronic inflammation in 
spontaneous colitic Winnie mice. The study also underscored the application of Synbiotic in 
reducing the overall inflammation profile in this murine IBD model by targeting different 
mechanistic approaches to resolve the recurrent inflammatory cycle. The significant 
therapeutic effects of B. coagulans and PSCF in a synbiotic combination, evidenced in this 








7.1 Summary of main findings 
The main purpose of this research was to determine the efficacy of probiotic and 
prebiotic combinations of supplementary food ingredients for improving gut health. The work 
presented in this thesis has examined the effects of probiotic Bacillus coagulans MTCC 5856 
spore alone and in a synbiotic combination with either whole plant prebiotic sugar cane fibre 
or green banana resistant starch flour on the disease outcomes of experimental acute and 
chronic colitis in murine models of IBD. It is worthwhile to note that while the effects were 
demonstrated in IBD pathogenesis, the anti-inflammatory effects could also be applied to low-
grade inflammatory conditions including obesity, diabetes and related comorbidities involving 
gut inflammation. The ultimate goal of the investigation was to generate useful information to 
guide the development of functional synbiotic combinations that could potentiate beneficial 
effects for improving health outcomes through food. A specific outcome objective was to 
present a solution to the technical issues that limit application of conventionally used PB in 
shelf-stable functional foods owing to their low viability during industrial processing, storage 
and gastric transit (38, 348, 615). Using DF sources that more closely represented that of 
fruits and vegetables, with the biochemical complexity and cellular matrices of whole plant 
foods was a pragmatic choice due to their potential for influencing gut microbiota diversity 
for optimal wellbeing (52-54). This research hence, focussed on utilisation of effective 
functional ingredients: 1) probiotic B. coagulans spores that presented robustness in terms of 
survival in hostile conditions combined with substantial bioefficacy that could be applied in 
designing shelf-stable food products and 2) prebiotic fibres – whole plant PSCF and GBRS 
flour, both, derived from natural plant sources and prepared to retain nutritional biologically 
active components and more accurately represent natural whole plant foods. The prophylactic 
and therapeutic efficacies of these functional ingredients alone or in synbiotic combination 
were evaluated in ameliorating colitis in acute DSS-induced and chronic spontaneous Winnie 
colitic murine models.  
 
The initial in-vitro screening in Chapter 3 successfully identified B. coagulans spores as 
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survival of B. coagulans spores during simulated digestion supports their incorporation into 
wide variety of functional food matrices and pharmaceutical preparations without the need for 
encapsulation to preserve its bioactivity. Their substantial adherence to human colonic 
epithelial HT-29 and LS174T cells indicated their potential to interact with immune cells. 
Significantly more anti-inflammatory and immunomodulatory effects were exerted by B. 
coagulans spores when applied to non-inflamed and co-treated LPS-inflamed HT-29 cells 
than when applied to post-treated LPS-inflamed cells. This study therefore highlighted the 
importance of its application before (prophylactic agent) or during (therapeutic agent) the 
onset of inflammation to achieve optimum benefits. The excellent probiotic attributes 
evidenced in the in-vitro study thus confirmed its selection as an efficacious functional 
ingredient to be further tested for its anti-inflammatory potential in modulating gut health.  
 
 
Table 7.1. Key findings of in-vitro screening analysis of B. coagulans spores presented in Chapter 3 
Chapter 3 – Probiotic Bacillus coagulans MTCC 5856 spores exhibit excellent in-vitro functional 
efficacy in simulated gastric survival, mucosal adhesion and immunomodulation 
Screening parameter Key findings 
Simulated digestion x High survival rate (92%) following 240 mins of simulated digestion 
Adhesion to human colonic 
epithelial cells 
x 86% adhesion to HT-29 cells 
x 81% adhesion to LS174T cells 
Immunomodulatory 
capacity in non-inflamed 
and LPS-inflamed 
conditions in HT-29 cells  
x Non-inflamed condition:  IL-10 and  IL-8 
x LPS-induced co-treatment:  IL-10 and  IL-8 
x LPS-induced post-treatment: IL-10 - not detected and  
 IL-8 
x Reduction in elevated IL-8 secretion more significant (P = 0.018) 
for co-treatment than post-treatment condition 
 
 
The prophylactic and therapeutic efficacy of B. coagulans spore supplementation alone, 
and as a synbiotic combination, was further investigated in-vivo using murine acute and 
chronic models of colitis. Chapter 4 evaluated the prophylactic efficacy of dietary 
supplementation with B. coagulans spores and whole plant PSCF alone and as a synbiotic 
combination (PSCF-synbiotic) in influencing the onset and disease outcomes of DSS-induced 
acute colitis in C57BL/6J wild-type (WT) mice. Similarly, in Chapter 5, prophylactic efficacy 
of B. coagulans in synbiotic combination with a different whole plant DF source, the GBRS 
flour (GBRS-synbiotic) was investigated in attenuating the severity of DSS-induced acute 
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outcomes of the studies in Chapters 4 and 5 clearly supported the premise that pre-
conditioning of the gut with synbiotic supplementations containing compatible probiotic and 
prebiotic fibres can be extremely beneficial in ameliorating the symptoms and severity of 
DSS-induced acute colitis in mice. This could potentially be attributed to the synergistic 
functioning of the probiotic with the respective prebiotic ingredients used in the studies. The 
probable mechanisms of synergy were via modulation of immune parameters, via SCFAs and 
by providing protection to the colonic epithelial integrity.  
 
The potentiation of beneficial effects exerted by the synbiotic prompted the 
investigation into its efficacy in treating other gut inflammatory conditions. The study in 
Chapter 6 employed a spontaneous chronic colitic murine model, Winnie (Muc2 mutant), to 
evaluate the therapeutic efficacy of B. coagulans, PSCF and its synbiotic combination in 
ameliorating chronic colonic inflammation. The key findings are listed in Table 7.2. The 
results of this study also demonstrated marked efficacy of synbiotic supplementation 
carrying B. coagulans and PSCF in augmenting the attenuation of chronic inflammation. It 
therefore substantiated the conclusions derived from Chapters 4 and 5.  
 
Table 7.2. Key findings of synbiotic efficacy of in-vivo analysis in Chapters 4, 5 and 6 
Chapter 4 – Synbiotic supplementation containing whole plant sugar cane fibre and probiotic spores 
potentiates protective synergistic effects in mouse model of IBD 
Disease parameter Key findings 
DAI, 
 % body weight loss  
and  
macroscopic markers 
x Synbiotic most effective in reducing clinical manifestations  
(-72%), followed by PSCF (-53%) and B. coagulans (-47%)  
x PSCF imparted early improvement in stool consistency  
x All three supplementations effective in preventing body weight loss 
x Synbiotic most potent in improving all tested macroscopic markers 
Histology and MPO activity x Synbiotic significantly  histology score and MPO activity in PC and 
DC  
x PSCF ineffective in  histology score and MPO activity in PC  
Alcian Blue staining for 
mucus 
x Synbiotic, B. coagulans and PSCF prevented goblet cells and mucus 
production with synbiotic noted for highest Alcian blue staining intensity 
Immunohistochemical 
detection of epithelial TJ 
proteins 
x Synbiotic most efficacious in preserving the expressions of all the TJ 
proteins tested (ZO-1, Occludin and Claudin-1) 
x B. coagulans followed by PSCF also moderately preserved TJ proteins  
Immunomodulatory effects 
on colonic and serum 
cytokine levels, iNOS 
activity and CRP level 
x Consistently marked immunomodulatory effect exerted by synbiotic on 
colonic and serum cytokines  
x Differential effects observed with PSCF in PC and DC sections and no 
effect noted for colonic IL-12 and IFN-J and serum IL-1E and IL-10 
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x No effect on iNOS activity in PC with PSCF while, synbiotic and B. 
coagulans equally effective in both sections 
x Synbiotic significantly normalised serum CRP levels followed by B. 
coagulans and PSCF 
Faecal metabolite analysis x Synbiotic significantly efficacious in inducing modulations in the faecal 
metabolites 
SCFA profile of caecal, 
mucosal-associated and 
faecal samples 
x Highest concentration of SCFAs observed in caecum 
x B. coagulans lost ability of SCFA induction past caecum 
x Synbiotic most adequately  SCFA levels along the colon length 
 
Chapter 5 – Prebiotic green banana resistant starch and probiotic Bacillus coagulans spores synbiotic 
supplementation ameliorates gut inflammation in mouse model of IBD 
Disease parameter Key findings 
DAI, 
 % body weight loss  
and  
macroscopic markers 
x Synbiotic most effective in reducing DAI (-67%), followed by GBRS  
(-57%) and B. coagulans (-52%) 
x All three supplementations effective in preventing body weight loss 
x Synbiotic most significant in improving all tested macroscopic markers 
Histology and MPO activity x Synbiotic and B. coagulans followed by GBRS significantly  histology 
score only in DC  
x GBRS ineffective in reducing MPO activity in PC  
Alcian Blue staining for 
mucus 
x Synbiotic and B. coagulans noted for equivalently marked  improvement 
in Alcian blue staining intensity suggesting benefits to goblet cells and 
mucus production with PSCF showing moderate effect 
Immunohistochemical 
detection of epithelial TJ 
proteins 
x Synbiotic most potent in retaining the expressions of all the TJ proteins 
tested (ZO-1, Occludin and Claudin-1) 
x B. coagulans followed by GBRS also moderately preserved TJ proteins  
Immunomodulatory effects 
on colonic and serum 
cytokine levels, iNOS 
activity and CRP level 
x Consistently substantial immunoregulatory effect exerted by synbiotic 
on colonic and serum cytokines  
x Differential effects observed with GBRS in PC and DC sections and no 
effect noted for colonic IL-1D, IL-12 and TNF-D in DC and serum IL-
1E and IL-10 
x B. coagulans failed to reduce serum IL-1E level 
x GBRS ineffective in reducing iNOS activity in both colonic sections 
x Synbiotic effectively normalised serum CRP levels followed by B. 
coagulans and PSCF 
Faecal metabolite analysis x Synbiotic significantly induced modulations in the faecal metabolites 
SCFA profile of caecal, 
mucosal-associated and 
faecal samples 
x Highest concentration of SCFAs observed in caecum 
x B. coagulans lacked ability of eliciting SCFA production past caecum 
x Synbiotic and GBRS most adequately  SCFA levels along the colon 
length 
 
Chapter 6 – Efficacy of sugar cane fibre and probiotic spore synbiotic combination in attenuating 
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Disease parameter Key findings 
DAI, 
 % body weight change 
and  
macroscopic markers 
x Synbiotic and B. coagulans most effective in reducing diarrheic and 
bloody faeces (-69%), followed by GBRS (-60%)  
x B. coagulans (74%) followed by synbiotic (50%) and PSCF (33%) 
supplementations effective in preventing body weight loss 
x Synbiotic most significant in improving all tested macroscopic markers 
except for spleen weight 
x Only synbiotic prevented colon length shortening 
Histology  x Synbiotic significantly  histology score in both PC and DC sections 
x B. coagulans followed by PSCF  histology score only in DC with no 
effect in PC 
Immunomodulatory effects 
on colonic cytokine levels 
x Synbiotic exerted consistently significant immunoregulatory effect in 
DC section with no effect on specific cytokines in PC  
x B. coagulans effective in regulating the cytokine levels differently in PC 
and DC, while no effect on certain cytokines (IL-10, IL-17) in either 
colonic sections 
x PSCF induced varying effects in PC and DC sections for certain 
cytokines and showed no effect for IL-6, IL-10, IL-12 and IL-17 in 
neither PC nor DC sections 
Immunomodulatory effects 
on serum cytokine and CRP 
levels 
x Synbiotic significantly induced modulations in only specific cytokine 
levels in serum while had no effect on the levels of IL-1D, IL-17, GM-
CSF and MIP-1D 
x PSCF  levels of limited cytokines in serum – IL-E, IL-6, MIP-1E and 
TNF-D 
x B. coagulans  the levels of  limited cytokines in serum –  IL-E, IL-6, 
IFN-J, MIP-1D and TNF-D 
x Synbiotic and B. coagulans more effective than PSCF in suppressing 
serum CRP levels 
Microbiota modulations in 
caecal, mucosal-associated 
and faecal samples 
x Synbiotic  Shannon and Simpson indices in caecal and faecal samples  
x All Winnie samples showed clear demarcation from WT samples in 
terms of beta diversity 
x Synbiotic induced modulations in the levels of Firmicutes and 
Bacteroidetes and favoured abundance of Prevotella, while PSCF 
favoured abundance of  Verrucomicrobia 
SCFA profile of caecal, 
mucosal-associated and 
faecal samples 
x Winnie-control mice showed significant alteration the SCFA levels 
relative to WT 
x Highest concentration of SCFA observed in caecum 
x B. coagulans lacked ability of eliciting SCFA production past caecum 
x Synbiotic and PSCF most adequately  SCFA levels along the colon 
length 
 
Different prebiotic fibres, due to their varying biochemical make-up, have been 
demonstrated to impart different effects on the host (75, 616, 617). The PSCF and GBRS 
exerted some unique immune-regulating effects, particularly in the distal colon. PSCF alone 
(Chapter 4) caused significant reduction in secretion of IL-1D and TNF-D with no effect on 
IFN-J levels compared to the DSS-control. In contrast, GBRS supplementation (Chapter 5) 
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relative to DSS-control, PSCF caused more reduction in the secretion levels of colonic IL-1E 
(-64%) and IL-6 (-81%) compared to that induced by GBRS (-36% and -35% respectively). 
This is in agreement with a recent study (616) that showed that different prebiotic fibres 
modulate the immune response differently.  
 
The two prebiotic DF components alone, also varied in term of their ability to enhance 
the SCFA production. GBRS separately, and in synbiotic combination (Chapter 5), was more 
effective in inducing elicited SCFA levels along the colon length than that mediated by either 
PSCF or its synbiotic combination (Chapter 4). This indicates more rapid microbial 
metabolization of the RS from GBRS than the slowly-fermentable cellular material from 
PSCF. The amounts and ratios of SCFA produced, as well as the rate of production, varies 
with different fibres (59, 617, 618). Rapidly fermented fibres however, may lead to excessive 
gas production and bloating, so dose is an important consideration (619). The fermentation 
pattern of fibres is known to be influenced by factors including molecular weight, chain 
length and the structure of the fibre (59). The higher dose of GBRS (400 mg/day) compared to 
the PSCF (200 mg/day) administered in the two studies could also contribute to the difference 
in the SCFA levels produced.  
 
The loss of the ability by B. coagulans alone to elicit greater SCFA levels (either 
directly by metabolising available chow fibre or indirectly by stimulation of SCFA-producing 
gut bacteria via cross-feeding) beyond the caecum could be improved by addition of prebiotic 
fibre (as synbiotic) to generate complimentary/synergistic SCFA induction as evidenced in 
Chapter 4 and 5. While the B. coagulans spores were noted in the study to augment the SCFA 
production when applied as synbiotic, it was not confirmed whether this marked effect on 
SCFA levels was the result of either direct fermentation of fibres by B. coagulans vegetative 
cells or via in-direct means by influencing other SCFA producers in the gut. This could be 
more thoroughly studied by  employing an in-vitro human digestive and gut microbiota model 
system using human faecal samples (75) to understand the changes induced by B. coagulans 
supplementation. Additionally, the in-vivo screening trials could also be conducted to 
understand the interaction of either vegetative cells or heat-killed spores with these prebiotic 
fibres. Such information will further help delineate whether the live spores, spore components 
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Figure 7.1. The potential mechanism of synergistic synbiotic application (prophylactic or therapeutic) 
targeting different inflammatory circuit components of IBD in mice models of colitis. The synbiotic health 
outcome effect noted may be associated with a synergistic direct immune-regulating efficacy of the probiotic and 
prebiotic components (1), their ability to protect epithelial integrity (2), stimulation of probiotic spores and/or 
native gut microbiota by prebiotic fibre (3), and/or with stimulation of greater levels of fermentation of fibres 
releasing SCFAs (4) that mediate reduction in colonic inflammation.  
 
 
The animal model studies (Chapters 4, 5 and 6) in this research supported the 
application of the synbiotic combination as a two-point approach targeted at achieving 
augmented beneficial outcomes by encompassing the synergism between probiotic and 
prebiotic components. The potentiated effects of synbiotic combination observed in this 
research could be associated with its efficacy being due to multiple mechanisms of synergistic 
functioning that hinder the inflammatory circuit in IBD as illustrated in Figure 7.1. The study 
designs of the in-vivo mice feeding trials allowed determination of individual, as well as 
synbiotic outcomes, on the overall inflammatory status. The sacrifice of the animals allowed 
collection of serum and colonic tissues for cytokine measurements and histological grading as 
well as collection of contents from caecum and colon (mucosal) for SCFA and microbial 
profiling. These types of samples are often difficult to obtain in human studies, but the 
resulting molecular, biochemical and histological analyses of the colonic tissues helped 




    178 
SCFA and microbial profiling from the site-specific samples (caecal, mucosal-associated and 
faecal contents) was instrumental in delineating the synbiotic functioning. The synergistic 
synbiotic effect was more prominently noted as benefits that occurred along the colon length 
compared to the site-specific effects obtained using individual probiotic and prebiotic 
supplementation. 
 
However, while the mice models did allow the modulations in immune parameters, 
epithelial integrity, microbiota and associated metabolites (SCFA) to be studied in the 
controlled experiment, direct human trials will be required (620, 621). The variations in the 
evolved biology of humans, compared to mice, demands caution in translation of the results to 
impacts on human health and diseases (219). In addition, a small sample size for molecular 
analyses is also acknowledged to be a limitation in direct translation of such effects in 
humans. Also, care should be taken to translate the amount fed as a supplement to mice to 
human dose and the organoleptic tolerability of the supplements being tested for human 
application.   
 
7.2 Future research directions 
 
To achieve the goal of delivering the synbiotic functional ingredients in influencing 
health and eating practices in humans, development of convenient on-the-go food delivery 
forms is projected. The heat-resistant capacity of B. coagulans spores and its synergy with the 
prebiotic fibres – PSCF and GBRS could be particularly taken advantage of to develop shelf-
stable synbiotic food products. In this context, a snack bar is an ideal food matrix owing to its 
portability and as it allows storage without the need for refrigeration. A supplement snack bar 
carrying green banana flour is being currently evaluated for sensory acceptability among 
defence personnel in Australia (622). Such a food matrix could be further enhanced by adding 
probiotic ingredients as well as additional  prebiotic fibres to boost the gut immunity, while 
allowing slow energy release and promoting satiety. The studies focussing on developing and 
testing the stability of the snack bar carrying functional synbiotic ingredients will be required 
to guide the refinement of the formulation. The neutral taste and texture of PSCF and the 
ability of GBRS to stabilise emulsions could be expected to improve textural, functional and 
nutritional profile of these nutrient-dense food products. Sensory testing to evaluate the 
organoleptic acceptance by the consumers will be needed prior to health efficacy testing. Such 
value-added synbiotic products will offer greater choices of improved dietary quality food 
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A pilot human clinical trial in healthy volunteers (e.g. n = 30-40, 1-2 months duration) 
targeted for proactive prevention could be designed to determine if the consumption of 
synbiotic snack bar can reflect the beneficial changes that are seen with a healthy fruit and 
vegetable diet. The markers for health parameters could include testing for faecal microbiota 
and metabolomic profiling, serum CRP and serum/faecal cytokine profile (409). Besides 
providing the information on the efficacy of the tested synbiotic snack bar on health, such 
pilot trial could also allow determination of the dose responses and tolerability of ingredients 
in humans. The anti-inflammatory ability of synergistic synbiotic combinations tested in the 
research could also be applied to investigate its benefits in IBD patients through food delivery 
forms. However, any such research on synergistic combinations as a medical intervention 
would need to be conservatively applied in association with patients’ existing drug therapy. 
The functional synbiotic snack bar carrying the potent identified bioactive ingredients also 
offers potential for evaluating its benefits for weight maintenance and chronic low-grade 
inflammatory metabolic disorders. Thus, the outcomes of this research could be applied to 
facilitate the paradigm shift from passive healthcare recipients to active health care consumers 
seeking optimal wellness through improved functional food choices to negate the effects of 
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